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INTRODUCTION
Cholecystokinin (CCK) belongs to the family of brain-gut peptides, which are 
found in both the digestive tract and the central nervous system (CNS). The 
presence of CCK in mammalian CNS was suggested by the discovery of a 
gastrin-like peptide in the rat brain, subsequently identified as CCK octapeptide 
(CCK-8) (Vanderhaeghen et al., 1975; Dockray, 1976). CCK is present in diffe­
rent biologically active molecular forms cleaved from a 115-amino-acid precur­
sor molecule (pre-pro-CCK), including CCK-58, CCK-39, CCK-33, CCK-22, 
CCK-8 with its sulphated form CCK-8s, but also CCK-7, CCK-5, and CCK-4 
(Rehfeld and Nielsen, 1995, table 1). CCK peptides are abundant throughout the 
brain, with the highest levels in the cerebral cortex, limbic structures, and basal 
ganglia (Beinfeld et al., 1981; Savasta et al., 1988; Vanderhaeghen et al., 1992; 
Lindefors et al., 1993). CCK acts as a neurotransmitter and exerts a neuromodu- 
latory influence on several classical transmitters, including dopamine, serotonin 
(5-hydroxytryptamine, 5-HT), noradrenaline, y-aminobutyric acid (GABA), 
glutamate and endopioid peptides (Shlik et al., 1997; Noble et al., 1999). CCK 
receptors have been characterised (Hays et al., 1980; Innis et al., 1980) and 
cloned (Kopin et al., 1992; Wank et al., 1992). CCK interacts with two receptor 
subtypes: CCKA (peripheral or alimentary type) receptors, mainly located in the 
gastrointestinal tract, and CCKB (brain subtype) receptors that are abundantly 
found in the central nervous system (CNS) (Wank, 1995). Recently it has been 
proposed that CCKA and CCKB receptors should be renamed CCKi and CCK2, 
respectively (Noble et al., 1999). CCK-related peptides vary in their affinity to 
the subtypes of CCK receptors. CCK-8s and its amphibian analogue, caerulein, 
are non-selective agonists of CCK receptors, whereas unsulphated CCK-8, 
gastrin, pentagastrin (CCK-5), and CCK-4 are selective CCK2 receptor agonists.
CCK2 receptors are widely distributed in the brain and have been found to 
participate in the mediation of various physiological functions, including pain 
processing, learning, memory, motivated behaviour, locomotor activity, and 
anxiety (Singh et al., 1991; Costall et al., 1991; Shlik et al., 1997). Recently 
studies on the physiological role of CCK and CCK2 receptors have reached a 
new level because the targeted mutation of the CCK2 receptor gene has been 
achieved in mice (Nagata et al., 1996). CCK2 receptor-deficient mice are fertile. 
Despite the atrophy of gastric mucosa the oldest animals of this line have 
reached the age of 24 months and their general appearance is similar to their 
wild-type (+/+) littermates (Nagata et al., 1996; Kopin et al., 1999). According 
to the study of Kopin et al. (1999), the genetic invalidation of CCK2 receptors 
does not affect the weight gain and feeding behaviour in mice. Miyasaka et al. 
(2002) however reported that the energy metabolism and turnover are increased 
in these animals. When we started our experiments in 1998, very little was 
known about the behavioural and biochemical phenotype of CCK2 receptor-
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deficient mice. Therefore, the main task of the present work was to study the 
behavioural and biochemical phenotype of mice lacking CCK2 receptors. It is 
well known that CCK is located in the same neurons with dopamine and 
endopioid peptides in the mammalian brain (Hökfelt et al., 1980a,b; Gall et al., 
1987). This is an apparent reason why CCK closely interacts with the 
dopamine- and endopioidergic system in the regulation of various forms of 
behaviour (Shlik et al., 1997; Noble et al., 1999). Thus, a specific goal for the 
present work was to study, using the behavioural, biochemical, and 
pharmacological tools, the changes in the function of the dopamine- and 
endopioidergic system due to the genetic invalidation of CCK2 receptors.
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REVIEW OF LITERATURE
1. Cholecystokinin (CCK): 
distribution in brain and receptor subtypes
Neuropeptide CCK was first described in the mammalian nervous system in 
1975. Vanderhaeghen et al., (1975) discovered a gastrin-like peptide in the rat 
brain subsequently identified as CCK (Dockray 1976; Rehfeld 1985). CCK 
belongs to the group of peptides found in the digestive tract and the central 
nervous system (CNS). The biochemical studies have shown that the majority 
of neuronal CCK is expressed in the form of sulphated (in position 7 from the 
-COOH terminal — table 1) octapeptide — CCK-8s. The unsulphated form 
(CCK-8) of this peptide does exist, and also a larger (CCK-58, CCK-33), and 
smaller fragments (CCK-5, CCK-4) have been detected (Rehfeld and Nielsen
1995). These isoforms are cleaved from N terminus of pre-pro-CCK, a 115- 
amino-acid precursor molecule (Dockray 1992). Another peptide — gastrin, has 
an identical -COOH terminal pentapeptide sequence with CCK. CCK peptides 
are abundant throughout the brain, with the highest levels in the cerebral cortex, 
hippocampus, basal ganglia, hypothalamus, and periaqueductal grey matter 
(Beinfeld et al., 1981; Savasta et al., 1988; Vanderhaeghen et al., 1992; Linde- 
fors et al., 1993). It has been proposed that the brain contains at least three sub- 
populations of CCK neurones with different post-translational processing 
pathways (Rehfeld and Hansen 1986, Rehfeld 1992b). According to this view it 
is possible that different forms of CCK function independently in distinct 
neuronal settings. Pre-pro-CCK has been cloned in the rat and human 
(Deschenes et al., 1984; Takahashi et al., 1985), and mapping studies of pre- 
pro-CCK mRNA using in situ hybridisation histochemistry have been conduc­
ted (Savasta et al., 1988 and 1990; Ingram et al., 1989; Schalling et al., 1989; 
Vanderhaeghen and Schiffmann 1992). Certain discrepancies between the 
density of CCK immunoreactivity and CCK mRNA-containing neurones occur 
in some brain areas. This difference might come from the greater sensitivity of 
in situ hybridisation histochemistry compared to immunohistochemistry, 
because it allows to detect the putative neurones with long projections that 
synthesise CCK but transport it rapidly to the nerve terminals (Vanderhaeghen 
and Schiffmann 1992). High levels of CCK like immunoreactivity are present in 
synaptosomal preparations (Pinget et al., 1978; Emson et al., 1980), and CCK is 
synthesized de novo in the brain (Golterman et al., 1980). CCK is released from 
the brain slices or synaptosomes exposed to depolarising stimuli in a calcium- 
dependent manner (Pinget et al., 1979; Dodd et al., 1981; Emson et al., 1980; 
Verhage 1991). Furthermore, the specific high-affinity binding sites for CCK 
are widely distributed throughout the CNS (Inns and Snyder 1980; Saito et al., 
1980). CCK has been shown to induce excitation of central neurones (Dodd and 
Kelly 1979, 1981; Ishibashi et al., 1979; Boden and Hill., 1988). However,
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inhibitory postsynaptic effects have also been recorded (Ishibashi et al., 1979; 
MacVicar et al., 1987; Lopes da Silva et al., 1990). This is in accordance with 
the morphological studies suggesting that CCK is present in both excitatory and 
inhibitory neurones (Peters and al. 1983). Mechanisms terminating the action of 
CCK are less clear, but recently selective uptake into synaptosomal fraction in 
vitro has been demonstrated (Migaud et al., 1993).
Two types of high-affmity binding sites, initially termed as peripheral 
(alimentary) and central (brain) were characterised in 1980 by several groups 
(Hays et al., 1980; Innis and Snyder 1980; Saito et al., 1980; Sankaran et al., 
1980). Based on the autoradiographical studies of Moran and colleagues (1986) 
CCK receptors were originally named according to their preferential locali­
sation: the peripheral or alimentary type (CCKA) and the central or brain type 
(CCKB). CCKB receptors predominate in the brain (Wank, 1995) while CCKA 
receptors are present in the visceral organs and in some discrete brain nuclei 
(Hill et al., 1990). CCKA and CCKB receptors were cloned and the localisation 
of their mRNA in the brain was established (Kopin et al., 1992; Wank et al., 
1992; Lee et al., 1993; Ulrich et al., 1993). According to the nomenclature 
created by the authorised Committee on Receptor Nomenclature and Drug 
Classification of the International Union of Pharmacology, the receptors were 
renamed (Table 1): CCK, (formerly CCKA) and CCK2 (formerly CCKB) recep­
tors according to their affinity to the different CCK analogues. CCK-8s, like its 
amphibian analogue caerulein, is a non-selective agonist for CCK receptors. 
Unsulphated CCK-8, pentagastrin (CCK-5), and CCK-4 are selective CCK2 
receptor agonists (Woodruff and Hughes 1991). CCKi and CCK2 receptors 
possess seven trans-membrane domains and belong to the G-protein linked 
receptor superfamily with considerable amino acid sequence similarities to the 
other members of this family.
CCK] receptors (Table 1) are located mainly in peripheral tissues. On the other 
hand, it has been shown that CCKi receptors occur in certain brain regions 
including the area postrema, nucleus of the solitary tract, and interpeduncular 
nucleus (Moran et al., 1986). Further radioligand and electrophysiological 
studies revealed that the distribution of CCKi receptors was even more 
widespread in the brain. These receptors have been identified in the dorsal 
raphe, nucleus accumbens, substantia nigra, and ventral tegmental area (Hill et 
al., 1990; Barrett et al., 1989; Gerhard et al., 1989; Vickroy and Bianchi 1989). 
CCKi receptors, at least in the gastrointestinal tract, are coupled to a guanine 
nucleotide binding regulatory protein — G-protein, which activates phospholi- 
pase C, inducing the breakdown of inositol phospholipids, mobilisation of 
intracellular calcium, and activation of the protein kinase С (Jensen et al., 
1989).
In 1993 Song and colleagues described the gene for CCK2 receptors in 
humans (Table 1). It consists of 5 exons and 4 introns and is conformed simi­
larly in humans, mice (Nagata et al., 1996), and rabbits (Blandizzi et al., 1994). 
Three splice variants of CCK2 gene [long form, short form (Song et al., 1993)
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and Д form (Miyake 1995)] have been identified. The mRNA for CCK2 receptor 
was also found to express a wide range of splice diversity and is located also in 
the regions of CNS without the presence of functional receptors (Pélaprat et al., 
1987; Jagerschmidt et al., 1994). CCK2 receptors are widely distributed in the 
brain, with the highest concentration in the striatum, cerebral cortex, and limbic 
system (Beinfeld 1983), but these receptors are also present in the 
gastrointestinal tract. For a long time the CCK2 receptor has caused confusion 
for its similarity to the gastrin receptor. Recently it was revealed, that the canine 
parietal cell gastrin receptor and brain CCK2 receptor are highly homologous if 
not identical (Kopin et al., 1992). Indeed, the reported Southem-blot 
hybridisation analysis of human genomic DNA indicates that a single gene 
encodes both CCK2 and gastrin receptors (Lee et al., 1993). CCK2 receptor 
(belonging to the G-protein coupled receptor superfamily (Wank et al., 1992)) is 
linked to two effector pathways through pertussis toxin-sensitive and -insen­
sitive G-proteins (Roche et al., 1990; Pommier et al., 1999). MAP kinase 
pathway has also been shown to be activated via the stimulation of CCK2 
receptors (Taniguchi et al., 1994). Radioligand binding studies have also 
revealed the heterogeneity among CCK2 binding sites giving the possibility that 
there exist at least two subtypes of these receptors (Noble et al., 1999).
Table 1. Characterisation of subtypes of CCK receptors
Receptor
Structure -  human
Gene and location 
Human:
Mouse:
CCK!
CCKA /Alimentary / 
Peripheral
428 — aminoacid 
sequence 
(P32238 7TM)
CCK,
chromosome 4 
chromosome 5
CCK2
CCKB / Brain / Central
447 — aminoacid 
sequence 
(P32239 7TM)
CCK2
Chromosome 11 
Chromosome 7
Splice variants Yes (long form, short
form, A form)
Genetically induced Kopin et al., 1999 Nagata et al., 1996
disruption of gene in mice
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Distribution
Endogenous ligands 
according to their affinity 
to specific receptor
CCK-8s: (HOOC)F- 
D -M -W -G -M - 
Y (S03H)-D
CCK-8: (HOOC)F-D- 
M -W -G-M -Y-D
CCK-4: (HOOC)F-D- 
M-W
gastrin: (HOOC)F-D-M - 
W -G-Y (S 03H )-A -E-E - 
E-E-E-L-W -P-G -pQ
Agonist
Selective agonists 
Antagonists
Intracellular activation 
Functional role
Gall bladder, pancreas, 
pylorus, intestine, spinal cord, 
vagus nerve, limited brain 
areas (nucleus tractus 
solitarius, area postrema, 
nucleus interpeduncularis, 
posteromedial part of nucleus 
accumbens)
CCK-8s »  CCK-8 > gastrin 
> CCK-4
Caerulein (amphibian CCK 
analogue)
A 71623; A 70874; JMV-180
Proglumide; Lorglumide; 
Devazepide; Lintitript (SR 
27897)
G-protein q/11
Mediates CCK actions on gall 
bladder contraction, secretion 
of pancreatic enzymes, gastric 
emptying, inhibits feeding 
and respiration, potentiates 
dopamine-mediated 
behaviours and dopamine 
release in shell of nucleus 
accumbens
Throughout the brain 
(with the highest densities 
in the cerebral cortex, 
nucleus caudatus, 
anterolateral part of 
nucleus accumbens), 
vagus nerve, stomach, 
pancreas
CCK-8s > CCK-8 > 
gastrin = CCK-4
Caerulein
CCK-4; Boc-CCK-4;
BC 197; BC 264 
Proglumide; L-365,260; 
L-740,093; LY 288513; 
CI-988
G-protein q/11
Mediates CCK actions on 
increases in neuronal 
firing rates, nociception, 
anxiety, respiration, 
inhibits dopamine- 
mediated behaviours and 
dopamine release, 
regulates insulin release in 
pancreas
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2. Functional role of CCK and interaction 
with other neurotransmitter systems
2.1. Regulation of locomotor activity and interaction 
with the dopamine system
The motor inhibition induced by CCK agonists (CCK-8s and caerulein) in mice 
manifested as a reduction both in the motility and frequency of rearing. The 
parenteral and intracerebroventricular administration of CCK-8s and caerulein, 
but not CCK-4, induced hypolocomotion and blocked amphetamine-induced 
hyperlocomotion in mice (Zetler, 1985; Moroji et al., 1987; Hagino, Moroji, 
1989; Vasar et al., 1991; Hirosue et al., 1992). The pretreatment of mice with a 
selective CCKi receptor antagonist devazepide antagonised the motor 
depressant action of systemically and intracerebroventricularly administered 
CCK-8s and caerulein, reflecting the involvement of the CCKj receptors in the 
action of CCK agonists (Khosla, Crawley, 1988, O’Neill et al., 1991; Vasar et 
al., 1991). It is thought that the motor inhibition and suppression of dopami­
nergic activity induced by CCK agonists are of peripheral origin since they 
could be abolished by abdominal vagotomy in rats (Crawley, Kiss, 1985; 
Hamamura et al., 1989; Vasar et al., 1994a). However, not all authors have been 
able to reproduce the evidence that vagotomy can reverse the behavioural 
effects of CCK agonists in rodents. Moroji and Hagino (1987) have 
demonstrated that bilateral subdiaphragmatic vagotomy does not prevent the 
behavioural effects of subcutaneously injected caerulein in mice. The 
suppression of electrical self-stimulation by caerulein is also completely 
insensitive to vagotomy in rats (De Witte et al., 1986). Moreover, L-365,260, 
an antagonist of CCK2 receptors, caused an opposite action to devazepide 
because the motor inhibition elicited by caerulein and CCK-8 became stronger 
under the influence of CCK antagonist (Vasar et al., 1991, 1994b). These data 
demonstrate the opposite effect of CCK in the regulation of locomotor activity, 
depending on the CCK receptor subtype involved. CCK-8 is shown to co- 
localise with dopamine in the mesencephalic dopaminergic neurones (Höckfelt 
et al., 1980). Co-localisation of dopamine and CCK in the ventral tegmental 
area and in the ascending mesolimbic pathway suggests that CCK could act as a 
neuromodulator of dopaminergic transmission (Hökfelt et al., 1980b; 
Vanderhaeghen et al., 1980). Locomotor activity is obviously dependent on the 
functional activity of the mesolimbic dopaminergic system (Bradbury et al., 
1983; Costall et al., 1985). Dopaminergic drugs like apomorphine, an agonist of 
dopamine D, and D2 receptors, and L-DOPA, a precursor molecule of 
dopamine, induce the biphasic effect on the locomotor activity in rats and mice 
(Boissier and Simon 1966; Ungerstedt and Ljungberg 1977). Low doses of 
apomorphine and L-DOPA cause hypomotility due the stimulation of the 
dopamine autoreceptors (Di Chiara et al., 1976), which belong to the dopamine
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02 receptor family (Meitzer 1980; Sokoloff et al., 1992). Co-administration of 
caerulein with low doses of apomorphine induced an almost complete 
suppression of locomotor activity in mice (Vasar et al., 1986; 1991). On the 
other hand, the pre treatment of mice with devazepide significantly antagonized 
the motor suppression caused by apomorphine, whereas the CCK2 receptor 
antagonist L-365,260 apparently potentiated the sedative effect of apomorphine 
(Vasar et al., 1991). It shows that similar neurochemical mechanisms are 
responsible for the motor suppressant action of caerulein and apomorphine in 
mice. CCK-8s also significantly potentiates hypolocomotion induced by 
dopamine if simultaneously injected into the ventral tegmental area of rat brain, 
suggesting that CCK-8s acts as a facilitatory modulator of dopamine at CCK 
receptors on the dopamine A10 cell bodies (Crawley 1989). High doses of 
apomorphine and L-DOPA induce a significant increase in locomotor activity 
in rodents. This hypermotility can also be elicited by the specific dopamine D2 
receptor agonists (bromocriptine, quinipirole) but not by dopamine D] agonists 
(Jackson et al., 1988; Koller and Herbster 1988). However, dopamine D] 
agonists seem to enhance the hypermotility elicited by the dopamine D2 
agonists (Jackson et al., 1988; Koller and Herbster 1988). Higher doses of 
caerulein not only inhibit locomotor activity but also amphetamine-induced 
hyperlocomotion showing that central mechanisms are probably involved in the 
action of peripherally administered CCK agonist. This effect of caerulein was 
also antagonized by devazepide demonstrating the involvement of CCK] 
receptors (Vasar et al., 1991). In rats the effect of centrally administered 
CCK-8s on amphetamine-induced hyperlocomotion is dependent on the brain 
site administered. In the anterolateral part of nucleus accumbens CCK-8s 
suppresses via CCK2 receptors the amphetamine-induced hyperlocomotion, 
whereas in the posteromedial part CCK-8s potentiates via CCK, receptors the 
action of a dopamine agonist (Crawley, Corwin, 1994).
Repeated administration, but not acute treatment, of different dopamine 
antagonists (clozapine, chlorpromazine and haloperidol) evidently increases the 
amount of CCK-8s in the striatum and in mesolimbic structures (Frey et al., 
1983). Chang et al. (1983) showed that the long-term treatment with haloperidol 
increases the density of CCK receptors in the cortical and limbic structures of 
mice and guinea pigs. By contrast, chronic administration of metamphetamine, 
an indirect dopamine agonist, decreases the number of CCK-8 receptors in the 
rat cerebral cortex (Suzuki and Moroji 1989). Moreover, only the repeated 
administration of dopamine antagonists (haloperidol, chlorpromazine, clozapine 
etc.) induced the CCKi receptor mediated depolarisation and the subsequent 
inactivation of the dopaminergic neurones in the rat midbrain (Chiodo and 
Bunney 1983; Bunney et al., 1985; Jiang et al., 1988; Zhang et al., 1991; 
Minabe et al., 1991).
Brain dopamine is also related to the motivational mechanisms and reward 
(Wise and Rompre 1989). Therefore, by influencing the dopamine system CCK 
has also a role in the regulation of motivated behaviour. As could be expected
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considering the existence of multiple CCK-ergic subsystems in the mesolimbic 
area and the complex nature of CCK -  dopamine interactions (Crawley 1991), 
the action of CCK receptor agonists and antagonists is diverse in motivated 
behaviour. Peripherally injected CCK-8s can produce conditioned place 
aversion in food-deprived rats (Swerdlow et al., 1983). However, micro­
injection of CCK-8s into the ventral tegmental area potentiates the 
amphetamine-conditioned place preference (Pettit and Mueller 1989). Intra- 
accumbal injection of CCK-8s can either enhance or reduce the behavioural 
effects of amphetamine dependent on the injection site and receptor subtype 
(Vaccarino and Rankin 1989). A part of the anxiogenic-like effect of CCK-8s is 
also mediated via the dopaminergic mechanisms in the nucleus accumbens. For 
example, CCK-8s injected in to the posterior part of nucleus accumbens, 
reduces novelty-related exploratory activity through CCK] receptors, and this 
effect is probably related to the reduction of dopamine metabolism and 
mediated by the modulation of dopamine D2 receptors (Derrien et al., 1993).
2.2. Pain sensitivity and opioid-induced antinociception: 
interaction with the endopioidergic system
At the beginning of the eighties two studies described the ability of CCK-8s to 
antagonize opioid-induced analgesia (Faris et al., 1983; Itoh et al., 1985). These 
findings aroused considerable interest in exploring the possibility that CCK-8s 
may act as an endogenous antagonist of the endopioidergic system (Faris 
1985a,b). In addition, the distribution of CCK peptides in CNS matches that of 
opioid peptides — enkephalin, ß-endorphin, and dynorphin (Gall et al., 1987; 
Baber et al., 1989; Ghilardi et al., 1992; Skinner et al., 1997). It was shown that 
CCK2 antagonists are able to prevent the development of opioid tolerance and 
dependence (Idanpää-Heikkila et al., 1997; Kaysler et al., 1998). There is also 
some evidence that CCKi receptors are responsible for the rewarding properties 
of morphine, whereas CCK2 receptors modulate the analgesic activity of 
morphine (Singh et al., 1996). Interestingly, the increased number of CCK 
receptors in the supraoptic nucleus after the chronic morphine administration 
suggests that CCK could have a role in the development of tolerance to the 
analgesic effect of morphine (Munro et al., 1998). A clear anti-opioid action of 
CCK-8s is described on the level of the spinal cord (Suh and Tseng 1990). The 
supraspinal structures, particularly the periaqueductal grey matter, are also 
involved in the interaction between CCK-8s and endopioid peptides (Hendrie et 
al., 1989a; Dourish 1992). However, the cellular mechanisms of this 
antagonism are not clear. Electrophysiological studies demonstrated that 
CCK-8s diminished morphine-induced inhibition of dorsal horn neuronal firing 
in response to painful stimuli, whereas CCK antibodies and antagonists 
enhanced this inhibition (Suberg and Watkins 1987). This effect seems to
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involve the intracellular calcium content because CCK-8s has been shown to 
increase the level of intracellular calcium in the presynaptic terminals by 
mobilization from the intracellular stores and, therefore, antagonising the 
suppression of cytosolic calcium levels induced by the opioid agonists (Wang 
et al., 1992).
2.3. Emotional behaviour, learning, and memory
CCK interacts in neural systems that form the networks of fear, anxiety, and panic 
behaviour (Harro et al., 1993b, Bradwejn, Vasar 1995; Crawley 1995). The 
electrophysiological experiments by Bradwejn and De Montegny (1984) 
demonstrated that the anxiolytic drugs belonging to benzodiazepines could block 
the excitatory effect of CCK in the hippocampus at clinically relevant doses. An 
anecdotal observation was made by Jens Rehfeld and Thue Schwartz, who self­
injected CCK-4, the CCK2 receptor agonist, and experienced severe anxiety and 
de-realization (Rehfeld 1992a). This study lead to a systematic assessment of 
CCK-4 in healthy volunteers and psychiatric patients, and subsequently 
confirmed the panic-like action of CCK-4 (De Montegny 1989; Koszycki et al.,
1991). In animal experiments CCK-related peptides produce an anxiogenic-like 
effect in mice, rats, cats, and monkeys (Fekete et al., 1984; Csonka et al., 1988; 
Harro et al., 1990; Harro and Vasar 1991a; Singh et al., 1991; Palmour et al.,
1992). Similarly to people, in animal experiments the dose response and 
behavioural patterns after CCK-4 challenge depend on the baseline anxiety of 
the animal. In monkeys the uptight animals — typically restless, submissive to 
threat, and excessively reactive to the environment, are affected by low doses of 
CCK-4 (Palmour et al., 1992). Rodents with anxious behaviour, as assessed in 
the elevated plus-maze, had a significantly higher density of CCK receptors in 
the cerebral cortex as compared to animals with the opposite behaviour (Harro 
et al., 1990). The non-selective CCK receptor antagonist proglumide and 
selective CCK2 antagonists (L 365,260, CI-988, and LY 262691) show an 
anxiolytic effect in animals in several anxiety tests. The selective CCK] receptor 
antagonist lorglumide and devazepide show similar properties, but at doses 
probably active also at CCK2 receptors (Woodruff and Hughes 1991; Harro and 
Vasar 1991a,b). However, in some cases the anxiolytic effect of CCK2 
antagonists as the only treatment has not been evident (Harro and Vasar 1991b; 
Crawley 1992). This can be explained in the light of the evidence that the 
peptidergic neurotransmission is activated by bursting or high-frequency 
neuronal activity; the peptide antagonists therefore should not necessarily show 
any effect under normal tonic activity (Hökfelt 1991). Thus, it is possible that 
the anxiolytic effect of peptide antagonist is observed only if the endogenous 
neurobiological mechanisms underlying anxiety are already activated. As stated 
above, a part of the anxiogenic-like action of CCK is mediated via dopaminergic
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mechanisms in the posterior part of nucleus accumbens (Daugé et al., 1989; 
Derrien et al., 1993). Recent evidence suggests that the antagonistic interaction 
between CCK and endopioid peptides exists in the mechanisms regulating 
anxiety behaviour (Kõks et al., 1998; 1999). The concurrent administration of 
subeffective doses of CCK agonists and naloxone induces a significant 
anxiogenic-like action in rats (Kõks et al., 1998), and pretreatment of rats with 
CCK-4 completely antagonizes the anxiolytic-like action of morphine in the 
elevated plus-maze (Kõks et al., 1999).
There is an increasing amount of evidence from preclinical studies that CCK 
may be involved in memory processing. CCK availability is conspicuous in 
such brain regions as hippocampal formation, amygdaloid nuclei, and cerebral 
cortex, which are believed to underlie memory functions (Rehfeld et al., 1995). 
Parenteral administration of non-selective agonists of CCK receptors, such as 
CCK-8s and caerulein, prolongs extinction of already learned tasks (Kadar et 
al., 1981; Derrien et al., 1994), accelerates habituation to a novel environment 
(Crawley, 1984), and prevents experimental amnesia in rodents (Kadar et al., 
1984; Katsuura et al., 1986a; Vasar et al., 1988; Itoh et al., 1990; Maurice et al., 
1994). Recent evidence suggests that CCKj and CCK2 receptors may have 
different roles in memory functions (Harro et al., 1993a). In particular, a 
balance has been proposed between CCKi receptor mediated facilitative effects 
and CCK2 receptor mediated inhibitory effects on memory retention (Lemaire et 
al., 1992; 1994). However, the data describing the effects of CCK2 receptor 
agonists on memory in laboratory animals are inconsistent. For instance, some 
researchers reported that administration of selective CCK2 receptor agonists 
(CCK-4, BC-264) impairs memory functions in rodents (Katsuura et al., 
1986a,b; Derrien et al., 1994; Lemaire et al., 1994) while others demonstrated 
memory enhancement (Gerhardt et al., 1994). Administration of BC264 
increased vigilance in monkeys and behavioural arousal in rodents (Daugé et 
al., 1995), suggesting a role of CCK2 receptors in attentional activation that may 
facilitate learning. Considering the role of CCK in anxiety, it cannot be 
excluded that much of the influence of CCK-related peptides on memory is due 
to their anxiogenic-like action.
3. Phenotype of CCK2 receptor-deficient mice
Recently, mice with targeted disruption of CCK2 receptor gene have been 
generated (Nagata et al. 1996). These mice are fertile and no obvious 
behavioural abnormalities have been observed up to the age of 24 months 
(Nagata et al., 1996; Kopin et al., 1999). The animals without CCK2 receptors 
display atrophic development of gastric mucosa and altered learning abilities 
(Nagata et al., 1996; Sebret et al., 1999). The feeding behaviour in general
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seems not to be disturbed in CCK2 receptor-deficient mice compared to wild- 
type (+/+) littermates (Kopin et al., 1999). Nevertheless, the lack of CCK2 
receptors results in increased energy expenditure and a higher basal metabolic 
rate (Miyasaka et al., 2002). The activity of the dopaminergic system is also 
affected in mice by a corrupted function of CCK2 receptors, and the sensitivity 
of dopamine D2 receptors tended to be increased in mutant mice (Daugé et al., 
2001a; Pommier et al., 2002). The performed studies also suggest that the 
function of the endopioidergic system is significantly altered in mice lacking 
CCK2 receptors. Pommier et al. (2002) demonstrated that these mice displayed 
hyperalgesia and a reduced response to morphine-induced analgesia in the 
hotplate test. Moreover, the studies show that mutant mice exhibited 
hypersensitivity to morphine-induced locomotor activity and developed a more 
severe withdrawal syndrome after chronic morphine treatment (Pommier et al., 
2002) leading the authors to the statement that the deletion of CCK2 receptors 
has resulted in the upregulation of the endopioidergic system in these mice.
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OBJECTIVES
The present work characterizes the behavioural and biochemical phenotype of 
mice lacking CCK2 receptors. As described above, CCK is located in the same 
neurones with dopamine and endopioid peptides in the mammalian brain (Hökfelt 
et al., 1980a,b; Gall et al., 1987). This is an obvious reason why CCK closely 
interacts with the dopamine- and endopioidergic system in the regulation of 
various forms of behaviour (Shlik et al., 1997; Noble et al., 1999). Therefore, an 
attempt was made to study, using the behavioural, biochemical and pharma­
cological means, changes in the function of the dopamine- and endopioidergic 
system in mice without CCK2 receptors.
The specific objectives of the present study are as follows:
1. To study the properties of dopamine D2 and |i-opioid receptors in the forebrain 
structures of mice with the corrupted function of CCK2 receptors.
2. To evaluate the changes in the locomotor activity and motor coordination of 
genetically modified mice.
3. To study the changes in the behavioural effects of apomorphine, an agonist of 
dopamine receptors, and amphetamine, increasing the release of dopamine 
from presynaptical terminals, in mice lacking CCK2 receptors.
4. To measure the performance of genetically modified mice in the nociceptive 
tests.
5. To study the changes in the behavioural effects of morphine, an agonist of 
|i-opioid receptors, and naloxone, an antagonist of opioid receptors, in CCK2 
receptor-deficient mice, using the behavioural tests reflecting pain sensitivity, 
motivational responses, and locomotor activity.
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MATERIALS AND METHODS
1. Animals
CCK2 receptor-deficient mice were provided from the original background 
129Sv/C57Bl/6 mice (Nagata et al., 1996). CCK2 receptor-deficient mice were 
generated by homologous recombination by replacing a part of exon 2 and 
exons 3, 4, and 5 (Nagata et al., 1996). Breeding and genotype analysis were 
performed in the Department of Physiology, University of Tartu. Genotyping 
was carried out by means of polymerase chain reaction (PCR) using two pairs 
of primers. HE2F (TGG AGT TGA CCA TTC GAA TCA C) and LacZrev 
(GTG CTG CAA GGC GAT TAA GTT G) were designed to detect the mutant 
allele, and HE3F (TAT CAG TGA GTG TGT CCA CTC T) and HE3R (АСА 
TTT GTT GGA CAC GTT CAC) were designed for the wild-type allele. For 
PCR we used the following protocol: 96°C for 10 min (initial dénaturation); 
96°C for 50 s, 60°C for 50 s and 72°C for 2 min (25 cycles); and 72°C for 
10 min (final amplification). PCR products were stored at 4°C until 
electrophoresis. During the studies mutant mice were crossed back six times to 
the C57B1/6 background to minimize possible genetic effects from the 129Sv 
strain. The mice were kept in the animal house at 20±2°C under a 12—h/12—h 
light/dark cycle (lights on at 0700). Tap water and food pellets were available 
ad libitum. All animal procedures were approved by the University of Tartu 
Animal Care Committee in accordance with the European Communities 
Directive of 24 November 1986 (86/609/EEC).
2. Drugs
All the injections were performed intraperitoneally, and the drugs were 
dissolved in sterile 0.9% NaCl (saline) solution. The injections were given in a 
volume 10 ml/kg.
The locomotor effects of amphetamine sulphate (3.0 and 6.0 mg/kg; Sigma), 
and apomorphine hydrochloride (0.1 mg/kg; Sigma) were studied in separate 
groups of animals. Both drugs were injected intraperitoneally 20 min and 
15 min, respectively, before the beginning of an experiment.
Morphine sulphate (Boehringer-Ingelheim) in doses 1-10 mg/kg, was used 
in pain assessment experiments to evaluate the analgesic effect of this drug, and 
it was administered 15 min before the test.
In the plantar-analgesia test, 1 mg/kg of morphine sulphate was chosen, 
since lower doses (0.05—0.5 mg/kg i.p.) of the drug did not cause any 
statistically significant effect (data not shown). The effect of higher doses of 
morphine was impossible to study because of the increased locomotor activity
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of mice and, therefore, the correct measurement of hind paw withdrawal latency 
was impossible. Injections were made after a 30 min adaptation period of mice 
at the enclosure assembly of the test equipment. After the injection, mice were 
released back to the enclosure assembly. The test was started after 15 min, the 
time being sufficient for mice to calm down again.
In the hotplate test the mice were taken out for injection and released back to 
the home cage 15 min before the test. Morphine sulphate (5-10 mg/kg) was 
used and saline injections served as controls in both the plantar-analgesia and 
hotplate tests.
In place preference tests the doses of naloxone hydrochloride (Sigma, 1 and 
10 mg/kg) and morphine sulphate (3 and 9 mg/kg) were selected according to 
the data available in the literature. These doses are shown to induce a significant 
action in the place conditioning studies. In the locomotor activity studies the 
higher doses of morphine were applied since the pilot study revealed that only 
10 mg/kg of morphine induced a significant increase in locomotor activity in 
mice with 129Sv/C57Bl/6 background.
3. Radioligand binding studies
Mice were decapitated, the brains were rapidly removed, quickly dissected on 
ice, and cooled down in the liquid nitrogen. The following brain areas were 
dissected from the sections according to the atlas by Franklin and Paxinos 
(1997): the cerebral cortex, both striata, mesolimbic structures (nucleus accum­
bens and tuberculum olfactorium), and the hippocampus. The dissected tissues 
were frozen in liquid nitrogen and stored at -80°C until sample preparation. The 
brain structures from six mice were pooled. The radioligand binding studies 
were performed according to the method of Kõks et al. (1997). The tissue was 
homogenized in 20 volumes of ice-cold 50 mM Tris-HCl (pH 7.4 at 4°C) using 
a Potter-S glass-teflon homogenizer (1000 rpm, 12 passes). The membranes 
were washed twice in the same buffer by centrifugation (48000 x g for 20 min) 
and resuspension. After the last centrifugation the crude brain cell membranes 
were suspended in the incubation buffer (50 mM Tris-HCl, pH 7.4 at 4°C) for 
the binding assay. The protein content was measured according to the method of 
Bradford (1976). The saturation curves of [3H]-labelled ligand binding were 
analysed using GraphPad Prism (Version 3.00) for Windows software. The 
experiments were repeated four times.
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3.1. Measurement of parameters of CCK receptors
The cerebral cortex and subcortical structures (involving the striatum, 
mesolimbic structures, and septum pellucidum) were used. [Propionyl- H]- 
propionylated-CCK-8-sulphated ([3H]-pCCK-8s, with specific activity of 
73 Ci/mmole, Amersham Radiochemicals) was used for the labelling of CCK 
receptors. The parameters of the receptors were determined in the presence of
0.05-2.4 nM of [3H]-pCCK-8s at 23°C for 120 min. An antagonist of CCK2 
receptors L-365,260 (from Merck Sharp & Dohme, 1 цМ) was added to 
determine the non-specific binding.
3.2. Measurement of parameters of dopamine and 
serotonin (5-HT) receptors
In one experiment the cerebral cortex and subcortical structures (involving the 
striatum, mesolimbic structures, and septum pellucidum) were dissected. In the 
other experiment the striata, and mesolimbic structures were separated. The 
striata, mesolimbic, and subcortical structures were used to study the parameters 
of dopamine D2 receptors, whereas 5-HT2 receptors were studied in the cerebral 
cortex. The parameters of dopamine and serotonin receptors were determined in 
the presence of 0.06-2 nM [3H]-spiperone (specific activity 107 Ci/mmole, 
Amersham Radiochemicals) incubated at 37°C for 30 min. Raclopride (Astra, 
1 |iM), an antagonist of dopamine D2 receptors, was added to determine the 
non-specific binding at dopamine D2 receptors. Ritanserin (RBI, 1 цМ), an 
antagonist of 5-HT2 receptors, was used to detect the non-specific binding of 
5-HT2 receptors.
3.3. Measurement of parameters of opioid receptors
The cerebral cortex (including the frontal and parietal cortices), striata, 
mesolimbic structures, and the hippocampus were dissected. The parameters of 
opioid receptors were determined in the presence of 0.05-2.5 nM [3H]- 
diprenorphine (specific activity 58.0 Ci/mmole, Amersham Radiochemicals) 
incubated at 23°C for 60 min. Naloxone hydrochloride (Sigma, 1 [iM), an 
antagonist of opioid receptors, was added to determine the non-specific binding 
at opioid receptors.
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4. Behavioural experiments
The animals were brought into the experimental room one hour before the 
experiment. All behavioural experiments were performed between 11:00 and 
19:00. The locomotor activity and conditioned place preference tests were 
performed on separate groups of animals. Since some behavioural experiments 
lasted 6-8 h (place preference test; locomotor activity test), precautions were 
taken to control the possible daily fluctuations in the locomotor activity of 
animals. Therefore, these experiments were always performed in randomised 
order — wild-type (+/+) mice were always used in parallel with mutant animals. 
In the radioligand binding study we used animals that had not been exposed to 
behavioural testing. In some cases pilot studies were performed to establish the 
optimal experimental conditions.
4.1. Rotarod test
A 1-min training session was given to mice on the rotarod (diameter 8 cm, 
9 rpm) 5 min before the first measurement. Time until the first fall was 
registered during a 2-min session on three consecutive days to evaluate the 
motor performance of mice.
4.2. Locomotor activity
For the study of locomotor activity, an animal was placed singly into the 
photoelectric motility boxes (448x448x450 mm) connected to a computer (TSE 
Technical and Scientific Equipment GMBH, Germany). The illumination level of 
transparent test boxes was -450 lux. Time in locomotion (s), distance of 
locomotion (m), the number of rearings and comer entries was registered during 
the 30-min observation period.
4.3. Nociceptive tests
4.3.1. Plantar-analgesia test
The plantar-analgesia test was performed according to the method of Har­
greaves et al. (1988). The instrument for the measurement of plantar-analgesia 
(TSE Technical & Scientific Equipment Gmbh, Germany) consists of a
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movable infrared generator, platform, mice enclosure assembly, and controller. 
In order to avoid the confounding effects of novelty and handling stress, prior 
handling of mice and habituation to the test equipment was performed. The 
animals were adapted to the equipment for three consecutive days, a 60-minute 
session each day. Before the experiment, mice were allowed a sufficient time to 
explore the equipment without a stimulus. The mice were also observed during 
the adaptation sessions to assess any unusual behaviour of mutant mice. The 
mice entered the adaptation session according to their cage mates and always in 
the same order to adapt also to the odours. After every session the enclosures 
were cleaned with a 5% alcohol solution. After the adaptation period the 
animals stayed quietly in a resting position, with occasional bouts of grooming, 
allowing to direct a beam of infrared light (intensity equal to 50°C) to the 
palmar surface of a hind paw. Latency for the mouse to withdraw the hind paw 
was measured automatically by the equipment. The stimulation of the hind paw 
was repeated up to four times, and the mean latency was calculated. There was 
at lest two-minute interval (usually longer) between two measurements. After 
the injections 15 minutes was sufficient for the animals to calm down to 
perform the measurements. The plantar-analgesia test was favoured instead of 
the tail-flick test, both reflecting the function of the spinal mechanisms of 
nociception, to avoid the stress from handling in mice.
4.3.2. Hotplate test
The animal was placed on a surface (30 x 50 cm) maintained at 52±0.3°C and a 
glass funnel (diameter 15 cm, height 12.5 cm) was used to restrict the movements 
of the animal. The time to the licking or to a clear shake of either of the hind paw 
was noted manually (using the stopwatch) as the pain threshold in seconds. The 
mice were taken out and released back to the home-cage after the experiment and 
observed for possible thermal damage. Another experiment was performed where 
the latency to jump was measured and a 2 minute cut-off time was used in this 
case. The two minute cut-off time was chosen according to our pilot studies, 
where we noticed that the majority of wild-type (+/+) and CCK2 receptor- 
deficient mice responded with a jump during that period. After the experiment the 
mice, when released to the home-cage, did not show any behaviour to conclude 
that they had been damaged in any way by the temperature.
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4.4. Place preference and aversion test
Place preference and aversion experiments were performed in three identical 
shuttle boxes (50x25x30). Each shuttle box was divided into two compartments 
of equal size by a sliding door having a partition. The door allows free 
movement of a test animal between the two compartments if opened or restricts 
the movement of a mouse to the other compartment if closed. These compart­
ments were distinguished by wall and floor colour (dark green versus pale 
green). The illumination level in the shuttle boxes was -250 lux. The place 
conditioning experiment was performed according to the method described by 
Bespalov et al. (1999). Each experiment consisted of pre-conditioning, conditio­
ning, and post-conditioning periods. During the pre-conditioning period mice 
were placed three times into the apparatus for 15 minutes. The first and the 
second pre-conditioning tests were held on day 1. The third pre-conditioning 
test was held on day 2 of the experiment, and the time spent in the pale green 
compartment was measured. During the pre-conditioning and post-conditioning 
tests, animals were allowed to explore both compartments freely. Each pre- and 
post-conditioning session began with initial placement of an animal into the 
dark green compartment. The shuttle boxes were cleaned carefully after each 
animal using a 5% ethanol solution. The conditioning period consisted of a 
30-min experimental session performed twice a day for four consecutive days 
(days 3-6). On each day animals received a saline injection before being placed 
into one compartment and were then injected with morphine (3 and 9 mg/kg) or 
naloxone (1 and 10 mg/kg) before placement into the opposite compartment. 
Injections were given immediately before the conditioning sessions. One half of 
the animals received saline as the first injection, whereas the other half were at 
first treated with morphine or naloxone. The morphine injections were paired 
with the placement of a mouse into the pale green compartment avoided in the 
pre-conditioning test (conditioning of place preference) and the naloxone 
injections were paired with the placement of an animal into the preferred 
compartment (dark green, conditioning of place avoidance). The control 
animals received the injection of saline in both compartments. Fifteen-minute 
post-conditioning tests were performed on day 7 of the experiments and the 
time spent in the pale green side of the shuttle box was measured. The beha­
viour of the animals was recorded on the videotape, and it was analysed by the 
experienced person unaware about the previous conditioning sessions and the 
genotype of mice. On day 8 we also studied the effect of morphine on place 
preference, but the response of the animals did not differ from that in the drug- 
free state. Therefore, these data were not included in the further analysis. This 
biased design has often been criticized because it may lead to false-positive 
results in the place conditioning test (Tzschentke, 1998). For example, the drugs 
with a strong anxiolytic action may overcome the initial aversion for the non­
preferred compartment. Several steps were taken to minimize the problem 
linked to the biased design. The animals having a significantly different
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response profile in the pre-conditioning session were excluded from further 
experiments. The effect of morphine was not compared with the pre­
conditioning session but with a group of animals receiving saline injections in 
both compartments.
5. Data analysis
Age- and weight-matched mice were used. The results are expressed as mean 
values ± S.E.M. The results were analysed by using one- or/and two-way 
analysis of variance (ANOVA/MANOVA). Post hoc comparisons between the 
individual groups were performed by the Statistica software for Windows. The 
saturation curves of [3H]-labelled ligand binding were analysed using GraphPad 
Prism (Version 3.00) software for Windows. The Student’s t-test was applied 
for radioligand binding studies.
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RESULTS
1. Radoligand binding studies (papers I, II, III, IV)
1.1. CCK receptors (papers I, II)
In wild-type mice (+/+) the density of CCK binding sites was significantly 
higher in the cerebral cortex compared to the subcortical structures. In 
heterozygous (+/-) mutant mice the density of CCK binding sites was signi­
ficantly lower — about 30-50% of the corresponding value in wild-type (+/+) 
animals, but it was again higher in the cerebral cortex than in the sub-cortical 
structures. The specific binding of [3H]-pCCK-8 was not detectable in the 
cortical and subcortical regions of homozygous (-/-) mutant mice as had been 
expected showing that the majority of CCK binding sites in these brain 
structures belong to the CCK2 receptor subtype.
1.2. Dopamine D2 and 5-HT2 receptors (papers I, II)
The parameters of dopamine D2 and 5-HT2 receptors were evaluated by means 
of radio-labelled antipsychotic drug [3H]-spiperone. The parameters of 
dopamine D2 receptors were studied in the subcortical structures (including the 
striatum, tuberculum olfactorium, nucleus accumbens, and septum) in one study 
and in the striatum and mesolimbic structures (tuberculum olfactorium and 
nucleus accumbens) in other study. Therefore, the results were somewhat 
different. In the subcortical structures of homozygous (-/-) mice the affinity of 
[3H]-spiperone binding sites was increased compared to wild-type (+/+) 
littermates reflecting an increased affinity of dopamine D2 receptors for ligand. 
In the striatum of homozygous (-/-) animals the number of [3H]-spiperone 
binding sites was significantly elevated compared to wild-type (+/+) mice. In 
heterozygous (+/-) mice the increase of [3H]-spiperone binding was not 
statistically significant. We did not find any significant changes in the 
parameters of [3H]-spiperone binding sites in the mesolimbic region. 
Nevertheless, the functional meaning of two studies is the same because there is 
an increase in the functional activity of dopamine receptors in the subcortical 
structures of CCK2 receptor-deficient mice, and this change is located in the 
striatum. The parameters of [3H]-spiperone binding were not affected in the 
cerebral cortex of the mice lacking CCK2 receptors. Consequently, the targeted 
mutation of CCK2 receptors in male mice induces changes in dopamine D2 
receptors but not in 5-HT2 receptors.
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1.3. Opioid receptors (papers 1П, IV)
The parameters of opioid receptors labelled by [3H]-diprenorphine were 
evaluated in four brain regions, including the cerebral cortex, striatum, 
mesolimbic structures, and the hippocampus. Like in the case of [ H]-spiperone 
binding the targeted genetic invalidation of CCK2 receptors induced distinct 
changes in the parameters of opioid receptors in various brain regions. Again, as 
in the case of [3H]-spiperone binding the biggest changes in the parameters of 
[3H]-diprenorphine binding were found in the striatum. In homozygous (-/-) 
mice the density of [3H]-diprenorphine binding sites was significantly elevated, 
but their affinity was reduced compared to wild-type (+/+) littermates. By 
contrast, the affinity of [3H]-diprenorphine binding sites was increased in the 
cerebral cortex of homozygous (—/-) mice. In the mesolimbic structures and the 
hippocampus the parameters of [3H]-diprenorphine binding of homozygous 
(-/-) mice did not differ from that in wild-type (+/+) animals. The changes 
established in [3H]-diprenorphine binding of heterozygous (+/-) mice were not 
statistically significant. Altogether, the targeted genetic invalidation of CCK2 
receptors induced significant alterations in the parameters of opioid receptors, 
but these changes are restricted to certain brain structures, including the striatum 
and the cerebral cortex.
2. Locomotor activity and motor 
coordination (papers I, II, IV)
2.1. Motor coordination in the rotarod test (paper I)
In the first rotarod experiment at day 1, the performance of heterozygous (+/-) 
and homozygous (-/-) CCK2 receptor-deficient mice was impaired relative to 
wild-type (+/+) littermates. This difference however was statistically significant 
only in the case of homozygous (-/-) mice. Significant difference remained 
between the mutant and wild-type mice in the second experiment on the second 
day. On the third day the behaviour of heterozygous (+/-) mice did not differ 
from that of wild-type (+/+) animals, whereas the ability of homozygous (-/-) 
mice to stay on the rotating wheel remained poor relative to wild-type (+/+) 
animals. This finding is in good agreement with the study by Daugé et al. 
(2001b), demonstrating an impaired motor coordination of CCK2 receptor- 
deficient mice compared to their wild-type (+/+) littermates. Nevertheless, the 
established difficulties in staying on the rotating wheel in homozygous (-/-) 
mice seem to depend on the genetic background. It is noteworthy that in the 
rotarod test C57B1/6 mice show much longer latencies to fall than 129Sv mice 
(Homanics et al., 1999). Moreover, our recent unpublished studies show that the 
backcrossing of mice to C57B1/6 genetic background obviously diminished the
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above-described motor coordination problems in CCK2 receptor-deficient mice. 
It is interesting that the same phenomenon was established in the case of 
dopamine D2 receptor deficient mice by Kelly et al. (1998). Therefore, the 
impairment of motor coordination induced by the genetic invalidation of CCK2 
receptors is present if the genes from the 129Sv strain dominate over the genes 
of the C57B1/6 strain.
2.2. Locomotor activity in motility boxes (papers I, II, IV)
The studies performed for the evaluation of spontaneous locomotor activity of 
CCK2 receptor-deficient mice show that the motor performance of mice 
depends on two major factors. First the genetic background and second, the 
adaptation of mice to the experimental environment. This statement is based on 
the data published in papers I, П, and IV. It should be noted that there is a 
difference between wild-type (+/+) mice in the first (paper П) and third study 
(paper IV) showing that moving out from the 129Sv genetic background 
obviously increases the motor activity in mice. In the beginning the locomotor 
activity (papers I, П) of mutant mice tended to be lower than in their wild-type 
(+/+) littermates, and in some experiments this difference reached a statistical 
significance. In the last experiment (paper IV), the locomotor activity of mutant 
mice, not habituated to the motility boxes, did not differ from that of wild-type 
(+/+) littermates. Only the number of rearing was higher in homozygous (-/-) 
animals. However, the situation changed when the animals were repeatedly 
exposed to the motility boxes. There was a significantly stronger inhibition of 
locomotor activity in the wild-type (+/+) mice compared to the homozygous 
(-/-) littermates. It has to be stressed that our data differ from that of Daugé et 
al. (2001 a,b) and Pommier et al. (2002) because we were unable to find the 
increase of the horizontal component of locomotor activity in homozygous (-/-) 
mice relative to the wild-type (+/+) animals not habituated to the motility boxes. 
Only the frequency of rearing was higher in mice without CCK2 receptors in the 
last experiment (paper IV), but not in the previous studies (papers I, П). 
The reason for the differences between our studies and Daugé et al. 
(2001 a,b, Pommier 2002) is unclear but could be attributed to different research 
designs — the motility study by the French group was performed in dark box 
and to the distinct genetic background of mice. The repeated exposure of mice 
to the motility boxes (paper IV) caused a significant reduction of locomotor 
activity in the wild-type (+/+) mice. The described behavioural change was 
significantly weaker in animals lacking CCK2 receptors. This difference can be 
explained in the light of the suggestion that CCK is an important factor in the 
adaptation of rodents to a novel environment (Wiertelak et al., 1992; Kõks 
et al., 1998; 1999). Thus, lack of CCK2 receptors apparently attenuates normal 
adaptation of mice to a novel environment.
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2.3. Changes in locomotor activity induced by dopamine- 
and endopioidergic drugs (papers I, II, IV)
2.3.1. Apomorphine-induced hypolocomotion (papers I, П)
The treatment with a low dose (0.1 mg/kg i.p.) of apomorphine, an unselective 
agonist of dopamine Dt and D2 receptors, reduced the locomotor activity in 
wild-type (+/+) mice. It should be noted that this dose of apomorphine did not 
cause any sign of stereotyped behaviour. The motor suppressant effect of 
apomorphine is believed to be caused by the stimulation of dopamine D2 
autoreceptors located on the dopamine neurones (Meltzer, 1980). Intrestingly, in 
two separate studies (papers I, П) the motor suppressant action of apomorphine 
was significantly stronger in mice lacking CCK2 receptors and it is important to 
stress that the increased effect of apomorphine was already present in 
heterozygous (+/-) mice, having still 50% of CCK2 receptors left in the brain 
(paper I). This finding is in agreement with our previous pharmacological 
studies, in which the CCK2 receptor antagonist L365,260 potentiated the motor 
suppressant action of apomorphine (Vasar et al., 1991). Altogether, it is likely 
that the genetic invalidation of CCK2 receptors increases the sensitivity of 
presynaptic dopamine receptors in the brain.
2.3.2. Amphetamine-induced hyperlocomotion (papers I, П)
The administration of amphetamine (3 and 6 mg/kg i.p.), increasing the release 
of dopamine from the pre-synaptic terminals (Kuczenski, 1983), induced a 
dose-dependent locomotor stimulation in wild-type (+/+) mice. However, as 
established in two separate studies (papers I, П), in mutant mice the effect of 
amphetamine was different. In heterozygous (+/-) mice, a lower dose of 
amphetamine (3 mg/kg) tended to increase the motor activity, but the higher 
dose had the same effect as in wild-type (+/+) animals. In homozygous (-/-) 
mice, a lower dose of amphetamine reduced the number of rearing, but did not 
affect the other parameters of locomotor activity. The treatment with a higher 
dose (6 mg/kg) of amphetamine induced in two separate studies (paper I, П) a 
significant increase in three parameters of locomotor activity: time in loco­
motion, travelled distance, and the number of corner entries. It should be noted 
that the stimulating effect of the higher dose (6 mg/kg) of amphetamine in 
homozygous (-/-) mice was significantly stronger compared with heterozygous 
(+/-) and wild-type (+/+) littermates. The increased action of amphetamine 
could be related to the enhanced sensitivity of the postsynaptic dopamine 
receptors in the forebrain regions. Indeed, the functional activity (see the data in 
the section 1.2.) of dopamine D2 receptors was significantly higher in the 
subcortical structures (including the corpus striatum) of homozygous (-/-) mice 
relative to their wild-type (+/+) littermates. The increased motor stimulating
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effect of amphetamine in CCK2 receptor-deficient mice is consistent with 
previous studies where CCK antagonists were used. The administration of CCK 
into the anterior nucleus accumbens inhibits dopamine-induced hyperloco­
motion, and this effect is mediated via CCK2 receptors (Daugé et al., 1990; 
Crawley et al., 1992). On the other hand, the blockade of CCK2 receptors in the 
nucleus accumbens increases amphetamine-induced dopamine release and 
hyperlocomotion (Altar, Boyar, 1989).
2.3.3. Action of morphine and 
naloxone on locomotor activity (paper IV)
In wild-type (+/+) mice, habituated to the motility boxes for three days, the 
administration of morphine (5 mg/kg i.p.) tended to increase the horizontal 
component of locomotor activity and significantly inhibited the frequency of 
rearing. A higher dose of morphine (10 mg/kg i.p.) induced significant 
hyperlocomotion in the wild-type (+/+) animals. By contrast, in the CCK2 
receptor-deficient mice this dose of morphine induced a significantly weaker 
motor activation. This finding contradicts the study of Pommier et al. (2002) 
demonstrating that in mutant mice the administration of morphine or inhibition 
of enkephalin metabolism induces a significantly stronger hyperlocomotion 
compared to wild-type (+/+) littermates. As mentioned above, the reason for 
these differences could be attributed to the different research design and distinct 
genetic background of mice used in these studies. Also differently from the 
study of Pommier et al. (2002) only a high dose (10 mg/kg i.p.) of naloxone 
reduced the horizontal component in mice not habituated to the motility boxes, 
and this effect was similar in the wild-type (+/+) and mutant mice. 
Nevertheless, a lower dose of naloxone (1 mg/kg i.p.) antagonized the increased 
frequency of rearing established in homozygous (-/-) mice showing that the 
elevation of this behavioural parameter is probably due to the increased function 
of the endopioidergic system in mice lacking CCK2 receptors. Moreover, we 
established that naloxone caused a different effect in the wild-type (+/+) and 
homozygous (-/-) mice adapted to the motility boxes. In these mice a high dose 
of naloxone (10 mg/kg) induced a significant inhibition of locomotor activity in 
homozygous (-/-) but not in wild-type (+/+) mice. Therefore, it is likely that the 
impaired adaptation of CCK2 receptor-deficient mice to the novel environment 
is due to the increased function of the endopioidergic system.
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3. Assessment of nociceptive sensitivity (paper III)
3.1. Plantar-analgesia test (paper Ш)
The testing of heterozygous (+/-) and homozygous (-/-) mice in the plantar- 
analgesia test established a significantly increased hind paw withdrawal latency 
in these mice compared to wild-type (+/+) littermates. The latency was two to 
three times longer in both homozygous (-/-) and heterozygous (+/-) animals 
compared with wild-type (+/+) littermates. The pretreatment of mice with saline 
decreased the nociceptive threshold in all genotypes. However, the subsequent 
statistical analysis established a significant reduction only in mutant mice. The 
administration of morphine (1 mg/kg i.p.), a fi-opioid receptor agonist, induced 
a significant decrease in pain sensitivity in wild-type (+/+) mice compared to 
the injection of saline. However, the antinociceptive effect of morphine (1 
mg/kg) was significantly stronger in homozygous (-/-) CCK2 receptor-deficient 
mice compared to heterozygous (-/+) and wild-type (+/+) mice. Consequently, 
CCK2 receptor-deficient mice display significantly reduced pain sensitivity in 
the plantar-analgesia test, and this effect is probably related to the increased 
sensitivity of ji-opioid receptors.
3.2. Hotplate test (paper III)
In the hotplate test homozygous (-/-) mice also displayed a delayed hind paw 
licking/shaking time compared to wild-type (+/+) littermates. The pretreatment 
of mice with saline similarly reversed this phenomenon in mutant mice if the 
measurement was performed 15 min after the injection. However, when we 
tested the mice 90 min after the treatment with saline, we did not find any 
differences between the saline-injected and untreated homozygous (-/-) mice. 
Also isolation of mice for 30 min attenuated the reduced nociception in 
homozygous (-/-) mice. The experiment performed 24 hours after the last saline 
injection (once daily for 10 days) demonstrated that this manipulation abolished 
the reduced nociception in homozygous (-/-) mice. Differently from the plantar 
test a significantly higher dose of morphine (7,5 mg/kg) was necessary to 
induce a significant antinociceptive effect. However, the antinociceptive effect 
of morphine (5-10 mg/kg) did not differ in mutant and wild-type (+/+) mice 
compared to saline treatment. If the jumping latency was used as a measure of 
nociception, then the results were totally opposite to those established by 
measuring the hind paw licking/shaking response. Namely, the jump latency 
was significantly longer in wild-type (+/+) mice compared to heterozygous 
(-/+) and homozygous (-/-) animals. Accordingly, in the hotplate test, the 
response of mutant mice was exactly related to the endpoint used to determine
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the threshold of nociceptive behaviour. The reduced jump latency established in 
the present study is in good agreement with the study by Pommier et al. (2002).
4. Place conditioning experiments (paper IV)
In the pre-conditioning test the wild-type (+/+) and homozygous (-/-) mice 
preferred to stay in the dark green compartment of the shuttle box. The wild- 
type (+/+) animals spent only 115±15 sec in the pale green compartment, 
whereas the respective value for the homozygous (-/-) animals was 177±22 sec. 
The pairing of the dark and pale green boxes with saline injections did not 
change the preference of animals compared to the pre-conditioning session. The 
pairing of the dark green box with naloxone (1 and 10 mg/kg i.p.) induced a 
significant shift of exploratory activity from the dark to the pale green 
compartment. However, the effect of naloxone was stronger in the wild-type 
(+/+) animals compared with the homozygous (-/-) mice. Already 1 mg/kg of 
naloxone tended to shift the preference in the wild-type (+/+) mice, whereas in 
the homozygous (-/-) mice even the highest dose (10 mg/kg) did not cause any 
significant effect. The highest dose of naloxone (10 mg/kg) induced a 
significant place aversion in the wild-type (+/+) mice because they started to 
prefer the initially non-preferred side. These data are in favour of the 
assumption that the activity of the endopioidergic system in CCK2 receptor- 
deficient mice increases in the neural circuits related to the development of 
place aversion. This could be an explanation why the effect of naloxone, an 
antagonist of opioid receptors, is weaker in mutant mice. The pairing of 
morphine (3 mg/kg) with the pale green compartment induced a significant shift 
of exploratory activity from the dark green to the pale green part both in the 
wild-type (+/+) and homozygous (-/-) mice. However, a higher dose of 
morphine (9 mg/kg) induced a significant effect only in homozygous (-/-) 
mice. Accordingly, the similar effect of morphine in mutant and wild-type (+/+) 
mice shows that the sensitivity of opioid receptors related to the reward system 
is probably not altered due to the targeted mutation of CCK2 receptors in mice.
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DISCUSSION
1. Changes in locomotor activity: evidence for increased 
sensitivity of dopamine D2 receptors (Papers I and II)
1.1. Motor coordination and spontaneous locomotor activity
As expected, the mice lacking the CCK2 receptor gene (-/-) did not have a 
measurable specific binding of [3H]-pCCK-8 in the cerebral cortex and 
subcortical structures. In the heterozygous mutant (+/—) mice, the density of 
CCK receptors was about 30-50% of the corresponding value of the wild-type 
(+/+) animals. In heterozygous (+/-) mice, the affinity of CCK receptors was 
also somewhat reduced compared to wild-type (+/+) animals. This finding is 
different from the study by Nagata et al. (1996), who did not find any difference 
in the affinity of CCK receptors in wild-type (+/+) and heterozygous (+/-) 
animals. We used the saturation of CCK receptors by increasing the 
concentration of [3H]-pCCK-8, whereas Nagata et al. (1996) applied the 
method of single concentration binding study with [,25I]-CCK. Several studies 
have shown that CCK] receptors have a wide distribution in the brain and they 
are not located only in the discrete brain nuclei (Hill at al., 1990; Honda et al.,
1993). However, their density in most brain regions is very low and therefore 
not detectable by the method used in the present study. Mice lacking CCK2 
receptors displayed impaired motor coordination in the rotarod test. Motor 
impairment was stronger in homozygous (-/-) than in heterozygous (+/-) 
animals. On the third day of the study, the difference between wild-type (+/+) 
and heterozygous (+/-) mice disappeared, whereas the performance of 
homozygous (-/-) animals remained poor compared to their wild-type (+/+) 
littermates. The established differences between wild-type (+/+) and mutant 
mice may be related to some extent to the impaired learning abilities of 
homozygous (-/-) CCK2 receptor-deficient mice (Sebret et al., 1999). However 
in our unpublished data the performance of heterozygous (+/-) mice in the 
memory tests did not differ from that of wild-type (+/+). In our first studies the 
locomotor activity of mutant mice was lower compared to wild-type (+/+) 
littermates. However, after the repeated back-crossings of mice into C57B1/6 
background the differences between the genotypes became less evident and 
finally the locomotor activity of mutant mice did not differ from that of their 
wild-type (+/+) littermates. Also the performance of mutant mice in the rotarod 
test improved considerably after back-crossings into C57B1/6 background. It 
has been shown that the performance of C57B1/6 mice is much better in the 
rotarod test compared to 129Sv mice (Homanics et al., 1999). Altogether it 
shows that the effect of targeted mutagenesis of CCK2 receptors on locomotor 
activity is dependent on the genetic background of mice. Therefore, the 
impairment of motor coordination and reduction of locomotor activity, induced
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by the genetic invalidation of CCK2 receptors, is present if the genes from 
129Sv strain dominate over the genes of the C57B1/6 strain. Despite this 
significant improvement in locomotor activity of CCK2 receptor-deficient mice 
we were unable to find that the horizontal component of locomotor activity of 
mutant mice, not habituated to the motility boxes, is increased compared to their 
wild-type (+/+) littermates. Only the frequency of rearing was higher in mice 
without CCK2 receptors. A repeated exposure of mice to the motility boxes 
caused a significant reduction of locomotor activity in wild-type (+/+) mice. 
The latter behavioural change was significantly weaker in the animals lacking 
CCK2 receptors. This difference can be explained in the light of the suggestion 
that CCK is an important factor in the adaptation of rodents to a novel 
environment. Namely, the administration of CCK antagonizes morphine- 
induced antinociception in a novel, but not in a familiar environment (Wiertelak 
et al., 1992). Therefore, lack of CCK2 receptors apparently attenuates normal 
adaptation to a novel environment. As stated above, the learning ability of the 
mice without CCK2 receptors is significantly affected in the T-maze and in the 
Morris water-maze tests (Sebret et al., 1999, our unpublished data). CCK2 
receptor-deficient mice display an impaired response in these learning tasks. 
However, it is unclear whether the affected adaptation to a novel environment 
and diminished learning abilities are linked to the same neurochemical changes 
in these mice.
1.2. Amphetamine-induced hyperlocomotion and 
apomorphine-induced hypolocomotion
The effect of apomorphine and amphetamine was studied twice. In the first 
experiment (paper П) we found that the response of CCK2 receptor-deficient 
mice to the administration of dopamine agonists, amphetamine and 
apomorphine, was significantly altered. Treatment with a low dose (0.1 mg/kg) 
of apomorphine, an agonist of dopamine Di/D2 receptors, reduced the loco­
motor activity in wild-type (+/+) mice. This effect is linked to the stimulation of 
dopamine autoreceptors located on the dopamine neurones (Meltzer, 1980). 
However, the motor suppressant action of apomorphine was apparently stronger 
in mice, lacking CCK2 receptors. This finding is in good agreement with our 
previous studies, where the pre-treatment with CCK2 receptor antagonist 
L-365,260 potentiates the motor suppressant action of apomorphine in male 
mice (Vasar et al., 1991). Electrophysiological studies in rats demonstrated that 
the acute and long-term administration of LY262691 and related pyrazolidinone 
CCK2 antagonists, decreased the number of spontaneously active dopamine 
cells in the midbrain structures, probably via action in the nucleus accumbens 
and prefrontal cortex (Rasmussen et al, 1993). The other dopamine agonist 
amphetamine increases the release of dopamine from the presynaptic terminals
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(Kuczenski, 1983) and thus stimulates the pre- and postsynaptic dopamine 
receptors. The administration of amphetamine (3-6 mg/kg) induces dose- 
dependent locomotor stimulation in wild-type (+/+) mice. However, in mice 
lacking CCK2 receptors a lower dose (3 mg/kg) of amphetamine reduces the 
number of rearing, whereas a higher dose (6 mg/kg) causes significantly 
stronger locomotor stimulation compared to wild-type (+/+) animals. The 
reduced effect of lower dose of amphetamine could be related to the increased 
sensitivity of dopamine autoreceptors in mutant mice established in the studies 
with apomorphine, whereas the increased effect of a higher dose of ampheta­
mine seems to be related to the increased sensitivity of post-synaptic dopamine 
receptors. Indeed, the affinity of dopamine D2 receptors labelled by [3H]- 
spiperone is significantly increased in the forebrain subcortical regions of CCK2 
receptor-deficient mice. This finding is in accordance with the experiments by 
Ferraro et al. (1996) showing that the application of CCK-8s to the striatal 
membranes reduces the affinity of dopamine D2 receptors, and this effect is 
counteracted by the CCK2 receptor antagonist PD134308. By contrast, the 
affinity of 5-HT2 receptors is not affected in male mice lacking CCK2 receptors. 
In the second experiment (paper I) the treatment with a low dose (0.1 mg/kg) of 
apomorphine caused the same reduction of locomotor activity in wild-type (+/+) 
mice as in the first study. It should be noted that this dose of apomorphine did 
not cause any sign of stereotyped behaviour. As in the first study, the motor- 
depressant effect of apomorphine (0.1 mg/kg) was apparently stronger in 
heterozygous (+/-) and homozygous (-/-) CCK2 receptor-deficient mice com­
pared to their wild-type (+/+) littermates. The administration of amphetamine 
(3 and 6 mg/kg) again induced a dose-dependent motor stimulation in wild-type 
(+/+) mice as in the previous study. And again, the impact of amphetamine in 
the mutant mice differed from that seen in wild-type (+/+). In heterozygous 
(+/-) mice, a lower dose of amphetamine (3 mg/kg) tended to increase the 
motor activity, but the higher dose of this indirect dopamine agonist (6mg/kg) 
had the same effect as in wild-type (+/+) animals. In homozygous (-/-) mice the 
effect of amphetamine (3-6 mg/kg) on locomotor activity was exactly the same 
as in the previous study. A lower dose of amphetamine (3 mg/kg) reduced the 
number of rearing but did not affect the other parameters of locomotor activity. 
The treatment with a higher dose (6 mg/kg) of amphetamine induced a signi­
ficant increase in two parameters of locomotor activity: the distance travelled 
and number of comer entries. It should be noted that the effect of a higher dose 
(6 mg/kg) of amphetamine in homozygous (-/-) animals on these parameters 
was significantly different from that seen in heterozygous (+/-) and wild-type 
(+/+) animals. Despite the behavioural changes we did not find any significant 
difference in the content of dopamine and serotonin, and their metabolites in 
three brain structures of wild-type (+/+) and homozygous (-/-) mice. Only the 
concentration of dopamine and its major metabolite homo vanillic acid (HVA) 
tended to be somewhat lower in mutant mice (Kõks et al., 2001). Corwin et al.
(1995) showed that the local administration of CI-988, an antagonist of CCK2
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receptors, increases the levels of dopamine in the nucleus accumbens without 
changing dopamine metabolites (DOPAC and HVA). However, this effect was 
apparent only at high concentrations of CI-988, lacking specificity for the 
CCK2 receptors. Therefore, the increase in the action of amphetamine could be 
related to the increased sensitivity of the postsynaptic dopamine receptors in the 
forebrain structures. Indeed, the density of dopamine D2 receptors was 
significantly increased in the striatum of homozygous (-/-) mice compared to 
their wild-type (+/+) littermates. In heterozygous (+/-) mice, the density of 
dopamine D2 receptors was also somewhat elevated in the striatum. By contrast, 
the density of serotonin 5-HT2 receptors in the cerebral cortex was not different 
in homozygous (-/-) and heterozygous (+/-) mice compared to wild-type (+/+) 
animals. The increased motor stimulating effect of amphetamine in CCK2 
receptor-deficient mice is consistent with the previous studies of CCK antago­
nists. The administration of CCK into the anterior nucleus accumbens inhibits 
dopamine-induced hyperlocomotion, and this effect is mediated via CCK2 
receptors (Daugé et al., 1990; Crawley 1992). On the other hand, the blockade 
of CCK2 receptors in the nucleus accumbens increases amphetamine-induced 
dopamine release and hyperlocomotion (Altar and Boyar 1989).
Altogether, the results of two independent studies demonstrate that the 
targeted mutation of CCK2 receptor gene induces significant changes in the 
motor performance of animals. The performance of CCK2 receptor-deficient 
mice was impaired in the rotarod test and their general locomotor activity 
tended to be reduced. However, as noted above this motor impairment and the 
inhibition of locomotor activity in the CCK2 receptor-deficient mice largely 
depends on the genetic background of mice. Moreover, the motor suppressant 
action of a small dose of apomorphine was stronger in mutant mice and 
homozygous (-/-) animals displayed an increased response to the administ­
ration of a higher dose of amphetamine. A clear gene-dose effect is evident 
from these studies since the rotarod performance is the most impaired in 
homozygous (-/-) mice, and an increased response to amphetamine-induced 
locomotor stimulation is also established in mice lacking CCK2 receptors. 
Although we did not find any major differences in the metabolism of dopamine 
in three brain structures, these changes in the behaviour seems to be related to 
the above-established changes in the dopaminergic system. One possible reason 
for not finding any differences in the metabolite content could be the detection 
limits of post-mortem HPLC analysis of 'crude' brain regions. Therefore, more 
sensitive techniques (in vivo microdialysis for example) should be used for 
further analysis. The reduced locomotor activity, impaired motor performance 
in the rotarod test, and the increased response to apomorphine-induced motor 
suppression are probably related to the increased sensitivity of the presynaptic 
dopamine receptors. The increased response to amphetamine in homozygous 
(-/-) animals is probably related to the increased sensitivity of the postsynaptic 
dopamine receptors as confirmed in radioligand binding studies. It is therefore 
obvious that targeted mutation of CCK2 receptors leads to compensatory
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changes in the activity of dopaminergic system, for the sensitivity of both pre- 
and postsynaptic dopamine receptors is increased.
2. Changes in pain sensitivity and morphine-induced 
antinociception: evidence for altered function 
of the endopioidergic system (Paper III)
A major finding of pain sensitivity studies is that the nociceptive response of 
mice lacking CCK2 receptors depends on the paradigm used for the mea­
surement of pain sensitivity. In the plantar-analgesia test, the pain sensitivity of 
heterozygous (+/-) and homozygous (-/-) mice was significantly lower 
compared to wild-type (-/-) littermates. In the hotplate test, the response of 
mutant mice was related to the point used to determine the threshold for painful 
stimuli. If the hind paw licking/shaking was used as the endpoint, homozygous 
(-/-) mice had a significantly delayed response to the noxious influence. The 
situation was completely different when we used jump latency as the threshold. 
The jump latency of wild-type mice (ч-/+) was significantly longer compared to 
heterozygous (+/-) and homozygous (-/-) mutant animals. It is important to 
note that heterozygous (+/-) animals, having 50% of CCK2 receptors left, have 
a clear phenotype both in the plantar-analgesia and hotplate tests. In the plantar- 
analgesia test these mice responded similarly to homozygous (-/-) mice while 
in the hotplate test their response profile was closer to that in wild-type (+/+) 
littermates. In the jump latency experiment the heterozygous (+/-) mice reacted 
again like their homozygous (-/-) littermates. It is remarkable for heterozygous 
(+/-) animals, differently from homozygous (-/-) mice, do not have any 
disturbances in the development of gastric mucosa (Nagata et al., 1996), which 
may potentially interfere with the pain sensitivity in mice without CCK2 
receptors. The reduced jump latency is in good agreement with a recent study 
by Pommier et al., (2002), where wild-type (+/+) and homozygous (-/-) mice 
were compared. Nevertheless, it is unclear whether the jump latency is a true 
threshold to the pain stimuli. Wilson and Mogil (2001) believe that the best 
endpoint in the mouse is almost always hind paw licking or vigorous shaking, 
whichever occurs first. Hotplate-naive mice very rarely jump until long after 
they have responded in another way (Wilson, Mogil, 2001). The jump response 
is considered as a measure of pain tolerance, and it is heavily influenced by 
morphine (Frederickson et al., 1977; Bar-Or, Brown, 1989). This behavioural 
response is clearly an escape from the noxious stimuli and therefore involves 
more complex neural circuits (probably involving fear, anxiety, and central 
motor circuits) than hind paw licking/shaking. The reduced jump latency along 
with the increased pain thresholds in the plantar-analgesia and hotplate tests 
could be explained as a compensatory reaction to reduced pain sensitivity in
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mice lacking CCK2 receptors. Otherwise, these animals would inflict significant 
injuries due to the inadequate response to the noxious stimuli. Distinct 
behavioural responses in the models of pain sensitivity are also established in 
the animals lacking the other genes related to the regulation of nociceptive 
behaviour. The animals lacking pre-pro-enkephalin, tachykinin-1, and cannabi- 
noid receptor CB1 genes were all reported to display altered sensitivity in the 
hotplate test but unchanged sensitivity in the tail-flick test (König et al., 1996; 
Zimmeret al., 1998, 1999).
Another interesting finding of the present study is that the reduced pain 
sensitivity in mice lacking CCK2 receptors is affected by the administration of 
saline and isolation of mice for 30 min. The treatment with saline and isolation 
of mice attenuates the reduced pain sensitivity in mutant mice. It is worth noting 
that the effect was measured at 15 min, but not at 90 min, after the 
administration of saline in the hotplate test. Accordingly it has been shown that 
after saline injection there occur significant changes in the CCK system in the 
prefrontal cortex of experimental animals. Namely, the release of CCK is 
significantly diminished at 20 minutes after saline injection (Radu et al., 2001). 
Evidence suggests that CCK receptor antagonist proglumide antagonizes 
nocebo hyperalgesia induced by saline in humans (Benedetti et al., 1997). 
Moreover, Drago et al. (2001) found that the administration of saline increases 
the immobility of rats in the forced swimming test. It has been suggested that 
catecholamines and endorphins may play a role in the saline effect in the forced 
swimming test (Drago et al., 2001). Nevertheless, the background of saline- 
induced algesia remains unclear but could also be attributed to the previous 
findings that stressful factors affect the interaction between CCK and morphine 
in behavioural experiments. It has been shown that the administration of CCK 
antagonizes morphine-induced antinociception in a novel but not in a familiar 
environment (Wiertelak et al., 1992). The same is true about the potentiation of 
morphine-induced antinociception by the CCK2 receptor antagonists (Lavigne et 
al., 1992). This could be linked to the fact that CCK is also involved in the 
regulation of anxiety (Harro et al., 1993b). Indeed, CCK agonists induce an 
anxiogenic-like action in an unfamiliar stressful but not in a safe environment 
(Kõks et al., 2000a). The combination of sub-threshold doses of CCK agonists 
and opioid antagonist (naloxone) induces a significant neophobia in rats in the 
elevated plus-maze (Kõks et al., 1998). Therefore, it is possible that CCK and 
endopioid peptides play an opposite role in the adaptation to a novel environ­
ment. CCK signals that the environment is unsafe, whereas the endopioidergic 
system mediates the information that there is no danger in the surrounding 
environment (Kõks et al., 1998; 2000b). This could explain why the baseline 
pain sensitivity of mice without CCK2 receptors is reduced. Repeated treatments 
with saline increase alcohol consumption in low preference mice, and the effect 
of saline is blocked by the administration of CCK2 receptor antagonist 
CAM 1028 (Little et al., 1999). This is probably not linked to the anxiolytic 
action of CAM 1028 because diazepam (1 mg/kg) was ineffective under these
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circumstances. In agreement with this finding we found that repeated treatment 
with saline (once daily for 10 days) abolished the reduced nociception in mice 
lacking CCK2 receptors. Accordingly, it is obvious that the repeated stressful 
manipulations reverse the reduced nociception in CCK2 receptor-deficient mice.
The effect of morphine, ц-opioid receptor agonist, also depends on the 
approach used. In the plantar-analgesia test the antinociceptive effect of 
morphine ( 1 mg/kg) in homozygous (-/-) mice is significantly higher compared 
to wild-type (+/+) littermates. This is in good agreement with the previous 
studies where the administration of CCK2 receptor antagonists or use of CCK2 
receptor antisense potentiates morphine-induced antinociception in rodents 
(Vanderah et al., 1994; 1996). In the hotplate test a significantly higher dose of 
morphine (7.5 mg/kg) is necessary to induce the antinociceptive effect, and 
there is no difference in the action of opioid agonist in wild-type (+/+) and 
mutant mice. Pommier et al. (2002) established the reduction of opioid 
receptors on the supraspinal level in CCK2 receptor-deficient mice. We 
measured the density of opioid receptors by [3H]-diprenorphine in four 
forebrain structures (cerebral cortex, hippocampus, striatum, and mesolimbic 
area) and at least in these structures no decline in the density of opioid receptors 
can be observed. Indeed, the number of opioid receptors is elevated in the 
striatum of mutant mice, whereas the other structures reveal no difference in the 
density of receptors between the homozygous (-/-) and wild-type (+/+) animals. 
On the other hand, the affinity of opioid receptors is decreased in the striatum. 
This could be in favour of the initial idea of Pommier et al. (2002) that the 
levels of endopioid peptides are increased in certain brain regions, and therefore 
the affinity of opioid receptors is decreased. In contrast to the striatum the 
affinity of opioid receptors tended to be increased in the cerebral cortex of 
mutant mice compared to wild-type (+/+) littermates. Accordingly, the targeted 
mutation of CCK2 receptors affects differently the parameters of opioid 
receptors in the forebrain structures. The distinct changes in the sensitivity of 
opioid receptors in various brain structures may explain why the effect of 
morphine is increased in the plantar-analgesia test but remains unchanged in the 
hotplate test in CCK2 receptor-deficient mice. Pommier et al. (2002) showed 
that mutant mice revealed not only a reduced latency to jump, but their response 
to the anti-jumping effect of morphine was also reduced, which in turn may 
reflect the increased function of some anti-opioid systems in the brain. Indeed, 
Pommier et al. (2002) demonstrated the role of NMDA receptors as they found 
that MK-801, an antagonist of NMDA receptors, effectively reversed the 
increased response of CCK2 receptor-deficient mice.
Altogether, we established a reduced pain sensitivity of CCK2 receptor- 
deficient mice in the plantar-analgesia and hotplate tests. However, CCK2 
receptor-deficient mice seem to have a reduced tolerance to pain stimuli as 
measured by the jump latency in the hotplate test. Moreover, a clear dissociation 
of morphine effects is present in mice lacking CCK2 receptors. In the plantar- 
analgesia test the antinociceptive action of morphine is significantly stronger in
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mutant mice, whereas in the hotplate test the effect of ц-opioid receptor agonist 
remains unchanged compared with wild-type (+/+) littermates. In the jump 
latency test, as we consider it the measure of pain tolerance, the effect of 
morphine is significantly reduced in CCK2 receptor-deficient mice compared to 
wild-type (+/+) littermates (Pommier et al., 2002). The molecular background 
of these phenomena is unclear but could be explained in the light of the data 
that the targeted mutation of CCK2 receptors induces distinct changes in the 
properties of opioid receptors in various brain structures.
3. Changes in behavioural effects of morphine and naloxone: 
further support for affected function 
of the endopioidergic system (Paper IV)
In wild-type (+/+) mice, habituated to the motility boxes, the administration of 
morphine (5 mg/kg) tended to increase the horizontal component of locomotor 
activity and significantly inhibited the frequency of rearing. A higher dose of 
morphine (10 mg/kg) induced a significant hyperlocomotion in wild-type (+/+) 
animals. By contrast, in the CCK2 receptor-deficient mice this dose of morphine 
induced a significantly weaker motor activation. This finding contradicts the 
study by Pommier et al. (2002) demonstrating that the administration of 
morphine and the inhibition of enkephalin metabolism increases locomotor 
activity in mice without CCK2 receptors. The reason for these differences is 
unclear but could be attributed to the different research design and distinct 
genetic background of mice used in different studies. Differently from the study 
by Pommier et al. (2002) only a high dose (10 mg/kg) of naloxone reduced the 
horizontal component of locomotor activity in mice, and the effect was similar 
in wild-type (+/+) and mutant mice. Nevertheless, a lower dose of naloxone 
(1 mg/kg) antagonized the increased frequency of rearing established in the 
homozygous (-/-) mice showing that the elevation of this behavioural 
parameter is probably due to the increased function of the endopioidergic 
system in mice lacking CCK2 receptors. Moreover, we established that naloxone 
caused a different effect in the wild-type (+/+) and homozygous (-/-) mice 
adapted to the motility boxes. In these mice a high dose of naloxone (10 mg/kg) 
induced a significant inhibition of locomotor activity in the homozygous (-/-) 
but not in the wild-type (+/+) mice. It has been shown that naloxone at this high 
dose is lacking selectivity for the subtypes of opioid receptors (Tsuda et al.
1996). Therefore, it is likely that the impaired adaptation of CCK2 receptor- 
deficient mice to a novel environment is due to the increased function of the 
endopioidergic system.
Morphine (3 mg/kg) induces a similar effect both in the wild-type (+/+) and 
homozygous (-/-) mice in the conditioned place preference test by increasing
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the time spent in the drug-associated compartment during the post-conditioning 
phase. It should be noted that the pre-conditioning preference of animals for 
dark side of the compartment was very strong. This biased design has often 
been criticized because it may lead to false-positive results in the place 
conditioning test (Tzschentke et al., 1998). For example, the drugs with a strong 
anxiolytic action may overcome the initial aversion for the non-preferred 
compartment. Several steps were taken to minimize the problem linked to the 
biased design. The animals having a significantly different response profile in 
the pre-conditioning session were excluded from further experiments. The effect 
of morphine was not compared with the pre-conditioning session but with a 
group of animals receiving saline injections in both compartments. Indeed, the 
response of mice after saline treatments did no differ from that seen during the 
pre-conditioning session. During the conditioning session half of the animals 
received saline treatment as the first daily injection, whereas the other half were 
at first treated with morphine. Our previous studies had shown that morphine 
induced an anxiolytic-like action in rats (Kõks et al., 1998; 1999). However, 
morphine was effective in the elevated plus-maze and zero-maze when studied 
in rats that had not been handled and exposed repeatedly to the experimental 
room (Kõks et al., 2000b). Therefore, we tested the action of morphine (3 
mg/kg) in the non-habituated wild-type (+/+) mice using the dark-light 
exploration paradigm, and no increase in exploratory activity was established 
(our unpublished data). Accordingly, the described shift in the behaviour of 
mice in the place preference test is not linked to the anxiolytic-like properties of 
morphine. The results of the present study differ from the data of the 
pharmacological experiments where the blockade of CCK2 receptors induced a 
significant potentiation of morphine-induced place preference in rats (Higgins et 
al., 1992; Valverde et al., 1996). The compensatory changes in the other 
neurotransmitter systems due to the complete inactivation of CCK2 receptors 
may explain this discrepancy.
Moreover, the present study established dissociation in the action of 
morphine in the motor activity and place preference tests. It is noteworthy that a 
significantly lower dose of morphine was effective in the place preference test 
compared to the locomotor activity study. It is possible that the distinct neural 
circuits are responsible for these two behavioural effects of morphine. The 
stronger effect of morphine on the locomotor activity in the wild-type (+/+) 
mice may be a reason why a higher dose of morphine causes a weaker effect in 
the place preference studies in the wild-type (+/+) mice compared to mutant 
animals. Increased motor stereotypy (psychosis-like behaviour) in the wild-type 
(+/+) mice under the influence of morphine may cause impaired perception of 
the surrounding environment and reduce the conditioning to the drug-paired 
environment in comparison with the mutant animals. Interestingly, Maldonado 
et al., (1997) described dissociation between the opioid-mediated motor and 
motivational responses in mice lacking dopamine D2 receptors. They 
established that morphine-induced place preference was absent in these mice,
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whereas morphine-induced hyperlocomotion remained unchanged compared 
with the wild-type (+/+) mice. This study clearly demonstrates the role of 
dopamine D2 receptors of the nucleus accumbens in the mediation of the 
rewarding effects of morphine, whereas dopamine Dj receptors and non- 
dopaminergic mechanisms are responsible for the opioid-induced enhancement 
of locomotion (Kalivas et al., 1983; Longoni et al., 1987; Daugé et al., 1989; 
Maldonado et al., 1997).
In the place conditioning experiments a lower dose of naloxone (1 mg/kg) 
tended to cause a conditioned place aversion in the wild-type (+/+) mice, 
whereas a high dose of opioid antagonist (10 mg/kg) caused significant place 
aversion. By contrast, naloxone-induced place aversion was weaker in mice 
without CCK2 receptors because a high dose of naloxone (10 mg/kg) only 
tended to shift the behaviour of mutant mice from the non-preferred to the 
preferred side. Consequently, there is also dissociation in the behavioural effects 
of naloxone in the CCK2 receptor-deficient mice. These data may also reflect an 
increased tone of the endopioidergic system in the neural circuits responsible 
for the development of place aversion in mutant mice. It was shown that 
naloxone (10 mg/kg) failed to produce conditioned place aversion in ц-opioid 
receptor-deficient mice, whereas the effect of к-opioid agonist U50,488H 
remained unchanged (Skoubis et al., 2001). This finding obviously supports the 
involvement of ц-opioid receptors in the mediation of naloxone-induced place 
aversion. This behavioural phenomenon can be induced by the local 
administration of naloxone into the ventral tegmental area and nucleus 
accumbens but,not into the striatum and medial prefrontal cortex (Shippenberg, 
Bals-Kubik, 1995). Recent evidence suggests that naloxone-induced action is 
not linked only to the mesolimbic dopaminergic system because the blockade of 
ц-opioid receptors in the dorsal periaqueductal grey matter causes the conditio­
ned place aversion (Santé et al., 2000). We did not find any differences in the 
density of opioid and dopamine D2 receptors in the mesolimbic area, but we 
established, as stated above, a significant reduction in pain sensitivity in the 
CCK2 receptor-deficient mice. The role of periaqueductal grey matter in the 
regulation of pain sensitivity is well established (Mason, 1999). Therefore, it is 
tempting to speculate that the increased tone of the endopioidergic system in 
this brain region could be linked to the reduced effect of naloxone in 
homozygous (-/-) mice. To some extent this study tends to support the finding 
of pharmacological experiments showing that CCK2 receptor antagonists 
attenuate naloxone-induced place aversion in rats (Valverde, Roques, 1998).
Once again we were unable to repeat the results of radioligand binding 
studies performed by Pommier et al. (2002). First, they found that the number 
of opioid receptors was decreased if measured in the whole brain of CCK2 
receptor-deficient mice in in vivo conditions. Pommier et al. (2002) suggested 
that this effect was due to the increased levels of endopioid peptides in the brain 
of homozygous (-/-) mice. Second, in in vitro studies they did not found any 
changes in the parameters of opioid receptors if the cell membranes were
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prepared from the whole brain (Pommier et al., 2002). We measured the density 
of opioid receptors by [3H]-diprenorphine in four distinct forebrain structures 
(cerebral cortex, striatum, mesolimbic area, and hippocampus), and at least in 
these structures no decline in the density of opioid receptors was observed. 
Indeed, the number of opioid receptors was elevated in the striatum of mutant 
mice, whereas the other structures show no difference in the density of receptors 
between the homozygous (—/—) and wild-type (+/+) animals. On the other hand, 
the affinity of opioid receptors was reduced in the striatum. The reduced affinity 
of opioid receptors in the striatum could support the initial idea of Pommier et 
al. (2002) that the levels of endopioid peptides are increased in certain brain 
regions, and therefore the affinity of opioid receptors is decreased. A micro­
array study was performed in the striatum in order to reveal the differences 
between the wild-type (+/+) and homozygous (-/-) mice in the gene expression 
(our unpublished data). Accordingly the expression of the ц-opioid receptor 
gene was increased, whereas the expression of pre-proenkephalin, a precursor 
molecule of enkephalins, and nociceptin genes was reduced. In contrast with the 
striatum the affinity of opioid receptors was increased in the cerebral cortex of 
mutant mice compared to wild-type (+/+) littermates. Accordingly, the targeted 
mutation of CCK2 receptors affects differently the parameters of opioid 
receptors in the forebrain structures. These distinct changes in the sensitivity of 
opioid receptors in various brain structures may explain the dissociation of 
behavioural effects of morphine and naloxone described in animals without 
CCK2 receptors. The mesolimbic structures, and especially the nucleus 
accumbens, are targets for the rewarding effect of morphine (Maldonado et al.,
1997). However, we did not find any differences in the parameters of opioid 
receptors in the mesolimbic area, and no change in morphine-induced place 
preference was established when the wild-type (+/+) and mutant mice were 
compared. Maldonado et al. (1997) demonstrated the role of dopamine D2 
receptors in the nucleus accumbens for the motivational effects of morphine. As 
stated above, we did not find any significant differences in the density of 
dopamine D2 receptors in the mesolimbic area of wild-type (+/+) and CCK2 
receptor-deficient mice. Accordingly, the reduction of morphine-induced motor 
stimulation in mutant mice has to be explained by other mechanisms than 
opioid and dopamine D2 receptors in the mesolimbic structures. It could be 
associated with changes in the parameters of opioid receptors in the striatum 
where the increased number and reduced affinity was found. This may reflect an 
increased tone of the endogenous opioid system in the striatum and could 
explain the reduced morphine-induced motor stimulation in mice without CCK2 
receptors. Altogether, the distinct changes of opioid receptors in the striatum 
and mesolimbic area are most likely linked to the dissociation of behavioural 
effects of morphine in CCK2 receptor-deficient mice.
In conclusion, the results of our study support to some extent the initial idea 
of Pommier et al. (2002) that the activity of the endopioidergic system is 
increased due to the targeted invalidation of CCK2 receptor gene in mice.
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However, in these mice a clear dissociation of the effects of both morphine and 
naloxone occurs if different behevioumal paradigmas are employed. The 
molecular background of this phenomenon is unclear but could be explained in 
the light of the data that the targeted mutation of CCK2 receptors induces 
distinct changes in the properties of opioid receptors in various brain structures.
4. Concluding remarks and suggestions for further studies
Finally, it is time to summarise the major findings of the present thesis (Table 
2). Indeed, the present study clearly shows that the targeted mutation of the 
CCK2 receptor gene induces substantial alterations in the function of the 
dopamine- and endopioidergic system. Actually this is not surprising because 
CCK is co-localised with dopamine and endopioid peptides within the same 
neurones and brain regions (Hökfelt et al., 1980a,b; Gall et al., 1987). Despite 
some discrepancies the results of the present study are in accordance with the 
experiments conducted by Daugé and colleagues (Daugé et al., 2001a,b; 
Pommier et al., 2002). However, it should always be kept in mind that two 
mouse lines 129Sv and C57B1/6, differing markedly by their behavioural and 
neurochemical parameters, are used for the generation of genetically modified 
animals. Therefore, the background of genetically modified mice has to be 
considered if their biochemical and behavioural phenotype is analysed. It does 
mean that the behavioural and biochemical phenotype should be studied in the 
different stages of moving from 129Sv to C57B1/6 genetic background and, of 
course, the experiments have to be repeated several times in order to avoid 
false-positive results. Indeed, we found significant changes in the motor coordi­
nation and locomotor activity of mice at the beginning of our studies with the 
dominating 129Sv genotype. It is well documented that the performance of 
129Sv mice in the motor coordination and locomotor activity test is 
significantly inhibited compared to C57B1/6 mice (Homanics et al., 1999; 
Võikar et al., 2001). The back-crossings to the C57B1/6 genetic background 
apparently attenuated disturbances in the motor performance of mice lacking 
CCK2 receptors. In this respect our findings are in good agreement with a 
number of previous studies showing that the genetic background plays a major 
role in the behavioural and biochemical phenotype of genetically modified mice 
(Tang et al., 2001; Võikar et al., 2001; Gerlai 2002a,b,c; Vyssotsky et al., 
2002). As a matter of fact, only a part, but not all, of the effects induced by the 
targeted mutation of CCK2 receptors are dependent on the genes of 129Sv mice.
As mentioned above, the behavioural and biochemical analysis revealed 
significant alterations in the activity of the dopamine- and endopioidergic 
system in CCK2 receptor-deficient mice. It is important to stress that changes 
occurring in these two neurotransmitter systems are not similar throughout the
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brain because these established alterations are localized in discrete brain 
regions. The radioligand binding studies detected significant changes in the 
parameters of dopamine D2 receptors in the striatum but not in the mesolimbic 
area. Moreover, the pharmacological studies demonstrated that the sensitivity of 
both pre- and postsynaptic dopamine receptors is increased in mice lacking 
CCK2 receptors. The increased affinity of presynaptic dopamine receptors 
explains not only the increased hypolocomotion induced by apomorphine, an 
agonist of dopamine receptors, but it could explain why a low dose of 
amphetamine tended to reduce the exploratory activity in mutant mice. It is 
noteworthy that the levels of dopamine and its major metabolite homo vanillic 
acid are somewhat lower in the striatum of CCK2 receptor-deficient mice (Kõks 
et al., 2001), and this change can also be attributed to the increased function of 
presynaptic dopamine receptors. The significantly stronger amphetamine- 
induced hyperlocomotion together with the increased binding of [3H]-spiperone 
in the striatum are in favour of the increased sensitivity of postsynaptic dopa­
mine D2 receptors in mutant mice. On the other hand, the membrane potential of 
dopamine-containing neurones and release of dopamine from presynaptic 
terminals are not affected directly by morphine, the agonist of ц-opioid 
receptors. The increased release of dopamine, induced by morphine is caused 
via the inhibition of afferent GABA-containing neurones in the midbrain and 
reduced release of GABA from presynaptic terminals (Johnson, North, 1992). 
Recent evidence suggests that the activity of the GABAergic system is 
increased in the brain of mice lacking CCK2 receptors (Raud et al., 2003), and 
this may be a reason for the reduced effectiveness of morphine in inducing 
hyperlocomotion in mutant mice.
The changes in pain sensitivity and dissociation of behavioural effects of 
morphine in mice lacking CCK2 receptors are in favour of distinct changes in 
the endopioidergic system in the brain. This statement is confirmed by the 
radioligand binding studies showing that the parameters of opioid receptors are 
affected in the striatum and cerebral cortex but not in the other structures. 
Nociceptive response of homozygous (-/-) mice is reduced in the plantar- 
analgesia and hotplate test, but their response is significantly augmented if the 
jumping response in the hotplate test is used as the endpoint of nociceptive 
behaviour. Therefore, it is likely that CCK2 receptor-deficient mice have 
decreased pain sensitivity but reduced pain tolerance. Moreover, the anti­
nociceptive effect of morphine is significantly increased in the plantar-analgesia 
test, not changed in the hotplate test, and apparently reduced in the jumping test 
(Pommier et al., 2002). In the experiments where the adaptation of mice to the 
motility boxes, was studied, the altered function of the endopioidergic system 
was confirmed. CCK2 receptor-deficient mice demonstrated decreased 
adaptation to the motility boxes and this effect was antagonized by the 
administration of naloxone, an antagonist of opioid receptors. The dissociation 
of behavioural effects of morphine in mice lacking CCK2 receptors was also 
evident in other behavioural tests. The place conditioning induced by
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morphine was unaffected, whereas morphine-induced hyperlocomotion was 
significantly lower in the genetically reduced mice. These findings are in good 
agreement with the study by Maldonado et al. (1997) showing that the described 
behavioural effects of morphine are mediated via distinct dopaminergic 
mechanisms. Indeed, we found changes in opioid and dopamine D2 receptors in 
the striatum but not in the mesolimbic structures. This may be a likely reason 
for the dissociation of behavioural effects of morphine in CCK2 receptor- 
deficient mice. There is also a difference in positively and aversively motivated 
behaviour in these mice. Differently from the place conditioning effect of 
morphine, naloxone-induced place aversion is apparently reduced in homo­
zygous (-/-) mice compared to their wild-type (+/+) littermates. One possible 
explanation is that the effects of morphine and naloxone are mediated via 
different neural circuits displaying different changes in the activity of the 
endopioidergic system. On the other hand, according to our recent study, 
anxiety of CCK2 receptor-deficient mice is reduced compared to their wild-type 
(+/+) littermates (Raud et al., 2003). Kõks et al. (1998) have shown that the 
administration of CCK-4, a selective agonist of CCK2 receptors, and naloxone 
at subeffective doses induces a significant anxiogenic-like action in rats. 
Therefore, the reduced anxiety could be a possible reason for the decreased 
effectiveness of naloxone in inducing a place aversion in mutant mice.
One might ask whether CCK2 receptor-deficient mice can be used for the 
pre-clinical screening of new drugs. Concerning the distinct changes in the 
activity of the dopamine- and endopioidergic system at least three different 
groups of drugs, including antipsychotic, analgetic, and anti-addictive com­
pounds, can be evaluated using these genetically modified mice. Indeed, further 
research has to be planned and performed in this direction. For example, the 
behavioural and biochemical effects of distinct groups of antipsychotic drugs 
(including haloperidol, raclopride, and clozapine) should be explored in these 
mice. It is interesting that patients suffering from schizophrenia have an 
increased sensitivity of the dopamine receptors and an enhanced response to the 
psychotomimetic action of amphetamine (Gainedtinov et al., 2001). This is 
exactly the same what we have established in mice lacking CCK2 receptors. 
Taking into account the distinct changes in the effectiveness of morphine in the 
models of nociception and place preference, it is of a great interest to explore 
the effects of drugs affecting pain sensitivity and motivational responses in mice 
without CCK2 receptors. The drugs interacting with the CB1 cannabinoid 
receptors are of particular interest. Moreover, there is some evidence that CB1 
cannabinoid receptors are expressed predominantly by axons of CCK- 
containing inter-neurones in the hippocampus, amygdala, and neocortex, and 
that reduction of GABA and CCK release occures when there receptores are 
activated (Freund, 2003). In conclusion, we believe that this model can be of 
great interest for the pre-clinical screening of new drugs interacting with the 
neurotransmitter systems mediating nociception, motivational responses, and 
psychotic behaviour.
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Table 2. Established changes in the function of the dopamine- and endopioidergic 
system due to genetic invalidation of CCK2 receptors
Established change in 
the function
Characteristic behavioural and biochemical features
1. Increase in the 
activity of the 
dopaminergic system
2. Partial increase in 
the activity of the 
endopioidergic system
3. Partial reduction in 
the activity of the 
endopioidergic system
1. Elevated number of dopamine receptors in the striatum
2. Enhanced apomorphine-induced hypolocomotion 
(increased sensitivity of presynaptic dopamine receptors)
3. Enhanced amphetamine-induced hyperlocomotion 
(increased sensitivity of postsynaptic dopamine receptors)
1. Increased number of ц-opioid receptors in the striatum
2. Increased affinity of ц-opioid receptors in the cerebral 
cortex
3. Reduced pain sensitivity and increased effect of morphine 
in the plantar-analgesia test (increased sensitivity of opioid 
receptors)
4. Reduced adaptation to the novel environment antagonised 
by naloxone, an antagonist of opioid receptors
5. Reduced effectiveness of naloxone in place aversion test
1. Reduced tolerance to pain and decreased effect of 
morphine against the jumping behaviour in the hotplate test 
(decreased sensitivity of opioid receptors)
2. Reduced morphine-induced hyperlocomotion (increased 
activity of the GABAergic system in the midbrain?)
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CONCLUSIONS
1. The moving from 129Sv to C57B1/6 genetic background affects several, but 
not all, behavioural effects induced by the genetic invalidation of CCK2 
receptors. The back-crossings of animals into the C57B1/6 genetic 
background apparently attenuate the disturbances of motor coordination and 
diminished locomotor activity established at the beginning of studies with 
the dominating 129Sv genetic background.
2. The targeted mutation of CCK2 receptors induces changes in the activity of 
the dopaminergic system. According to the radioligand binding studies, the 
number of dopamine D2 receptors is significantly increased in the striatum 
but not in the mesolimbic area. The enhanced apomorphine-hypolocomotion 
is in favour of the increased sensitivity of presynaptic dopamine receptors, 
whereas enhanced amphetamine-induced hyperlocomotion reflects an 
increased sensitivity of postsynaptic dopamine receptors.
3. The genetic invalidation of CCK2 receptors causes changes in the affinity 
and number of ц-opioid receptors. The affinity of ц-opioid receptors is 
reduced in the striatum but increased in the cerebral cortex, and the number 
of ц-opioid receptors is increased in the striatum.
4. CCK2 receptor-deficient mice show decreased pain sensitivity and reduced 
pain tolerance. Nociceptive sensitivity of mice lacking CCK2 receptors is 
significantly decreased in the plantar-analgesia and the hotplate tests. By 
contrast, the jumping response of genetically modified mice is apparently 
augmented in the hotplate test compared to their wild-type littermates.
5. There is a dissociation of behavioural effects of morphine, an agonist of 
ц-opioid receptors, in various behavioural tests. The effect of morphine is 
increased in the plantar-analgesia test, unchanged in the place conditioning 
and the hotplate test, and reduced in the jumping behaviour and locomotor 
activity tests. These behavioural changes reflect distinct changes in the 
parameters of opioid receptors in the forebrain structures.
6. CCK2 receptor-deficient mice show reduced adaptation in a novel 
environment, and this effect is reversed by naloxone, an opioid receptor 
antagonist, demonstrating an increased activity of the endopioidergic system. 
Moreover, naloxone-induced place aversion is decreased in mutant mice 
showing that the targeted mutation of CCK2 receptors also inhibits 
negatively motivated learning.
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SUMMARY IN ESTONIA
Koletsiistokiniini teist tüüpi retseptori puudulikkusega hiirte 
käitumuslik ja biokeemiline iseloomustus: muutused dopamnn- 
ja endopioidergilise süsteemi talitluses
Sissejuhatus
Esimest korda kirjeldasid koletsüstokiniini (CCK) imetaja kesknärvisüsteemis 
1975.a. Vanderhaeghen ja tema kolleegid. CCK on peptiid, mis esineb nii 
seedetraktis kui kesknärvisüsteemis (KNS-is). Peptiid esineb mitme alavormina 
ja KNS-is on esindatuim kaheksast aminohappest koosnev, positsioonis 7 
(alates -COOH terminaalsest otsast) sulfakteeritud vorm CCK-8s. 
Koletsüstokiniinil on suur sarnasus teise olulise seedetrakti peptiidi — 
gastriinga. Mõlemal peptiidil on identne järjestus viie aminohappe ulatuses 
alates -COOH terminaalsest otsast ning nii CCK kui gastriin on endogeensed 
ligandid ülekaalukalt KNS-is esinevale CCK2 retseptorile. CCK toimet 
organismi talitlusele ja  käitumisele on laialdaselt uuritud. On leitud, et 
anatoomiliselt kattub CCK-ergiline süsteem KNS-is nii dopamiinergilise kui 
opioidergilise süsteemiga. Funktsionaalselt pärsib CCK oma teist tüüpi reteptori 
— CCK2 vahendusel nimetatud süsteemide aktiivsust
Uuringute eesmärk
Käesoleva töö eesmärgiks oli iseloomustada koletsüstokiniini teist tüüpi 
retseptori (CCK2) puudulikkusega hiirte fenotüüpi — võimalikke käitumuslikke 
iseärasusi ning muutusi neurokeemilistes protsessides. Põhiline tähelepanu on 
suunatud KNS-i dopamiin- ja  endopioidergiliste süsteemide uurimisele, sest 
nende virgatsainete esinemine kesknärvisüsteemis kattub suuresti CCK-ergilise 
süsteemiga.
Töö konkreetsemateks eesmärkideks oli uurida CCK2 retseptori puudulikkusega 
hiirtel:
1. dopamiini teist tüüpi (D2) retseptorite ning opioid retseptorite afiinsust ja 
tihedust erinevates KNS-i struktuurides nagu ajukoores, juttkehas, meso- 
limbilistes struktuurides ja  hipokampuses;
2. võimalikke muutusi liikumisaktiivsuses ja  motoorses koordinatsioonis;
3. dopamiinergiliste ühendite apomorfiini, mitteselektiivse dopamiini Di ja D2 
retseptorite agonisti, ja  amfetamiini, põhjustab KNS-is dopamiini vabane­
mise, toimet katseloomade liikumisaktiivsusele;
4. muutusi valutundlikkuses, kasutades selleks erinevaid uurimismeetodeid;
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5. morfiini, ц-opioid retseptorite agonisti, analgeetilist toimet ning morfiini ja 
naloksooni, mitteselektiivse opioidi retseptorite antagonisti, mõju katse­
loomade liikumisaktiivsusele ning koha-eelistusele.
Meetodid
CCK2 retseptori puudulikkusega hiired saadi professor Toshimitsu Matsui 
laboratooriumist (Nagata et al., 1996) ning neid paljundati ja  kasvatati TÜ 
Biomeedikumi vivaariumis. Radioligandi sidumiskatsetes mõõdeti CCK2, 
dopamiini D2 ja  ц-opioid retseptori omadusi kesknärvisüsteemi erinevates 
struktuurides: ajukoores, juttkehas, mesolimbilistes struktuurides ja  hipo- 
kampuses. CCK2 retseptorite märgistamiseks kasutati [3H]-pCCK-8 ja  mitte­
spetsiifilise sidumise määramiseks CCK2 retseptorite antagonisti L-365,260. 
Dopamiini D2 retseptorite märgistamiseks kasutati [3H]-spiperooni ning 
mittespetsiifilist sidumist määrati selle retseptorite antagonisti, raklopriidi abil. 
Opioidi retseptorite märgistamiseks rakendati [3H]-diprenorfiini ja  mittespet­
siifilist sidumist määrati naloksooni abil. Motoorset aktiivsust hinnati apara­
tuuriga, mis koosnes fotosensoritega varustatud pleksiklaasist kastis ja  arvuti­
süsteemist. Selle katse puhul hinnati hiirte üldist motoorset aktiivsust ja 
uudistamisaktiivsust — tõusu tagakäppadele. Samuti hinnati kohanemise mõju 
motoorsele aktiivsusele ning uuriti amfetamiini, naloksooni ja  morfiini toimet 
selles katsekeskkonnas adaptatsiooni foonil. Motoorse koordinatsiooni hinda­
miseks kasutati rotarodi testi, kus uuriti katseloomade võimet püsida pöörleval 
silindril. Valutundlikkuse spinaalsete mehhanismide hindamiseks kasutati 
Hargreaves’i testi, mille puhul katselooma tagumise käpa alla juhiti kindla 
intensiivsusega infrapunaste kiirte kimp (intensiivsus vastas temperatuurile 
50°C) ning automaatselt registreeriti katselooma reaktsiooni aeg ärritusele — 
tagumise käpa äratõmbamine. Valutundlikkuse supraspinaalsete mehhanismide 
uurimiseks kasutati kuumplaaditesti, mis kujutab endast katselooma reaktsiooni 
aja mõõtmist ja  käitumise iseloomustamist kindla temperatuuriga (52°C) 
metallplaadil. Katselooma liikumine metallplaadil piirati klaasist koonuse abil. 
Kuumplaaditestis määrati kaks parameetrit: esmane valureaktsioon ehk valulävi 
ja  võime taluda valu. Esmaseks valureaktsiooniks võeti hetk, mil katseloom kas 
lakkus või raputas tugevalt tagakäppa. Valu taluvusena mõõdeti aeg hetkeni 
millal hiir püüdis hüppamisega katsesituatsioonist põgeneda. Nii Hargreaves'i 
kui ka kuumplaaditesti hinnati morfiini antinotsitseptiivset toimet. Koha- 
eelistuse katses kasutati puuri, mis oli jagatud luugiga vaheseina abil heledaks 
ja tumedaks osaks. Selles katses hinnati morfiini ja  naloksooni toimet 
katseloomade valikule puuri heleda ja tumeda osa vahel, eeldades, et hiirtel on 
loomulik eelistus puuri tumedama osa vastu.
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Tulemused
Ühe vanemliku hiireliini — 129Sv hiireliini geneetiline taust mõjutab mitmeid 
käitumuslikke avaldusi CCK2 retseptori puudulikkusega hiirtel. Korduv 
tagasiristamine C57B1/6 hiireliiniga parandas oluliselt katseloomade motoorset 
koordinatsiooni ja  langetas liikumisaktiivsust CCK2 retseptor puudulikkusega 
hiirtel. CCK2 retseptori geeni väljalülitamine tekitab olulisi muutusi dopa- 
miinergilise süsteemi talitluses. Radioligandi sidumiskatsed näitasid, et dopa- 
miini D2 retseptorite arv on suurenenud juttkehas, kuid mitte mesolimbilistes 
struktuurides. Apomorfiini hüpolokomotoorse toime oluline võimendumine 
CCK2 retseptori puudulikkusega hiirtel viitab presünaptiliste dopamiini 
retseptorite aktiivsuse tõusule. Samas amfetamiini hüperlokomotoorse toime 
suurenemine mutageensetel hiirtel näitab postsünaptiliste dopamiini retseptorite 
aktiivsuse tõusu. CCK2 retseptorite geeni väljalülitamine põhjustab muutusi ka 
ji-opiodi retseptorite biokeemilistes parameetrites. Juttkehas on nende 
retseptorite arv suurenenud, nende afiinsus on aga langenud. Samas on 
ajukoores ц-opioidi retseptorite afiinsus tõusnud. Valutundlikkus on CCK2 
retseptori puudulikkusega hiirtel oluliselt muutunud. Valulävi on antud hiirtel 
oluliselt tõusnud nii spinaalset kui ka supraspinaalset valu impulsi regulatsiooni 
kajastavates mudelites. Samas on CCK2 retseptori puudulikkusega hiirtel 
oluliselt vähenenud valu taluvuse võime. Seega on neil hiirtel kõrgem valulävi, 
kuid madalam valutaluvus. Morfiini, |n-opioidi retseptori agonisti, toimes esineb 
CCK2 retseptori puudulikkusega hiirtel olulisi lahknevusi erinevates käitumis- 
katsetes. Morfiini toime on oluliselt suurenenud Hargreaves'i testis, kuid pole 
muutunud kuumplaaditestis, kui mõõta esmast valureaktsiooni, ega koha- 
eelistus katses. Samas ei avalda morfiin olulist aktiveerivat toimet nende hiirte 
liikumisaktiivsusele ega suurenda nende valu taluvuse võimet (Pommier et. al. 
2002). Sellised vastuolulised muutused käitumises peegeldavad hästi kirjeldatud 
nihkeid ц-opioidi retseptorite afiinsuses juttkehas ja  ajukoores. Liikumis- 
aktiivsuse mõõtmise tulemused näitavad, et CCK2 retseptor puudulikel hiirtel on 
langenud kohanemisvõime uudses keskkonnas, kuna võrreldes kontroll hiirtega 
püsis nende aktiivsus üksteisele järgnevate katsete käigus kõrge. Dmselt on 
viimane seotud endopioidergilise süsteemi aktivatsiooniga, sest naloksoon, 
opioidi retseptorite antagonist, kõrvaldab selle muutuse. Lisaks eeltoodule ei 
kutsu naloksoon CCK2 retseptori puudulikkusega hiirtel esile olulist koha- 
vältimise käitumist, mis on ilmselt seotud asjaoluga, et nimetatud hiirtel on 
väiksem ärevus võrreldes CCK2 retseptoriga liigikaaslastega. Tulenevalt 
märkimisväärsetes muutustes dopamiin- ja  edopioidergilise süsteemi talitluses 
peame CCK2 retseptori puudulikkusega hiirt heaks mudeliks uute psühho- 
farmakoloogiliste ravimite uurimisel. Selle mudeli abil oleks võimalik sedastada 
ja  uurida uusi antipsühhootilisi aineid, medikamente ravimsõltuvuse ärahoidmi­
seks ning valu leevendamiseks.
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A bstract Rationale: Cholecystokinin (CCK) has been 
shown to coexist and interact with dopamine in the regu­
lation of behaviour. Two different CCK receptors (CCK] 
and CCK2) have an opposite influence on the activity of 
dopamine neurons. Stimulation of CCK2 receptors de­
creases the release of dopamine and that receptor could 
mediate the neuroleptic-like effect of CCK. Objective: To 
investigate the activity of the dopaminergic system in 
pharmacological experiments on CCK2 receptor (CCK2R)- 
deficient mice. Methods: We used age- and sex-matched 
littermates in all our experiments. To evaluate the behav­
ioural differences, we performed the rotarod test and 
measured the locomotor activity of animals using com­
puter-connected photoelectric motility boxes. Amphet­
amine and apomorphine, two dopaminergic drugs with 
different pharmacodynamic properties, were used to in­
fluence the activity of the dopaminergic system in the 
brain. Neurochemical differences related to the different 
genotype were analysed by means o f high-performance 
liquid chromatography and radioligand binding studies. 
Results: Motor co-ordination was significantly impaired 
in the rotarod test o f CCK2R receptor-deficient mice. 
Moreover, the locomotor activity of heterozygous (+/-) 
and homozygous ( - /- )  CCK2R receptor-deficient mice 
was somewhat reduced. A low dose of apomorphine 
(0.1 mg/kg), an unselective agonist o f dopamine recep-
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tors, suppressed locomotor activity significantly more in 
homozygous (—/-)  and heterozygous (+/—) mutant mice 
than in their wild-type (+/+) littermates. Amphetamine 
(3 -6  mg/kg), increasing release of dopamine from the 
presynaptic terminals, caused a dose-dependent motor 
stimulation in wild-type (+/+) mice. In heterozygous 
(+/-) and homozygous ( - /- )  mice, a lower dose of am­
phetamine (3 mg/kg) did not alter the locomotor activity, 
whereas the higher dose of (6 mg/kg) induced a signifi­
cantly stronger increase in locomotor activity in homozy­
gous ( - /- )  mice than in their heterozygous (+/-) and 
wild-type (+/+) littermates. Despite the changes in the ac­
tion of apomorphine and amphetamine in homozygous 
( - /- )  mice, we did not find any significant differences in 
the concentration of dopamine and their metabolites in 
the striatum or cortex. However, the density of dopamine 
D2 receptors was significantly increased in the striatum of 
homozygous (-/- )  animals compared with wild-type 
(+/+) mice. Conclusions: The targeted mutation of the 
CCK2 receptor gene induced gene dose-dependent chang­
es in the activity of the dopaminergic system. The sensi­
tivity of presynaptic dopamine receptors was increased in 
heterozygous (+/-) and homozygous ( -/- )  animals, 
whereas the increase in sensitivity of postsynaptic dopa­
mine receptors was apparent only in homozygous (-/- )  
mice.
Keywords Targeted mutagenesis • Wild-type • 
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Locomotor activity
Introduction
Cholecystokinin (CCK) coexists with dopamine (DA) in 
some mesencephalic neurones, innervating mesolimbic 
and cortical regions, and interacts with DA in the regula­
tion of behaviour (Hökfelt et al. 1980). These interac­
tions are complex and depend on the route of administra­
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tion of CCK agonists and the subtype of CCK receptor 
involved (Altar and Boyar 1989; Crawley and Corwin 
1994; Ladurelle et al. 1997). There are two distinct sub- 
types of CCK receptors, namely CCK, (“alimentary” 
subtype, CCK1R, former CCK-A) and CCK2 (“brain” 
subtype, CCK2R, former CCK-B) receptors (Noble et al.
1999). Both subtypes are found in the brain structures 
linked to the mesolimbic DA system; the ventral tegmen­
tal area and nucleus accumbens (Hökfelt et al. 1980; Hill 
et al. 1990; Honda et al. 1993). The behavioural and bio­
chemical studies have shown that CCK1R and CCK2R 
receptors mediate the opposite effects of CCK on the ac­
tivity of DA neurones in mice and rats (Vasar et al. 1991; 
Noble et al. 1999). CCK increases the release of DA in 
the medial posterior nucleus accumbens by stimulating 
the CCK1R receptors, whereas the stimulation of 
CCK2R receptors in the anterior nucleus accumbens 
does the opposite (Vickroy et al. 1988; Altar and Boyar 
1989; Marshall et al. 1991). Both subtypes of CCK re­
ceptors have been cloned, and targeted disruption of 
CCK1R and CCK2R receptor genes has been achieved 
in mice (Nagata et al. 1996; Kopin et al. 1999). The ani­
mals lacking CCK1R receptors did not respond to the 
hypophagic effect of CCK, but otherwise the feeding be­
haviour of these mice was not impaired relative to their 
wild-type littermates (Kopin et al. 1999). The animals 
without CCK2R receptors display disturbances in the de­
velopment of gastric mucosa (Nagata et al. 1996) and in 
learning (Sebret et al. 1999).
Taking into account a role of CCK2R receptors in the 
regulation of activity of DA neurones (Studier et al. 
1986; Crawley and Corwin 1994), an attempt has now 
been made to explore alterations in the DA system due to 
the genetic mutation of the CCK2R receptor gene in 
mice. It is known that mesolimbic DA plays a crucial 
role in the regulation of locomotor activity in rodents 
(Bradbury et al. 1983; Costall et al. 1985). Therefore, the 
motor co-ordination of mice in the rotarod test and their 
locomotor activity in the motility boxes were studied. 
Moreover, the action of two drugs, apomorphine (unse- 
lective D1 and D2 receptor agonist) and amphetamine 
(increases release of DA), was studied in CCK2R recep- 
tor-deficient mice. In a separate study, the concentrations 
of DA, serotonin (5-hydroxytryptamine; 5-HT) and their 
major metabolites were measured in the two brain struc­
tures of wild-type (+/+) and homozygous ( - /- )  mice. 
Also, the receptor-binding parameters of CCK, serotonin 
5-HTj and DA D2 receptors were measured in the 
CCK2R receptor-deficient and wild-type mice.
Materials and methods
Animals
Nagata et al. (1996) generated CCK2 receptor-deficient mice by 
replacement of a part of exon 2 and exons 3, 4 and 5. Breeding 
and genotype analysis were performed in the Department of Phys­
iology, University of Tartu. Genotyping was carried out by means 
of polymerase chain reaction (PCR) using two pairs of primers -
HE2F (TGG AGT TGA CCA TTC GAA TCA С) and LacZrev 
(GTG CTG САА GGC GAT TAA GTT G) were designed to de­
tect the mutant allele, and HE3F (TAT CAG TGA GTG TGT CCA 
СТС T) and HE3R (АСА TTT GTT GGA САС GTT САС) were 
designed for the wild-type allele. For PCR, we used the following 
protocol: 96°C for 10 min (initial dénaturation); 96°C for 50 s, 
60°C for 50 s and 72°C for 2 min (25 cycles); and 72°C for 
10 min (final amplification). PCR products were stored at 4°C un­
til electrophoresis. Male homozygous (-/-) CCK2 receptor-defi­
cient, male heterozygous mutant (+/-) and male wild-type (+/+) 
(3-months old) mice were used. Mutant mice were crossed back 
three times to the C57/BL6 background to minimise the possible 
genetic effects from the 129 sv strain. The mice were kept in the 
animal house at 20±2°C under a 12-h/12-h light/dark cycle (lights 
on at 0700 hours). Tap water and food pellets were available ad 
libitum. All animal procedures were approved by the University of 
Tartu Animal Care Committee in accordance with the European 
Communities Directive of 24 November 1986 (86/609/EEC).
Behavioural testing
The animals were brought into the experimental room 1 h before 
the beginning of the experiments which were performed between 
1300 hours and 1900 hours.
Rotarod test
A 1-min training session was given to mice on the rotarod (diame­
ter 8 cm, 9 rpm) 5 min before the first measurement. Motor per­
formance (time until first fall) was registered during a 2-min ses­
sion on three consecutive days.
Motility test
For the study of locomotor activity, an animal was placed singly 
into the photoelectric motility boxes (448x448x450 mm) connect­
ed to a computer (TSE Technical and Scientific Equipment 
GMBH, Germany). The illumination level of transparent test 
boxes was -750 lux. Time in locomotion (s), distance of locomo­
tion (m), number of rearing and number of comer entries were 
registered during the 30-min observation period.
The locomotor effects of amphetamine (3 mg/kg and 6 mg/kg) -  
increasing a release of catecholamines -  and apomorphine 
(0.1 mg/kg) -  an unselective agonist of DA D, and D2 receptors -  
were studied in the separate groups of animals. Amphetamine 
(Sigma) and apomorphine (Sigma) were injected intraperitoneally
20 min and 15 min, respectively, before the beginning of an exper­
iment.
Analysis of DA, 5-HT and their metabolites in the mouse 
brain samples
Mice were decapitated, the brains were rapidly removed and 
cooled in liquid nitrogen. The following brain areas were dissect­
ed from the sections according to the atlas of Franklin and Paxinos 
(1997): (i) the cerebral cortex, (ii) both striata, and (iii) hypothala­
mus. The dissected tissues were frozen in liquid nitrogen and 
stored at -80°C until sample preparation.
The brain samples were homogenised in 10-50 volumes of
0.1 N HC104, depending on the tissues. The homogenates were 
centrifuged at 16,500 rpm (15 min +4°C, Heraeus Sepatech, Bio- 
fuge 17RS). The supernatant was removed, separated into two 
separate Eppendorf tubes and stored at -80°C until analysed.
Two different high-performance liquid chromatography 
(HPLC) runs determined DA, 5-HT and their metabolites: one 
assay for DA and its metabolite dihydroxyphenylacetic acid 
(DOPAC), and another assay for measuring homovanillic acid 
(HVA), 5-HT and 5-hydroxyindoleacetic acid (5-HIAA).
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Both chromatographic systems consisted of an isocratic Waters 
510 pump (Waters, Milford, Mass.), a Waters 717 plus autosam­
pler with cooler (Waters), a reverse-phase Cl 8 column (Ultra­
sphere ODS, 4.6x250 mm, 5-цт particle size, Beckmann) and 
Hewlett Packard HP-3396A integrators. In HPLC system 1, the 
detector (ESA Coulochem II, ESA, Chelmsford, Mass.) was 
equipped with a 5021 (ESA) conditioning cell and a two-channel 
(Det 1 and Det 2) 5011 (ESA) analytical cell. The potentials ap­
plied were +0.10 V (conditioning cell), +0.375 V (Det 1) and 
-0.350 V (Det 2). The sensitivities were set at 100 nA (Det 1) and
5 nA (Det 2). In HPLC system 2, the detector (ESA Coulochem 
5100A, ESA) was equipped with a 5021 conditioning cell 
(+0.10 V) and a 5014A analytical cell (+0.35 V, Det 1). The sensi­
tivity was set at 15x100. The detection limits were 18 fmol for DA 
and DO РАС in HPLC 1 and 100 fmol for 5HT, 5HIAA and HVA 
in HPLC 2.
The mobile phase consisted of sodium acetate buffer (0.1 M), 
citric acid (0.1 M), methanol (7.5%) and sodium octyl sulphate 
45 mg/1 for the first HPLC method and 90 mg/1 for the second. 
The pH of the mobile phase was adjusted to 3.6 with phosphoric 
acid, and the flow rate was 1.1 ml/min.
Radioligand binding studies
After decapitation, the brains were quickly dissected on ice. The 
cerebral cortex, both striata and mesolimbic structures were dis­
sected (Franklin and Paxinos 1997). The brain structures from six 
mice were pooled, and the experiment was repeated three times. 
CCK receptor binding was performed in the cerebral cortex and in 
the striatum. The striatum and mesolimbic structures were used 
for studying the parameters of DA D2 receptors, whereas the cere­
bral cortex was used for 5-HT2 receptor studies. The radioligand 
binding studies were performed as described by Kõks et al. 
(1997). For labelling of DA D2 and 5-HT2 receptors, [3H]-spiper- 
one (specific activity 107 Ci/mmol, Amersham Radiochemicals) 
was used. The parameters of DA and 5-HT receptors were deter­
mined in the presence of 0.06-2 nM [3H]-spiperone at 37°C for 
30 min. Raclopride (Astra, 1 цМ), an antagonist of DA D2 recep­
tors, was added to determine the non-specific binding at DA D2 
receptors. Ritanserin (RBI, 1 pM), an antagonist of 5-HT2 recep­
tors, was used to detect the non-specific binding at 5-HT2 recep­
tors. [Propionyl-3H]-propionylated-CCK-8-sulphated (pH]-pCCK-8) 
(specific activity 73 Ci/mmol, Amersham Radiochemicals) was 
used for labelling of CCK receptors. The parameters of CCK re­
ceptors were determined in the presence of 0.05-2.4 nM pH]- 
pCCK-8 at 23°C for 120 min. L-365,260 (Merck Sharp & Dohme, 
1 цМ), an antagonist of CCK2R receptors, was added to determine 
the non-specific binding. The brain tissue was homogenised in 20 
volumes of ice-cold 50 mM Tris-HCl (pH 7.4 at 4°C) using a 
Potter-S glass-teflon homogeniser (1000 rpm, 12 passes). The 
membranes were washed twice in the same buffer by centrifuga­
tion (48000xg for 20 min) and re-suspension. After the last cen­
trifugation, the crude brain membranes were suspended in the in­
cubation buffer for the appropriate binding assay (Kõks et al. 
1997). The protein content was measured according to the method 
of Bradford (1976). The saturation curves of [3H]-pCCK-8 and 
[3H]spiperone binding were analysed using GraphPad Prism 
(Version 3.00) for Windows software.
Statistics
Results are expressed as mean values ±SEM. The behavioural 
studies were analysed using one- and two-way analysis of vari­
ance. Post-hoc comparisons between individual groups were per­
formed using Tukey HSD tests using the Statistica for Windows 
software. The student’s r-test was applied for the analysis of radio­
ligand binding data.
Fig. 1 The parameters of [3H]-pCCK binding in the brain struc­
tures of cholecystokinin (CCK)2R receptor-deficient mice. The 
number of animals in each group was 18, brains of 6 mice were 
pooled, and the mean is a result of three experiments. While bars 
wild-type, striped bars heterozygous, Kd apparent dissociation 
constant, В apparent number of binding sites
Results
[3H]-pCCK-8 binding in the brain
In wild-type mice (+/+), the density of CCK receptors 
was significantly higher in the cerebral cortex than the 
striatum (Fig. 1). In heterozygous (+ /-) mutant mice, the 
density of CCK binding sites was lower and the affinity 
of these binding sites was decreased relative to their 
wild-type (+/+) littermates. The specific binding of 
[3H]-pCCK-8 was not detectable in the cortex and stria­
tum of homozygous ( - /- )  mutant mice.
Rotarod test
In the first rotarod experiment, the performance of het­
erozygous (+ /-) and homozygous ( - /- )  CCK2R receptor- 
deficient mice was impaired relative to wild-type (+/+) 
animals (FW7=5.53, P<0.01, Fig. 2). However, only in 
the case of homozygous ( - /- )  mutant mice was this dif­
ference statistically significant. There was a statistically 
significant difference between the mutant and wild-type 
mice in the second experiment (F2 27=4.15, /40 .05). On 
the third day, the behaviour of heterozygous (+ /-) mice 
did not differ from that of wild-type animals, whereas 
the ability of homozygous ( - /- )  mice to stay on the rotat­
ing wheel remained poor relative to wild-type (+/+) ani­
mals (F2 27=5.56, P<0.01).
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Locomotor activity
Effect o f  apomorphine (0.1 mg/kg)
After the administration of saline, the locomotor activity 
of homozygous ( - /- )  and heterozygous (+ /-) mutant 
mice was slightly but statistically insignificantly reduced 
compared with wild-type (+/+) animals (Fig. 3). The ad­
ministration of a low dose of apomorphine (0.1 mg/kg), 
an unselective agonist of DA receptors, reduced the trav­
elled distance [F542=10.88, P<0.01, one-way analysis of 
variance (ANOVÂ)] and number of corner visits in wild- 
type (+/+) mice (F542=7.63, PcO.Ol, one-way ANOVA) 
(Fig. 3). It should be noted that this dose of apomorphine 
did not cause the stereotyped behaviour in mice (data not 
shown). The application of two-way ANOVA did not re­
veal any statistical differences when the genotype and 
treatment data were compared. However, in mutant ani-
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Fig. 2 The perfoimance of cholecystokinin (CCK)2R receptor- 
deficient mice in the motor co-ordination test. The number of ani­
mals in each group was ten. The study was repeated on three consec- 
Htive days. White bars wild-type, striped bars heterozygous, black 
bars homozygous. *P<0.05 (compared with wild-type animals; 
Tukey HSD test after significant one-way analysis of variance)
mais, the motor suppressant effect of apomorphine was 
stronger than in wild-type mice, since the DA agonist re­
duced not only the distance travelled and corner entries 
but also the time of locomotion (F5 42=10.83, /40 .01 , 
one-way ANOVA) and number of rearing (F542=5.87, 
/4 0 .0 1 , one-way ANOVA).
Effect o f  amphetamine
The applying of two-way ANOVA (genotype; treatment) 
established the statistically significant differences when 
the effect of amphetamine (3 mg/kg and 6 mg/kg) was 
compared between wild-type (+/+) and mutant mice 
(time of locomotion F4 U7=5.51, Я<0.01; distance trav­
elled F4117=5.85, P<0.01; F4117=2.90, P<0.05; number 
of corner visits F4117=5.11, PcO.Ol). In this study, even 
after the treatment with saline, the locomotor activity of 
heterozygous (+/-) and homozygous ( - /- )  mutant mice 
was significantly lower than in wild-type (+/+) animals 
(Fig. 4). In heterozygous (+/-) mice, the time of locomo­
tion and number of rearing were significantly decreased 
compared with wild-type (+/+) littermates; whereas, in 
homozygous ( - /- )  mice, number of rearing was reduced. 
The administration of amphetamine (3 mg/kg and 
6 mg/kg) to wild-type mice induced a dose-dependent in­
crease o f the time of locomotion, distance travelled and 
number of comer visits but reduced the number of rear­
ing. A lower dose of amphetamine (3 mg/kg) slightly, 
but insignificantly, increased the time of locomotion and 
distance travelled in heterozygous (+/-) mice, but not in 
homozygous ( - /- )  animals. The higher dose of amphet­
amine (6 mg/kg) caused a significant increase of the lo­
comotor activity in mutant mice. In (+/-) heterozygous 
mice, the effect o f amphetamine (6 mg/kg) did not differ 
from that in wild-type (+/+) littermates; whereas, in ho­
mozygous ( - /- )  mice, the higher dose of amphetamine
Fig. 3 Apomorphine 
(0.1 mg/kg) induced motor 
suppression in cholecystokinin 
(CCK)2R receptor-deficient 
mice. The number of animals 
in each group was 8. White 
bars saline, black bars apomor­
phine. +Я<0.05 (compared with 
the respective saline-treated 
group; Tukey HSD test after 
significant one-way analysis of 
variance)
Wild-type Heterozygous Homozygous
X
III
Wild-type Heterozygous Homozygous
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Table 1 The content of dopa­
mine, serotonin and their me­
tabolites in the brain structures 
of wild-type and cholecystoki- 
nin (CCK)2 receptor-deficient 
mice (pmol/mg wet weight tis­
sue). The number of mice in 
each group was three. HVA ho- 
movanillic acid, DOPAC dihy- 
droxyphenylacetic acid, 5-HI­
AA 5-hydroxyindoleacetic acid
Cerebral cortex Striatum Hypothalamus
Wild type Homozygous Wild type Homozygous Wild type Homozygous
Dopamine
HVA
DOPAC
Serotonin
5-HIAA
032±0.12
0.32±0.06
0.42+0.06
5.1±0.7
1.5±0.1
0.27±0.11
0.35±0.11
0.30±0.10
5.7±0.3
1.6±0.1
65.5±6.0
7.1±0.7
4.7±0.2
3.5±0.5
2.8±0.2
53.2±3.5
6.1+1.3
5.4±0.8
4.0±0.5
2.8±0.3
1.3+0.3 
1.5±0.2 
0.40±0.03 
8.7±0.7 
4.5±0.3
1.2±0.2 
1.4+0.1 
0.43±0.01 
8.8+0.7 
4.4+0.2
Fig. 4 Amphetamine 
(3-6 mg/kg) induced motor 
stimulation in cholecystokinin 
(CCK)2R receptor-deficient 
mice. The number of animals 
in each group was 14. White 
bars saline, striped bars am­
phetamine 3 mg/kg, black bars 
amphetamine 6 mg/kg. +Я<0.05 
(compared with the respective 
saline-treated group; Tukey 
HSD test after two-way analy­
sis of variance), *P<0.05 (com­
pared with the respective wild- 
type group)
Wild-type Heterozygous Homozygous Wild-type Heterozygous Homozygous
Wild-type Heterozygous Homozygous
caused the significantly stronger increase of distance 
travelled and number of com er visits.
Content of DA, 5-HT and their metabolites 
in the brain structures
The assay of DA, 5-HT and their metabolite levels in the 
cortex and hypothalamus did not reveal significant differ­
ences between wild-type (+/+) and homozygous (-/-)  mice. 
Only in the striatum were the levels of DA and its metabo­
lite HVA slightly lower in homozygous ( - /- )  animals, but 
this difference was not statistically significant (Table 1).
[3H]-spiperone binding in the brain
The density of [3H]-spiperone binding sites was signifi­
cantly higher in the striatum of homozygous ( - /- )  mice 
than their wild-type (+/+) littermates (Fig. 5). Also in the 
mesolimbic structures, the number o f [3H]-spiperone 
binding sites was somewhat increased (not statistically 
significant) in the homozygous ( - /- )  mice. A similar 
trend of increased [3H]-spiperone binding was apparent 
in the striatum of heterozygous (+ /-) animals. In the ce­
rebral cortex, we did not find any differences between 
the wild-type (+/+) and mutant mice.
Cerebral Striatum Mesolimbic
Fig. 5 The parameters of pH]-spiperone binding in the brain 
structures of cholecystokinin (CCK)2R receptor-deficient mice. 
The number of animals in each group was 18, brains of 6 mice 
were pooled, and mean is a result of three experiments. White bars 
wild-type, striped bars heterozygous, black bars homozygous. 
*P<0.05 (compared with wild-type group, student’s /-test)
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Discussion
As expected, the mice lacking the CCK2R receptor 
gene ( - /- )  did not have a measurable specific binding of 
[3H]-pCCK-8 in the cerebral cortex and striatum. In het­
erozygous mutant (+ /-) mice, the density of CCK recep­
tors was about 30-50%  of the corresponding value of the 
wild-type (+/+) animals. In heterozygous (+ /-) mice, the 
affinity of CCK receptors was also somewhat reduced 
compared with wild-type animals. This finding is differ­
ent from the study of Nagata et al. (1996), who did not 
find any difference in the affinity of CCK receptors in 
wild-type (+/+) and heterozygous (+ /-) animals. We used 
the saturation of CCK receptors by increasing the con­
centration of [3H]pCCK-8, whereas Nagata et al. (1996) 
applied a method of single concentration binding study 
with [125I]-CCK. Several studies have shown that 
CCK1R receptors have a wide distribution and they are 
not located only in the discrete brain nuclei (Hill at al. 
1990; Honda et al. 1993). However, their density in most 
of the brain regions is very low and therefore not detect­
able with the method used in the present study.
The mice lacking CCK2R receptors displayed im­
paired motor co-ordination in the rotarod test. The motor 
impairment was stronger in homozygous ( - /- )  mice than 
in heterozygous (+/-) animals. On the third day of a 
study, the difference between wild-type (+/+) and hetero­
zygous (+ /-) mice disappeared, whereas the performance 
of homozygous ( - /- )  animals remained poor relative to 
their wild-type (+/+) littermates. The established differ­
ences between wild-type and mutant mice may be related 
to some extent to the impaired learning abilities of ho­
mozygous ( - /- )  CCK2R receptor-deficient mice (Sebret 
et al. 1999). The performance o f heterozygous (+/-) 
mice in the memory tests did not differ from that of 
wild-type (+/+) mice (our unpublished data). The loco­
motor activity of mutant mice tended to be lower than in 
their wild-type (+/+) littermates and, in one experiment, 
this difference reached a statistical significance.
The treatment with a low dose (0.1 mg/kg) of apo­
morphine, an unselective agonist of DA D,/D2 receptors, 
reduces the locomotor activity in wild-type (+/+) mice. It 
should be noted that this dose of apomorphine did not 
cause any sign of stereotyped behaviour. The motor sup­
pressant effect of apomorphine is believed to be caused 
by the stimulation of presynaptic DA “auto-receptors” 
located on the DA neurones (Meltzer 1980). The motor 
depressant effect of apomorphine (0.1 mg/kg) was appar­
ently stronger in heterozygous (+/-) and homozygous 
( - /- )  CCK2R receptor-deficient mice than their wild- 
type (+/+) littermates. This finding is in a good agree­
ment with our previous pharmacological studies, in 
which the pre-treatment of mice with the CCK2R recep­
tor antagonist L-365,260 potentiated the motor suppres­
sant action of apomorphine (Vasar et al. 1991). More­
over, electrophysiological studies in rats demonstrated 
that the acute and long-term administration of LY262691 
and related pyrazolidinone CCK2R receptor antagonists 
decreased the number of spontaneously active DA cells 
in the midbrain structures, probably via action in the nu­
cleus accumbens and prefrontal cortex (Rasmussen et al. 
1993).
The administration of amphetamine (3 mg/kg and 
6 mg/kg), increasing the release of DA and noradrena­
line from the presynaptic terminals (Kuczenski 1983), 
induced a dose-dependent motor stimulation in wild-type 
(+/+) mice. However, in the mutant mice, the effect of 
amphetamine was different. In heterozygous (+/-) mice, 
a lower dose of amphetamine (3 mg/kg) tended to in­
crease the motor activity, but the higher dose (6 mg/kg) 
had the same effect as in wild-type (+/+) animals. In ho­
mozygous ( - /- )  animals, the lower dose of amphetamine 
reduced the number of rearing, but did not affect the oth­
er parameters of locomotor activity. The treatment with 
the higher dose (6 mg/kg) of amphetamine induced a sig­
nificant increase in two parameters of locomotor activi­
ty: the travelled distance and number of comer entries. It 
should be noted that the effect of the higher dose 
(6 mg/kg) of amphetamine in homozygous animals (-/-)  
on these parameters was significantly different from that 
seen in heterozygous (+/-) and wild-type (+/+) animals.
Despite the behavioural changes, we did not find any 
difference in the content of DA, 5-HT and their metabo­
lites in three brain structures of wild-type (+/+) and ho­
mozygous ( - /- )  mice. Corwin et al. (1995) have shown 
that the local administration of CI-988, an antagonist of 
CCK2R receptors, increases the levels of DA in the nu­
cleus accumbens without changing DA metabolites (DO- 
PAC and HVA). However, this effect was apparent only 
at high concentrations of CI-988, lacking specificity for 
the CCK2R receptors. Therefore, the increase in the ac­
tion of amphetamine could be related to the increased 
sensitivity of the postsynaptic DA receptors in the fore­
brain structures. Indeed, the density of DA D2 receptors 
was significantly increased in the striatum of homozy­
gous ( - /- )  mice relative to their wild-type (+/+) litter­
mates, and in the mesolimbic area a similar trend was 
seen. In heterozygous (+/-) mice, the density of DA D2 
receptors was somewhat elevated in the striatum, but not 
at all in the mesolimbic area. By contrast, the density of 
serotonin 5-HT2 receptors in the cerebral cortex was not 
different in homozygous ( - /- )  and heterozygous (+/-) 
mice compared with wild-type (+/+) animals. The in­
creased motor-stimulating effect of amphetamine in 
CCK2R receptor-deficient mice is consistent with the 
previous studies with CCK antagonists. The administra­
tion of CCK into the anterior nucleus accumbens inhibits 
DA-induced hyperlocomotion, and this effect is mediat­
ed via CCK2R receptors (Daugé et al. 1990; Crawley
1992). However, the blockade of CCK2R receptors in 
the nucleus accumbens increases amphetamine-induced 
DA release and hyperlocomotion (Altar and Boyar 
1989).
In conclusion, the targeted mutation of the CCK2R 
receptor gene induces significant changes in the locomo­
tor behaviour of animals. The performance of CCK2R 
receptor-deficient mice was impaired in the rotarod test, 
and their general locomotor activity tended to be re­
duced. Moreover, the motor suppressant action of a 
small dose of apomorphine was stronger in the mutant
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mice, and homozygous (-/—) animals displayed the in­
creased response to the administration of higher dose of 
amphetamine. A clear gene-dose effect is evident from 
these studies since the rotarod performance is impaired 
most in homozygous ( - / - )  mice, and the increased re­
sponse to amphetamine-induced locomotor stimulation is 
also established in mice with the null mutation. Although 
we did not find the major differences in the metabolism 
of DA in three brain structures, the alteration in the func­
tion of the dopaminergic system seems to be related to 
these behavioural changes. One possible reason for 
negative findings could be the detection limits of post­
mortem HPLC analysis of “crude” brain regions and 
more sensitive techniques (in vivo microdialysis) for fur­
ther analysis should be used. The reduced locomotor ac­
tivity, impaired performance in the rotarod test and in­
creased response to apomorphine-induced motor sup­
pression are probably related to the increased sensitivity 
of the presynaptic DA receptors. The increased response 
to amphetamine in homozygous ( - /- )  animals is proba­
bly related to the increased sensitivity o f the postsynap­
tic DA receptors, as is confirmed in the radioligand bind­
ing studies. It is therefore likely that the targeted muta­
tion of CCK2R receptors leads to compensatory changes 
in the activity of the dopaminergic system.
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Abstract
The present study supports a role of CCK? receptors in the regulation of dopamine neurones. In pharmacological studies 
conducted on male CCK? receptor-deficient mice the changes in the activity of dopamine system were established. A low dose of 
dopamine agonist apomorphine (0.1 mg/kg), stimulating the pre-synaptic dopamine receptors, induced significantly stronger sup­
pression of locomotor activity in mutant mice ( - / - )  compared to their wild-type littermates (+/+). The administration of am­
phetamine (3-6 mg/kg), a drug increasing dopamine release, caused a dose-dependent stimulation o f locomotor activity in wild-type 
mice. In mice lacking CCK2 receptors, a lower dose of amphetamine (3 mg/kg) tended to suppress the motor activity, whereas the 
higher dose (6 mg/kg) induced the significantly stronger motor stimulation in mutant mice. Moreover, in the CCK2 receptor-defi- 
cient mice the affinity of dopamine D2 receptors, but not 5-HT2 receptors, was increased. Altogether, the targeted genetic sup­
pression of CCK.2 receptors increased the sensitivity o f pre- and post-synaptic dopamine D2 receptors.
© 2003 Elsevier Science Ltd. All rights reserved.
Keywords: CCK? receptor-deficient mice; L ocom otor activity; 5-HT? receptors; D opam ine D ? receptors; Apom orphine; Am phetam ine
1. Introduction
Cholecystokinin (CCK) is a neuropeptide widely 
distributed in the central nervous system. CCK coexists 
with dopamine in some mesencephalic neurones, inner­
vating mesolimbic and cortical region (Hökfelt et al., 
1980). The interactions between dopamine and CCK are 
complex and depend on the route o f administration of 
CCK, and the subtype o f CCK  receptor involved 
(Crawley and Corwin, 1994; Ladurelle et al., 1997). 
CCK modulates the activity of dopamine system via two 
distinct subtypes o f CCK  receptors, namely CCKi 
(“alimentary” subtype) and CC K 2 (“ brain” subtype) 
receptors (Noble et al., 1999). Both subtypes o f CCK 
receptors are found in the brain structures linked to the 
mesolimbic dopamine system: the ventral tegmental area 
and nucleus accumbens (Crawley and Corwin, 1994; 
Noble et al., 1999). The behavioural and biochemical
Corresponding author. Tel.: +3727-374335; fax: +3727-374332. 
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studies have shown that CCKi and CCK 2 receptors 
mediate the opposite effects o f CCK on the activity o f 
dopamine neurones in mice and rats (Noble et al., 1999; 
Vasar et al., 1991). CCK  increases the release of dopa­
mine in the medial posterior nucleus accumbens by 
stimulating the CCKi receptors, whereas the stimulation 
o f CCK 2 receptors in the anterior nucleus accumbens 
induces an opposite action (Crawley and Corwin, 1994). 
Both the subtypes o f CCK receptors are cloned and 
targeted disruption o f CCKi and CCK 2 receptor genes 
has been achieved in mice (Nagata et al., 1996; Kopin et 
al., 1999). The animals lacking CCKi receptors do not 
respond to the hypophagic effect of CCK, but otherwise 
the feeding behaviour o f mice is not impaired compared 
to wild-type littermates (Kopin et al., 1999). The ani­
mals without CCK2 receptors display the disturbances 
in the development o f gastric mucosa (Nagata et al., 
1996) and in the learning abilities (Sebret et al., 1999).
Taking into account a role o f CCK 2 receptors in the 
regulation o f activity of dopamine neurones (Crawley 
and Corwin, 1994), in the present study an attempt was 
done for the establishing of alterations in the dopamine
0143-4179/03/S - sec front m atter ©  2003 E lsevier Science Ltd. A ll rights reserved, 
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system of ССКг receptor-deficient mice. It is known 
that the mesolimbic dopamine plays a crucial role in the 
regulation of locomotor activity in rodents (Bradbury 
et al., 1983; Costall et al., 1985). Therefore, in the 
present study the action o f two drugs, apomorphine and 
amphetamine, affecting the dopamine transmission, was 
studied on the locomotor activity of CCK 2 receptor- 
deficient mice. Also, in a separate study the parameters 
of CCK, 5 -HT2 and dopamine D 2 receptors were mea­
sured in CCK 2 receptor-deficient and wild-type mice.
2. Materials and methods
2.1. Animals
CCK 2 receptor-deficient mice were provided from the 
original background 129sv/C57BL6 mice (Nagata et al., 
1996). Breeding and genotype analysis have been done 
in the Department of Physiology, University of Tartu. 
Altogether, 62 male homozygous ( - / - )  CCK 2 receptor- 
deficient, 9 male heterozygous mutant (+ /-)  and 62 male 
wild-type mice (+/+) of 129sv/C57BL6 genetic back­
ground (3 months old) were used. The mice were kept in 
the animal house at 2 0 ± 2 ° C  in 12-h light/dark cycle 
(lights on at 07:00). Tap water and food pellets were 
available ad libitum. All animal procedures were ap­
proved by University of Tartu Animal Care Committee 
in accordance with the European Communities Direc­
tive of 24 November 1986 (86/609/EEC).
2.2. Behavioural testing
The animals were brought into the experimental 
room 1 h before the beginning of experiment. According 
to the preliminary studies the behaviour of heterozy­
gous (+ /-)  CCK 2 receptor-deficient mice did not differ 
from that in wild-type animals (+/+) (Vasar et al.,
2000). Therefore, for the following studies only wild- 
type animals and homozygous ( - / - )  CCK 2 receptor- 
deficient mice were chosen. The behavioural effects of 
amphetamine (3 and 6 mg/kg), increasing release of 
dopamine, and apomorphine, stimulating dopamine 
receptors, were studied in the separate groups of ani­
mals. (±)-amphetamine (Sigma) was injected intraperi- 
toneally 20 min and (±)-apom orphine subcutaneously 
(Sigma) 15 min before the beginning of an experiment. 
All behavioural experiments were performed between 
13:00 and 19:00. In the radioligand binding studies the 
animals, not exposed to the behavioural testing, were 
used.
2.3. Motility test
For the study o f locomotor activity an animal was 
placed singly into the photoelectric motility boxes
(448 X 448 X 450 mm) connected to a computer (TSE 
Technical and Scientific Equipment GM BH, Ger­
many). The illumination level of transparent test 
boxes was ~750 lux. Time in locomotion (in seconds), 
distance o f locomotion (in metres), number and time 
of rearing (in seconds), and number o f corner en­
tries were registered during the 15-min observation 
period.
2.4. Radioligand binding studies
For the radioligand binding studies we used 18 male 
homozygous ( - / - )  CCK 2 receptor-deficient mice, 9 male 
heterozygous (+ /-)  mutant and 18 male wild-type (+/+) 
animals. After decapitation the brains were quickly 
dissected on ice. The cerebral cortex and sub-cortical 
structures (involving the striatum, mesolimbic structures 
and septum pellucidum) were dissected. The brain 
structures from three mice were pooled and the experi­
ment was repeated three times. CCK receptor binding 
study was performed in the cerebral cortex and sub- 
cortical structures. The sub-cortical structures were used 
for studying of parameters of dopamine D 2 receptors, 
whereas in the cerebral cortex 5-hydroxytryptamine 
5-HT2 receptors were studied. The radioligand binding 
studies were performed according to Kõks et al. (1997). 
For labeling of dopamine D2 and 5-НТг receptors 
[3H] spiperone (specific activity 107 Ci/mmol, Amersham 
Radiochemicals) was used. The parameters of dopamine 
and 5-hydroxytryptamine receptors were determined in 
the presence of 0.06-2 nM pHjspiperone at 37 °C for 
30 min. Raclopride (Astra, 1 цМ), an antagonist of do­
pamine D 2 receptors, was added to determine the non­
specific binding at dopamine D2 receptors. Ritanserin 
(RBI, 1 цМ), an antagonist of 5-НТг receptors, was used 
to detect the non-specific binding of 5-НТг receptors. 
[Propionyl-3H]propionylated-CCK-8-sulphated-([3H]pC- 
CK-8) (specific activity 73 Ci/mmol, Amersham Radio­
chemicals) was used for labelling o f CCK receptors. The 
parameters of CCK receptors were determined in the 
presence o f 0.05-2.4 nM of pH)pCCK-8 at 23EC for 
120 min. L-365,260 (Merck Sharp and Dohme, 1 pM), 
an antagonist o f CCK 2 receptors, was added to deter­
mine the non-specific binding. The brain tissue was 
homogenized in 20 volumes of ice-cold 50 mM Tris-HCl 
(pH 7.4 at 4 ° Q  using a Potter-S glass-Teflon homoge- 
nizer (1000 rpm, 12 passes). The membranes were wa­
shed twice in the same buffer by centrifugation (48,000# 
for 20min) and re-suspension. After the last centri­
fugation the crude brain membranes were suspended in 
the incubation buffer for the appropriate binding assay. 
The protein content was measured according to the 
method of Bradford (1976). The saturation curves of 
pH]pCCK-8 and pHjspiperone binding were analysed 
using GraphPad Prism (Version 3.00) for Windows 
software.
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2.5. Statistics
Results are expressed as mean values ± S E M . The 
behavioural studies were analysed using one- and two- 
way analysis of variance. Post hoc comparisons between 
individual groups were performed by means of Scheffe 
test using the Statistica for Windows software. Student’s 
t test was applied for the analysis o f radioligand binding 
data.
3. Results
3.1. The increased affinity o f  D2 receptors in CCK2 
receptor-deficient mice
In wild-type mice (+/+) the density o f CCK receptors 
was significantly higher in the cerebral cortex 
№m* 242 ±  47 fmol/mg protein, 1.3 ±  0.3 nM) com­
pared to the sub-cortical structures (BmiX 125 ±  40 fmol/ 
mg protein, 1 .5± 0 .3nM ). In heterozygous (+ /-) 
mutant mice the density of CCK binding sites was sig­
nificantly lower, but again it was higher in the cerebral 
cortex (Smai 120 ±  60 fmol/mg protein, 2.7 ±  0.8 nM) 
than in the sub-cortical structures (Втлх 37 ±  24 fmol/mg 
protein, Kd 2.3 ±  1.3 nM ). The specific binding of 
[3HjpCCK-8 was not detectable in the cortical and sub- 
cortical regions of homozygous ( - / - )  m utant mice. The 
experiments with [3H]spiperone also revealed the differ­
ences between m utant ( - / - )  and wild-type (+/+) animals 
(Table 1). Namely, in the sub-cortical structures, but not 
in the cerebral cortex, the affinity o f [3H]spiperone bind­
ing sites was increased (Student’s t test p  <  0.01) in m u­
tant ( - / - )  mice.
3.2. Apomorphine suppresses motor activity more in CCK2 
receptor-deficient mice
The administration o f low dose o f apomorphine 
(0.1 mg/kg), an unselective agonist o f dopamine recep­
tors, induced the suppression of locomotor activity in 
wild-type (+/+) mice (Fj je =  63.5, p  <  0.01 [time in lo­
comotion]; F3 36 =  67.4 p  < 0.01 [distance in locomo­
tion]; F) 36 =  51.0, p  <  0.01 [number o f rearing];
36 =  37.7, p < 0.01 [time of rearing]; F3 36 =  63.5, 
p  < 0.01 [number o f com er entries]) (Fig. 1). The simi­
lar, but obviously stronger, inhibition o f locomotor
activity was established in mice lacking CCK 2 receptors 
( - / - ) .  The application of two-way ANOVA (geno­
type X treatment) established the difference in the action 
of apomorphine in wild-type (+/+) and mutant mice 
( - /—) (Fig. 1), if the number of rearing ( F ^  =  5.57, 
p  <  0.05) and time of rearing (/^ 36 — 7.59, p  <  0.01) 
were analysed.
3.3. The action o f  amphetamine is different in wild-type 
and CCK2 receptor-deficient mice
The administration of amphetamine (3 and 6 mg/kg), 
increasing the release o f dopamine, induced a dose-de- 
pendent increase in the m otor activity of wild-type mice 
(+/+) ( /-5  78 =  62.7, p  < 0.01 [time in locomotion]; 
F5 78 =  92.0, p  < 0.01 [distance in locomotion]; F5 jg =
9.7, p  < 0.01 [number of rearing]; =  11.1, p  < 0.01 
[time of rearing]; F5j% = 70.3, p  <  0.01 [number o f cor­
ner entries]) (Fig. 2). The application of two-way AN ­
OVA (genotype X treatment) established that the action 
of amphetamine was different in wild-type (+/+) and 
m utant mice ( - / - )  (F2 7 8  =  19.0, p  <  0.01 [time in loco­
motion]; F2 78 =  31.4, p  > 0.01 [distance o f locomotion]; 
^2,78 =  19.0, p  <  0.01 [number o f com er entries]). Three 
mg/kg of amphetamine induced a significant increase in 
the motor activity in wild-type mice (+/+), whereas in 
m utant animals ( - / - )  it reduced the number o f rearing 
(Fig. 2). By contrast, the higher dose of (±)-amphet- 
amine (6 mg/kg) caused the stronger m otor stimulation 
in mice, lacking CCK 2 receptors, compared to their 
wild-type littermates.
4. Discussion
As it was expected, the animals, lacking CCK 2 re­
ceptor gene ( - / - ) ,  did not have a specific binding of 
[3H]pCCK-8 in the cerebral cortex and sub-cortical 
structures. In heterozygous m utant (+/—) mice the den­
sity of CCK receptors was about 30-50% of the corre­
sponding value in wild-type (+/+) animals. Since we 
have not been able to establish the measurable differ­
ences in the behavioural reactions in heterozygous (+ /-) 
and wild-type (+/+) mice (Vasar et al., 2000), the ani­
mals, lacking one CCK 2 receptor allele, are not included 
to the present study. According to the performed 
behavioural studies a  response of CCK 2 receptor-defi-
Table 1
[}H]Spiperonc binding in the sub-cortical structures and cerebral cortex o f  C C K 2 receptor-deficient m ice
Sub-cortical structures (D 2) Cerebral cortex (5-H T 2)
Кл (nM ) Smax (fm ol/m g protein) Кл (nM ) Baa, (fm ol/m g protein)
W ild-type m ice 0.16  ± 0.02 243 ±  15 0.33 ±  0.08 1 5 9 ±  15
CCK 2 receptor-deficient m ice 0.08 ±  0 .0 Г 235 ±  16 0.28 ±  0.06 145 ±  13
*p  <  0.01 (com pared to w ild-type m icc. Student's t  test).
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Fig. 1. T he effcet o f  apom orphine (0.1 m g/kg) on  the locom otor activity o f  wild-type and C C K 2 receptor-dcficicnt mice. T he num ber o f  anim als in 
each group w as 10. W hite bars -  saline treatment; black bars -  apom orphine treatm ent. *p <  0.05 (com pared to  the corresponding saline-treated 
group, SchefTe test after the significant one-w ay A N O V A ); **p <  0.05 (com pared to  apom orphinc-treatcd wild-type mice).
Wild-type (+/+) Homozygous (-/-)
Wild-type (+/+) Homozygous (-7-) W1 Id-type (♦/■*■) Homozygous (-/-)
Fig. 2. T he cflcct o f  am phetam ine (3 and 6 m g/kg) on  the locom otor activity o f  wild-type and C C K , receptor-deficient mice. The num ber o f  animals 
in cach group was 14. W hite bars -  saline treatment; striped bars -  am phetam ine (3 m g/kg); black bars -  am phetam ine (6 m g/kg). * p < 0 .0 5  
(com pared to the corresponding saline-treated group, Seheffe test after the significant one-w ay A N O V A ); * 'p  <  0.05 (com pared to  am phetam ine- 
treated wild-type group).
cient mice to the administration o f dopamine agonists, 
amphetamine and apomorphine, is significantly altered. 
Treatment with a  low dose (0.1 mg/kg) o f apomorphine, 
an unselective agonist o f dopamine receptors, reduces 
the locomotor activity in wild-type mice. This effect is 
linked to the stimulation o f dopamine “auto-receptors” 
located on the dopamine neurones (Meltzer, 1980). 
However, the m otor suppressant action o f apomorphine 
is apparently stronger in mice lacking CCK 2 receptors. 
This finding is in a good agreement with our previous 
studies, where the pre-treatment with CCK 2 receptor 
antagonist L-365,260 potentiates the m otor suppressant 
action o f apomorphine in male mice (Vasar et al., 1991).
Electrophysiological studies in rats demonstrated that 
the acute and long-term administration o f LY262691 
and related pyrazolidinone CCK 2 antagonists decreased 
the number of spontaneously active dopamine cells in 
the midbrain structures, probably via action in the nu­
cleus accumbens and prefrontal cortex (Rasmussen et al.,
1993). The other dopamine agonist amphetamine in­
creases the release of dopamine from the pre-synaptic 
terminals (Kuczenski, 1983), and due to that stimulates 
the pre- and post-synaptic dopamine receptors. The 
administration o f amphetamine (3-6 mg/kg) induces a 
dose-dependent locomotor stimulation in wild-type 
mice. However, in mice lacking CCK2 receptors a lower
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dose (3 mg/kg) o f amphetamine reduces the number of 
rearing, whereas the higher dose (6 mg/kg) causes sig­
nificantly stronger locomotor stimulation compared to 
wild-type animals. The reduced effect o f lower dose of 
amphetamine could be related to the increased sensi­
tivity of dopamine “auto-receptors” in m utant ( - / - )  
mice established in the studies with apomorphine, 
whereas the increased effect o f higher dose o f amphet­
amine seems to be related to the increased sensitivity of 
post-synaptic dopamine receptors. Indeed, the affinity of 
dopamine D2 receptors labelled by [3H]spiperone is 
significantly increased in the forebrain sub-cortical re­
gions of CCK.2 receptor-deficient mice. This finding is in 
good accordance with the experiments o f Ferraro et al. 
(1996) showing that the application o f CCK-8 to the 
striatal membranes reduces the affinity o f dopamine D 2 
receptors and this effect is counteracted by the CCK2 
receptor antagonist P D 134308. By contrast, the affinity 
of 5-HT2 receptors is not affected in male mice lacking 
CCK.2 receptors. The increased m otor stimulating effect 
of amphetamine in the CCK2 receptor-deficient mice is 
consistent with the previous studies. The administration 
of CCK into the anterior nucleus accumbens inhibits 
dopamine-induced hyper-locomotion and this effect is 
mediated via CCK2 receptors (Daugé et al., 1990; 
Crawley, 1992). On the other hand, the blockade of 
CCK2 receptors in the nucleus accumbens increases 
amphetamine-induced dopamine release and hyper­
locomotion.
In conclusion, the targeted m utation of CCK2 re­
ceptor gene induces the significant changes in the ac­
tivity of dopamine system. CCK2 receptor-deficient mice 
have the increased sensitivity of pre- and post-synaptic 
dopamine D2 receptors. However, the molecular back­
ground of this change is unclear and remains to be 
established.
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A bstract Rationale: Cholecystokinin (CCK) interacts 
with the endopioid system in the regulation of various 
physiological functions, including the control of pain 
sensitivity, motor activity and emotional behaviour. 
Objective: The aim of the present work was to study 
the pain sensitivity, morphine-induced antinociception 
and density of opioid receptors in mice lacking CCK2 
receptors. Methods: Plantar analgesia and hotplate tests 
were used to evaluate pain sensitivity and morphine- 
induced antinociception. The parameters o f opioid recep­
tors were analysed by using [3H]-diprenorphine binding. 
Results: In the plantar analgesia test the latency of hind 
paw withdrawal was significantly increased in CCK2 
receptor deficient mice compared to wild-type (+/+) 
littermates. The treatment with saline reversed the 
reduced pain sensitivity in heterozygous (+ /-) and 
homozygous ( - /—) mice. The administration of morphine 
(1 mg/kg) induced a significantly stronger antinociceptive 
effect in homozygous (—/—) mice compared with wild- 
type (+/+) animals. In the hotplate test, only homozygous 
( - /- )  mutant mice displayed the delayed latency of hind 
paw licking/shaking in comparison with wild-type (+/+) 
mice. The injection of saline and isolation of mice for 
30 min reversed the delayed response in homozygous 
( - / - )  mice. However, in this test, the anti-nociceptive 
action of morphine (5-10 mg/kg) in mutant mice did not 
differ from that in wild-type (+/+) littermates. By
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contrast, the jump latency was decreased in both homo­
zygous ( - / - )  and heterozygous (+ /-) mice in the hotplate 
test. The increased density o f opioid receptors was 
established in the striatum of homozygous ( - / - )  mice. 
Conclusion: It is apparent that the targeted mutagenesis of 
the CCK2 receptor gene has different effects on the 
sensitivity of opioid receptors in various brain structures. 
This is a probable reason for the altered pain sensitivity 
and morphine-induced antinociception in mutant mice 
compared to wild-type (+/+) littermates.
Keywords Targeted mutagenesis • CCK - receptor ■ 
Wild-type • Heterozygous • Homozygous ■ (i-Opioid 
receptors • Pain sensitivity • Plantar analgesia test • 
Hotplate test • Mouse
Introduction
Cholecystokinin (CCK) is generally believed to be the 
most widespread and abundant neuropeptide in the brain 
(Noble et al. 1999). High levels of CCK and preproCCK 
mRNA have been identified throughout the brain, 
including the cerebral cortex, olfactory bulb, olfactory 
tubercle, hippocampus, basal ganglia, hypothalamus and 
periaquaductal gray (Savasta et al. 1988; Vanderhaeghen 
and Schiffmann 1992; Shlik et al. 1997). The effects of 
CCK are mediated by two distinct receptor subtypes 
(CCKi and CCK2) that have been cloned and functionally 
expressed (Noble et al. 1999). Binding and autoradiog­
raphy studies have detected CCK] receptors in high 
concentration throughout the gastrointestinal tract and in 
a few discrete brain regions such as the area postrema, 
nucleus of the solitary tract, interpeduncular nucleus, 
dorsal raphe, nucleus accumbens, substantia nigra and 
ventral tegmental area (Roques and Noble 1998). CCK2 
receptors are mainly distributed in the brain, with the 
highest concentrations in the striatum, cerebral cortex and 
limbic system, but they can also be found in the stomach 
(Noble et al. 1999). Various studies support the antago­
nistic interaction between two neuropeptide systems,
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CCK and endopioid peptides, in the regulation of 
physiological functions, including the control of pain 
sensitivity, motor activity and emotional behaviour. The 
administration of CCK attenuates, whereas the selective 
CCK2 receptor antagonists enhance, morphine-induced 
antinociception in rodents (Faris et al. 1983; Lavigne et 
al. 1992; Noble et al. 1995). The pretreatment of mice 
with the CCK2 receptor oligonucleotide antisense signif­
icantly increases morphine-induced antinociception (Van- 
derah et al. 1994). On the other hand, the CCK2  receptor 
antagonists can also facilitate the rewarding properties of 
morphine in the conditioned place preference test 
(Valverde et al. 1996). Moreover, a morphine-induced 
increase in locomotor activity can be antagonised by the 
pretreatment with CCK (Schnur et al. 1991). These 
findings suggest that CCK may act, via CCK2 receptors, 
as an endogenous anti-opioid peptide. It is also notewor­
thy that the distribution of both CCK and CCK2 receptors 
parallels with that of endopioid peptides and opioid 
receptors in the brain (Saito et al. 1980; Gall et al. 1987; 
Ghilardi et al. 1992).
Recently targeted disruption of CCK2 receptor genes 
has been achieved in mice (Nagata et al. 1996). The 
animals without CCK2 receptors display disturbances in 
the development of gastric mucosa (Nagata et al. 1996) 
and in the learning abilities (Sebret et al. 1999). The 
activity of the dopaminergic system is also affected in 
mice with corrupted function of CCK2 receptors (Daugé 
et al. 2001; Kõks et al. 2001). Pommier et al. (2002) have 
shown that mice without CCK2 receptors display hyper­
algesia and a reduced response to morphine-induced 
analgesia in the hot plate test. They have applied the 
jumping behaviour as a sign of nociceptive response in 
mice. This is in an obvious contradiction with the data of 
the above-cited pharmacological studies, where the CCK 2 
receptor antagonists potentiate morphine-induced analge­
sia (Faris et al. 1983; Lavigne et al. 1992; Noble et al. 
1995). However, according to various authors, the 
jumping response is not the true threshold of pain 
sensitivity, but rather reflects tolerance to pain in the 
hotplate test (Perissin et al. 2000; Wilson and Mogil 
2001). Therefore, the present study focused on pain 
sensitivity in the plantar analgesia and hotplate test, using 
the hind limb withdrawal and licking/shaking of a hind 
paw as thresholds of nociception. The jump latency was 
used as a measure of pain tolerance. The changes in 
morphine-induced antinociception were also evaluated in 
mice without CCK2 receptors. Additionally, the density of 
opioid receptors was studied in the forebrain structures of 
mutant and wild-type mice.
Materials and methods
A n im als
CCK2 receptor-deficient mice were provided from the original 
background 129sv/C57BL6 mice (Nagata et al. 1996). CCK2 
receptor-deficient mice were generated by homologous recombi­
nation by replacing a part of exon 2 and exons 3, 4 and 5 (Nagata et
al. 1996). Breeding and genotype analysis were performed at the 
Department of Physiology, University of Tartu. Genotyping was 
carried out by means of polymerase chain reaction (PCR) using two 
pairs of primers HE2F (TGG AGT TGA CCA TTC GAA TCA C) 
and LacZrev (GTG CTG CAA GGC GAT TAA GTT G) were 
designed to detect the mutant allele, and HE3F (TAT CAG TGA 
GTG TGT CCA CTC T) and HE3R (АСА TTT GTT GGA CAC 
GTT CAC) were designed for the wild-type allele. For PCR, we 
used the following protocol: 96°C for 10 min (initial dénaturation); 
96°C for 50 s, 60°C for 50 s and 72°C for 2 min (25 cycles); and 
72°C for 10 min (final amplification). PCR products were stored at 
4°C until electrophoresis. Mutant mice were back-crossed six times 
to the C57/BL6 background to minimize the possible genetic 
effects from the 129sv strain. The mice were kept in the animal 
house at 20±2°C under a 12/12-h light/dark cycle (lights on at 
0700 hours). Tap water and food pellets were available ad libitum. 
The male mice (3 months old) were used throughout the 
experiments and animals were used only once. Altogether, 377 
homozygous (- /-)  CCK2 receptor-deficient, 374 heterozygous 
mutant (+/-) and 355 wild-type (+/+) mice were used in the 
behavioural and radioligand binding studies. All animal procedures 
were approved by the University of Tartu Animal Care Committee 
in accordance with the European Communities Directive of 24 
November 1986 (86/609/EEC).
Plantar analgesia test
The plantar analgesia test was performed according to the method 
of Hargreaves et al. (1988). The instrument for the measurement of 
plantar analgesia consists of a movable infrared generator, 
platform, mouse enclosure assembly and controller (TSE Technical
& Scientific Equipment GMBH, Germany). In order to avoid the 
confounding effects of novelty and handling stress, prior handling 
of mice and habituation to the test equipment was performed. The 
animals were adapted for three consecutive days to the equipment, 
a 60-min session each day. Before the experiment a sufficient time 
(30 min) for exploration of the equipment, without presentation of 
stimulus, was allowed to each mice. After the adaptation period, the 
animals stayed quietly in a resting position, with occasional bouts 
of grooming, allowing to direct a beam of infrared light (intensity 
equal to 5(rC) to the skin of a hind paw. The equipment measured 
latency to withdraw the hind paw automatically. The stimulation of 
the hind paw was repeated up to four times and the medium latency 
was calculated. At least a 2-min interval was kept between two 
measurements. Saline and morphine (1 mg/kg IP) were adminis­
tered 15 min before the test. The morphine dose was chosen 
according to the pilot studies where the lower doses (0.05-0.5 mg/ 
kg IP) of morphine did not cause a statistically significant effect in 
wild-type animals.
Hotplate test
An animal was placed on a surface (30x50 cm) maintained at 
52±0.3°C and a glass funnel (diameter 15 cm, height 12.5 cm) was 
used to restrict the movements of the animal. The time when a 
mouse began to lick or shake its hind paw was noted as the pain 
threshold in seconds. Animals not exhibiting such aversive 
behaviour were removed at 40 s from the hotplate. Morphine (5; 
7.5; 10 mg/kg IP) and saline were administered 15 min before the 
test. The effect of saline was also studied 90 min after the 
administration. In the isolation experiment the animals were taken 
from the home cage and placed singly into boxes for 30 min. The 
hotplate test was performed after the isolation period. In one 
experiment, the animals were divided into two groups. One group 
was treated with the repeated injections of saline (once daily) for 10 
days in the experimental room, whereas the other half did not 
receive any manipulations and was kept in the animal facility. 
Twenty-four hours after the last injection of saline, both groups of 
animals were subjected to the hotplate test.
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The other experiment measured the latency to jump. A 2-min 
cut-off time was chosen according to our pilot studies, where we 
noticed that the majority of wild-type and CCK2 receptor-deficient 
mice responded during that period. After the experiment mice, 
when released to the home cage, did not show any behaviour to 
conclude that they had been damaged in any way by the noxious 
exposure. All pain measurements were carried out between 1100 
and 1800 hours.
Radioligand binding studies
After decapitation the brains were quickly dissected on ice. The 
cerebral cortex (including the frontal and parietal cortices), striata, 
mesolimbic structures and hippocampus were dissected (Franklin 
and Paxinos 1997). The brain structures from six mice were pooled. 
The radioligand binding studies were performed according to the 
method of Kõks et al. (1997). For the labelling of opioid receptors 
[3H]-diprenorphine (specific activity 58.0 Ci/mmol; Amersham 
Radiochemicals) was used. The parameters of opioid receptors 
were determined in the presence of 0.05-2.5 nM [3H]-diprenor- 
phine at 23°C for 60 min. Naloxone hydrochloride (RBI, 1 цМ), an 
antagonist of opioid receptors, was added to determine the non­
specific binding at opioid receptors. The brain tissue was homog­
enized in 20 vol ice-cold 50 mM Tris-HCl (pH 7.4 at 4° C) using a 
Potter-S glass-teflon homogenizer (1000 rpm, 12 passes). The 
membranes were washed twice in the same buffer by centrifugation 
(48,000 g for 20 min) and re-suspension. After the last centrifu­
gation, the crude brain membranes were suspended in the 
incubation buffer (50 mM Tris-HCl, pH 7.4 at 4°C) for the binding 
assay. The protein content was measured according to the method 
of Bradford (1976). The saturation curves of [3H]-diprenorphine 
binding were analysed using GraphPad Prism (Version 3.00) for 
Windows software. The experiment was repeated four times.
Statistics
Results are expressed as mean±SEM. The results were analysed by 
using one- and two-way analyses of variance (ANOVA). Post hoc 
comparisons between the individual groups were performed by 
means of the Tukey HSD test. The Statistica for Windows software 
was used.
Results
Plantar analgesia test
The testing of heterozygous (+ /-) and homozygous ( - / - )  
mice in the plantar analgesia test established a signifi­
cantly increased hind paw withdrawal latency in these 
mice compared to wild-type (+/+) littermates [F(2,135)= 
28,59, /*>0.01, Fig. 1А]. The latency was, on average, 
twice longer in both homozygous ( - / - )  and heterozygous 
(+/-) animals compared with wild-type (+/+) littermates. 
The pretreatment of mice with saline induced a decrease 
of nociceptive thresholds in mice [two-way ANOVA: 
treatment, F(l,42)=22.1, P>0.01; genotype F(2,42)=8.21, 
P>0.05; genotype x treatment, F(2,42)=1.99, P>0 . 1 ; 
Fig. 1В]. However, the subsequent statistical analysis 
established a significant reduction only in mutant mice 
(Tukey HSD test: wild-type (+/+) /*>0.1; heterozygous 
(+ /-) P>0.01; homozygous ( - / - )  P>0.01). The adminis­
tration of morphine (1 mg/kg), a ц-opioid receptor 
agonist, induced a significant decrease o f pain sensitivity 
in wild-type (+/+) mice compared to the injection of
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Fig. 1A-C The response of mice without CCK2 receptors in the 
plantar analgesia test. A Baseline response. n=46 for each group. 
*P <0.01 (compared with wild-type mice, Tukey HSD test after the 
significant one-way ANOVA). В Effect of saline. n=8 for each 
group. White bars baseline, black bars saline treatment *P<0.05 
(compared with the baseline response of wild-type mice, Tukey 
HSD test after the significant one-way ANOVA); +P<0.05 
(compared with the baseline response of heterozygous and homo­
zygous mice). С Effect of morphine (1 mg/kg). rt=8 for each group. 
White bars saline treatment, black bars morphine (1 mg/kg IP), 
*P<0.05 (compared with morphine-treated wild-type mice, Tukey 
HSD test after the significant two-way ANOVA), +P<0.05 
(compared with saline-treated homozygous mice)
saline. However, the antinociceptive effect of morphine 
(1 mg/kg) was significantly stronger in homozygous ( - / - )  
CCK2 receptor deficient mice compared to heterozygous 
(-/+ ) and wild-type (+/+) mice [two-way ANOVA: 
treatment F(l,42)=38,8, /ЪЮ.01; genotype F(2,42)=5.65, 
/*>0.01; genotype x treatment, F(2,42)= 3.32, P>0.05, 
Fig. 1C].
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Fig. 2A-D The response of mice without CCK2 receptors in the 
hot plate test. A Baseline response. The number of animals was as 
follows: wild-type 118, heterozygous 131 and homozygous 139. 
*/><0.01 (compared with wild-type mice, Tukey HSD test after the 
significant one-way ANOVA). В Effect of saline. The number of 
animals as follows: wild-type 58, heterozygous 62 and homozygous 
60. White bars baseline response, black bars saline treatment. 
*P<0.05 (compared with the baseline response of wild-type 
animals, Tukey HSD test after significant two-way ANOVA), 
+/’<0.05 (compared with baseline response of homozygous mice). 
С Effect of isolation for 30 min. n=24 for each group. White bars
Hotplate test
In the hotplate test homozygous (—/—) mice also displayed 
a delayed hind paw licking/shaking time compared to 
wild-type (+/+) littermates [one-way ANOVA, F(2,385)= 
55,44 /*>0.01, Fig. 2А]. The pretreatment of mice with 
saline reversed this phenomenon in mutant mice if a 
measurement was performed 15 min after the injection 
[two-way ANOVA: genotype F(2,174)=10.58, P>0.05, 
treatment F(l,174)=38.93, F>0.01; genotype x treatment, 
F(2,174)=9.95, P>0.01, Fig. 2В]. However, the testing of 
mice conducted 90 min after the treatment with saline did 
not reveal any differences between the saline-treated and 
untreated homozygous ( - / - )  mice (data not shown). Also, 
isolation of mice for 30 min attenuated the reduced 
nociception in homozygous ( - / - )  mice [two-way 
ANOVA: genotype F(2,132)=9.10, F*>0.01 ; isola­
tion F(l,132)=50.74, P>0.01; genotype x isolation, 
F(2,132)=5.00, P>0.01, Fig. 2С]. The experiment per­
formed 24 h after the last injection o f saline (once daily 
for 10 days) demonstrated that this manipulation abol­
ished the reduced nociception in homozygous ( - / - )  mice
Wild-type Heterozygous Homozygous
animals kept in the home cage, black bars isolated mice. */’<0.05 
(compared with the baseline response of wild-type animals, Tukey 
HSD test after significant two-way ANOVA), +/’<0.05 (compared 
with baseline response of heterozygous and homozygous mice). D 
Effect of repeated treatment with saline. Saline was administered 
once daily for 10 days and the experiment was performed 24 h after 
the last injection of saline. n=10 for each group. White bars 
untreated mice, black bars repeated treatment with saline. */’<0.05 
(compared with the untreated wild-type animals, Tukey HSD test 
after significant two-way ANOVA)
[two-way ANOVA: genotype F(2,54)=4.68, P>0.05; 
treatment F(l,54)=0.08, P>0.5; genotype x treatment, 
F(2,54)=5.23, P>0.01, Fig. 2D]. Differently from the 
plantar test, a significantly higher dose of morphine 
(7.5 mg/kg) was necessary to induce a significant 
antinociceptive effect However, the antinociceptive 
effect of morphine (5-10 mg/kg) did not differ in mutant 
and wild-type (+/+) mice [two-way ANOVA: geno­
type F( 1,168)= 1.04, P>0.35; treatment F(3,168)=88.4, 
P>0.01; genotype x treatment, F(6,168)=0.49, P>0.8, 
Fig. 3]. If the jumping latency was used as a measure of 
nociception, then the results were totally opposite to those 
established by the measuring of hind paw licking/shaking 
response. Namely, the jump latency was significantly 
longer in wild-type (+/+) mice compared to heterozygous 
(-/+ ) and homozygous ( - / - )  animals [one-way ANOVA, 
F(2,24)=6.80, P>0.01, Fig. 4].
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Fig. 3 The effect of morphine (5-10 mg/kg) on the response of 
mice without CCKi receptors in the hot plate test. n=15 for each 
group. White bars saline, striped bars morphine 5 mg/kg, checked 
bars morphine 7.5 mg/kg and black bars morphine 10 mg/kg. 
*/><0.05; **Я<0.01 (compared with the respective saline-treated 
group, Tukey HSD test after significant one-way ANOVA)
Fig. 4 The jump latency of mice without CCK2 receptors in the hot 
plate test. The numbers of animals were as follows: wild-type 18, 
heterozygous 22 and homozygous 18. *P<0.01 (compared with 
wild-type mice, Tukey HSD test after significant one-way 
ANOVA)
Radioligand binding studies
The radioligand binding studies with [3H]-diprenorphine 
demonstrated that the affinity o f opioid binding sites in 
the cerebral cortex of mutant mice tended to be increased 
compared to wild-type (+/+) littermates [F(2,6)=4.59, 
/*=0.062] (Fig. 5). However, a decreased affinity 
[F(2,6)=6.82, P>0.05] and increased density [F(2,6)= 
5.82, P>0.05] o f opioid binding sites was established in 
the striatum of homozygous ( - / - )  mice. The parameters 
of [3H]-diprenorphine binding were not affected in the 
mesolimbic structures and hippocampus.
Discussion
A major finding of the current study is that the 
nociceptive response o f mice, lacking CCK2  receptors, 
depends on the paradigm used for the measurement of 
pain sensitivity. In the plantar analgesia test pain sensi-
Cerebral Striatum Mesolimbic Hippocampus 
cortex area
1500-,
Cerebral Striatum Masolimbic Hippocampus 
cortex area
Fig. 5 The parameters of [3H]-diprenorphine binding in the brain 
structures of mice without CCK2 receptors. л=24 for each group. 
The brains of six mice were pooled, and the mean is a result of four 
experiments. White bars wild type, striped bars heterozygous, 
black bars homozygous. *P<Q.Q5 (compared with wild-type group, 
Tukey HSD test after significant one-way ANOVA)
tivity of heterozygous (+/—) and homozygous ( - /—) mice 
is significantly reduced compared to wild-type ( - / - )  
littermates. However, in the hotplate test, the response of 
mutant mice was related to the endpoint used to determine 
the threshold of nociceptive behaviour. If  the hind paw 
licking/shaking was used as the endpoint, then homozy­
gous ( - / - )  mice had a significantly delayed response to 
the noxious influence. The situation was completely 
different when we used the jump latency as the threshold 
for determining of nociceptive behaviour. The jump 
latency of wild-type mice (+/+) is significantly longer 
compared to heterozygous (+/—) and homozygous ( - /—) 
mutant animals. It is important that heterozygous (+ /-) 
animals, having 50% of CCK2 receptors left, have a clear 
phenotype in the plantar analgesia and hotplate tests. 
Differently from the homozygous ( - / - )  mice, heterozy­
gous (+ /-) animals do not have any disturbances in the 
development of gastric mucosa (Nagata et al. 1996), 
which may potentially interfere with the pain sensitivity 
in mice without CCK2 receptors. The reduced jump 
latency is in good agreement with a recent study of 
Pommier et al. (2002), where wild-type (+/+) and 
homozygous ( - / - )  mice were compared. Nevertheless, it 
is unclear whether the jump latency is a true threshold to 
the painful stimuli. Wilson and Mogil (2001) believe that
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the best endpoint in the mouse is almost always hind paw 
licking or vigorous shaking, whichever occurs first. 
Hotplate-naive mice very rarely jum p until long after 
they have responded in another way (Wilson and Mogil 
2001). The jump response is considered as a measure of 
pain tolerance, and it is heavily influenced by morphine 
(Frederickson et al. 1977; Bar-Or and Brown 1989). This 
behavioural response is clearly an escape from the 
noxious stimuli and therefore involves more complex 
neural circuits (probably involving fear and anxiety 
circuits) than hind paw licking/shaking. The distinct 
behavioural responses in the models o f pain sensitivity are 
also established in the animals lacking the other genes 
related to the regulation of nociceptive behaviour. The 
animals lacking pre-proenkephalin, tachykinin-1 and 
cannabinoid receptor CB1 genes were all reported to 
display altered sensitivity on the hotplate test but 
unchanged sensitivity on the tail-flick test (König et al. 
1996; Zimmer et al. 1998, 1999).
Another interesting finding of the present study is that 
the reduced pain sensitivity in mice, lacking CCK2 
receptors, is affected by the administration o f saline and 
isolation of mice for 30 min. The treatment with saline 
and isolation of mice attenuates the reduced pain sensi­
tivity in mutant mice. It is worth noting that the effect of 
saline was present 15 min, but not 90 min, after 
administration in the hotplate test. Therefore, it is likely 
that the injection of saline induces the release of unknown 
substances attenuating the reduced nociceptive response 
in mutant mice. Evidence suggests that CCK receptor 
antagonist proglumide antagonises nocebo hyperalgesia 
induced by saline in humans (Benedetti et al. 1997). 
Moreover, Drago et al. (2001) have found that the 
administration of saline increases the immobility of rats in 
the forced swimming test. It has been suggested that 
catecholamines and endorphins may play a role in the 
effect of saline in the forced swimming test (Drago et al.
2001). Nevertheless, the background of saline-induced 
reversal of reduced pain sensitivity remains unclear, but 
could also be attributed to the previous findings that 
stressful factors affect the interaction between CCK and 
morphine in behavioural experiments. It has been shown 
that the administration of CCK antagonises morphine- 
induced antinociception in a novel but not in a familiar 
environment (Wiertelak et al. 1992). The same is true 
regarding the potentiation of morphine-induced antinoci­
ception by the CCK2 receptor antagonists (Lavigne et al. 
1992). This could be linked to the fact that CCK is also 
involved in the regulation o f anxiety (Harro et al. 1993). 
Indeed, CCK agonists induce an anxiogenic-like action in 
an unfamiliar stressful, but not in a safe, environment 
(Kõks et al. 2000). The combination of sub-threshold 
doses of CCK-4 and opioid antagonist naloxone induces a 
significant neophobia in rats in the elevated plus-maze 
(Kõks et al. 1998). Therefore, it is possible that CCK and 
endopioid peptides play an opposite role in the adaptation 
to a novel environment. CCK signals that the environment 
is unsafe, whereas the endopioid system mediates the 
information that there is no danger in the surrounding
environment (Kõks et al. 1998, 2000). This could explain 
why the baseline pain sensitivity of mice without CCK2 
receptors is reduced. Repeated treatments with saline 
increase alcohol consumption in low preference mice and 
the effect of saline is blocked by the administration of the 
CCK2 receptor antagonist CAM1028 (Little et al. 1999). 
This is probably not linked to the anxiolytic action of 
CAM 1028 because diazepam (1 mg/kg) was ineffective 
under these circumstances. In agreement with this finding, 
we found that repeated treatment with saline (once daily 
for 10 days) abolished the reduced nociception in mice 
lacking CCK2 receptors. Accordingly, it is obvious that 
the repeated stressful manipulations reverse the reduced 
nociception in CCK2 receptor deficient mice.
The effect of morphine, ц-opioid receptor agonist, also 
depends on the approach used. In the plantar analgesia 
test, the antinociceptive effect of morphine (1 mg/kg) in 
homozygous ( - / - )  mice is significantly increased com­
pared to wild-type (+/+) littermates. This is in good 
agreement with previous studies where the administration 
of CCK2 receptor antagonists or use of CCK2 receptor 
antisense potentiates morphine-induced antinociception in 
rodents (Vanderah et al. 1994, 1996). In the hotplate test, 
a significantly higher dose of morphine (7.5 mg/kg) is 
necessary to induce the antinociceptive effect, and there is 
no difference in the action of opioid agonist in wild-type 
(+/+) and mutant mice. Pommier et al. (2002) established 
the reduction of opioid receptors at the supra-spinal level. 
We measured the density of opioid receptors by [3H]- 
diprenorphine in four forebrain structures (cerebral cor­
tex, hippocampus, striatum and mesolimbic area) and at 
least in these structures no decline in the density of opioid 
receptors was observed. Indeed, the number of opioid 
receptors is elevated in the striatum of mutant mice, 
whereas the other structures show no difference in the 
density of receptors between the homozygous ( - / - )  and 
w ild-type (+/+) animals. On the other hand, the affinity 
of opioid receptors is decreased in the striatum. This 
could argue in favour o f the initial idea of Pommier et al. 
(2002) that the levels of endopioid peptides are increased 
in certain brain regions and therefore the affinity of opioid 
receptors is decreased. A micro-array study was per­
formed in the striatum in order to reveal differences 
between the wild-type (+/+) and homozygous ( - / - )  mice 
in the gene expression (our unpublished data). According 
to this study, the expression of the ц-opioid receptor gene 
was increased, whereas the expression of pre-proenke­
phalin, a precursor molecule of enkephalins, and noci- 
ceptin genes was reduced. By contrast from the striatum 
the affinity o f opioid receptors tended to be increased in 
the cerebral cortex of mutant mice compared to wild-type 
(+/+) littermates. Accordingly, the targeted mutation of 
CCK2 receptors affects differently the parameters of 
opioid receptors in the forebrain structures. The distinct 
changes in the sensitivity of opioid receptors in various 
brain structures may explain why the effect of morphine 
is increased in the plantar analgesia test, but remains 
unchanged in the hotplate test in CCK2 receptor deficient 
mice. Pommier et al. (2002) showed that mutant mice
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revealed not only a reduced latency to jump, but their 
response to the anti-jumping effect of morphine was also 
reduced. This finding may reflect the increased function 
of anti-opioid systems in the brain. Indeed, Pommier et al 
(2002) demonstrated the role o f NMDA receptors because 
MK-801, an antagonist of NMDA receptors, effectively 
reversed the increased response of CCK2 receptor defi­
cient mice.
In conclusion, the present study established a reduced 
pain sensitivity of CCK2 receptor deficient mice in the 
plantar analgesia and hotplate tests. However, CCK2 
receptor deficient mice seem to have a reduced tolerance 
to painful stimuli as measured by the jump latency in the 
hotplate test. Moreover, a clear dissociation of morphine 
effects is present in mice lacking CCK2 receptors. In the 
plantar analgesia test the antinociceptive action of 
morphine is significantly stronger in mutant mice, 
whereas in the hotplate test the effect o f ц-opioid receptor 
agonist remains unchanged compared with wild-type (+/ 
+) littermates. In the jum p latency test, a measure of pain 
tolerance, the effect of morphine is significantly reduced 
in CCK2 receptor deficient mice compared to wild-type 
(+/+) littermates (Pommier et al. 2002). The molecular 
background of these phenomena is unclear but could be 
explained in the light of data showing that the targeted 
mutation of CCK2 receptors induces distinct changes in 
the properties of opioid receptors in various brain 
structures.
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Abstract
The с fleets of morphine, (x-opioid receptor agonist, and naloxone, a non-selective opioid receptor antagonist, in the locomotor activity 
and place conditioning tests were studied in the CCK2 rcccptor-deficient male mice. The exposure of mice to the motility boxes for 3 
consécutive days induccd a significant inhibition of locomotor activity in the wild-type (+ /+) mice compared to homozygous (—/—) 
animals. The administration of naloxone (10 mg/kg i.p.) to animals, adapted to the motility boxes, induced a significant reduction of 
locomotor activity in the homozygous (—/—), but not in the wild-type (+ /+) mice. Treatment of habituated mice with morphine (10 mg/kg 
i.p.) caused a stronger increase of locomotor activity in the wild-type (+ /+) mice compared to the homozygous (—/—) littermates. In 
the place preference test the pairing of the preferred side with naloxone (1 and 10mg/kg i.p.) induced a dose-dependent place aversion 
in the wild-type (+ /+) mice. The treatment with naloxone was less effective in the homozygous (—/—) mice, because the high dose of 
naloxone (10 mg/kg) tended to shift the preference. The pairing of morphine (3 mg/kg i.p.) injections with the non-preferred side induccd 
a significant place preference both in the wild-type (+ /+) and homozygous (—/—) mice. The increased density of opioid receptors was 
established in the süiatum of homozygous (—/—) mice, but not in the other forebrain structures. In conclusion, the targeted invalidation 
of CCK2 receptors induces a dissociation of behavioural effects of morphine and naloxone. Morphine-induced place preference remained 
unchanged, whereas hyper-locomotion was less pronounced in the mutant mice compared to the wild-type (+ /+) littermates. By conüast, 
naloxone-induced place aversion was weaker, but naloxone caused a stronger inhibition of locomotor activity in the homozygous (—/—) 
mice than in the wild-type (+ /+ ) animals. These behavioural alterations can be explained in the light of data that the targeted mutation of 
CCK2 receptors induces distinct changes in the properties of opioid receptors in various brain structures.
© 2003 Elsevier Science B.V. All rights reserved.
Keywords: CCK2 rcccptors; Targeted mutagenesis; Mouse; Wild-type; Homozygous; Opioid receptors; Morphine; Naloxone; Place conditioning; Locomotor 
activity
1. Introduction
Various studies support the antagonistic interaction bet­
ween two neuropeptide systems, cholecystokinin (CCK) and 
endogenous opioid peptides, in the regulation of behaviour. 
The administration of CCK attenuates, whereas the selec­
tive CCK2  receptor antagonists enhance, morphine-induced 
anti-nociception in rodents [6,17,22]. CCK2 receptor an­
tagonists, but not CCKi receptor antagonists, facilitate the 
antidepressant-like effect induced by endopioid peptides 
in the conditioned suppression of the motility test in mice
* Corresponding author. Tel.: +372-7374335; fax: +372-7374332. 
E-nuiil address.* Sulev.Koks@ut.ec (S. Kõks).
[30]. Moreover, the selective CCK2 antagonists potenti­
ate the rewarding effect of morphine in the place condi­
tioning paradigm [10,33]. The CCK2  receptor antagonists 
L-365,260 and PD-134,308 are shown to attenuate the place 
aversion induced by naloxone in morphine-dependent rats, 
whereas the CCKi receptor antagonist devazepide is inef­
fective [34]. A morphine-induced increase in the locomotor 
activity can also be antagonised by the pre-treatment with 
CCK [26]. These findings suggest that CCK may act, via 
CCK2  receptors, as an endogenous anti-opioid peptide. It is 
also noteworthy that the distribution of both CCK and CCK2 
receptors parallels with that of endopioid peptides and opi­
oid receptors in the brain [8,9,24]. Recently, the mice with 
targeted disruption of CCK2 receptor gene have been gen­
erated [21]. The animals without CCK2 receptors display
0166-4328/$ -  see front matter © 2003 Elsevier Science B.V. All rights reserved, 
doi: 10. !016/S0166-4328(03)00070-6
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disturbances in the development of gastric mucosa and in 
learning abilities [21,27]. The activity of the dopaminergic 
system is also affected in mice with a corrupted function of 
CCK2 receptors, because the sensitivity of dopamine D2 re­
ceptors is increased in mutant mice [5,16]. Recent evidence 
suggests the altered function of the endogenous opioid 
system in mice without CCK2 receptors. Pommier et al. 
demonstrated that mice, lacking CCK2 receptors, displayed 
hyperalgesia and a reduced response to morphine-induced 
analgesia in the hotplate test [23]. According to this study, 
mutant mice exhibit hypersensitivity to morphine-induced 
locomotor activity and develop a more severe withdrawal 
syndrome after chronic morphine treatment [23]. Therefore, 
Pommier et al. stated that the deletion of CCK2 recep­
tors resulted in an up-regulation of the endogenous opioid 
system [23].
Morphine, like psychostimulants (cocaine, amphetamine, 
and methamphetamine), induces conditioned place prefer­
ence and motor activation [3]. Maldonado et al. showed 
that morphine-induced hyperlocomotion and conditioned 
place preference could be dissociated in the genetically 
modified mice [19]. They found that in dopamine D2 
receptor-deficient mice morphine did not induce conditioned 
place preference, but increased the locomotor activity. Our 
previous study established that animals without CCK2 
receptors had an increased sensitivity of dopamine D2 re­
ceptors [16]. Therefore, the aim of the present study was 
to investigate whether morphine-induced hyperlocomotion 
and conditioned place preference were also dissociated in 
mice without CCK2 receptors. Also, we studied the effect of 
naloxone, a non-specific antagonist of opioid receptors, on 
locomotor activity and on the place conditioning paradigm 
of CCK2 receptor-deficient mice. Pommier et al. found that 
the affinity and density of opioid receptors was not changed 
in the whole brain of mice without CCK2 receptors [23]. 
However, the interaction of CCK with endogenous opioid 
peptides and opioid receptors is different in various brain 
structures, and that was an obvious reason why we per­
formed the radioligand studies with [3H]-diprenorphine in 
the distinct forebrain regions, including the cerebral cortex, 
striatum mesolimbic area, and hippocampus.
2. Materials and methods
2.1. Animals
Nagata et al. generated CCK2 receptor-deficient mice by 
replacing a part of exons 2-5 [21]. Breeding and geno­
type analysis were performed at the Department of Phys­
iology of the University of Tartu. Genotyping was carried 
out by means of polymerase chain reaction (PCR) using 
two pairs of primers—HE2F (TGG AGT TGA CCA TTC 
GAA TCA C) and LacZrev (GTG CTG CAA GGC GAT 
TAA GTT G) were designed to detect the mutant allele, and 
HE3F (TAT CAG TGA GTG TGT CCA CTC T) and HE3R
(АСА TTT GTT GGA CAC GTT CAC) were designed for 
the wild-type allele. For PCR we used the following proto­
col: 96 °C for 10 min (initial dénaturation); 96 °C for 50 s, 
60 °C for 50 s, and 72 °C for 2 min (25 cycles); and 72 °C 
for 10 min (final amplification). PCR products were stored 
at 4°C until electrophoresis. Altogether, 176 male homozy­
gous (—/—) CCK2 receptor-deficient and 176 male wild-type 
(+ /+ ) (3-month-old) mice were used in the behavioural and 
radioligand binding studies. Mutant mice were crossed back 
six times to the C57B1/6 background to minimise any possi­
ble genetic effects from the 129sv strain. The mice were kept 
in the animal house at 20 ±  2 °C under a 12:12-h light/dark 
cycle (lights on at 07:00 h). Tap water and food pellets were 
available ad libitum All animal procedures were approved 
by the Animal Care Committee of the University of Tartu 
in accordance with the European Communities Directive of 
24 November 1986 (86/609/EEC).
2.2. Drugs
Morphine sulphate (Boehringer-Ingelheim) and naloxone 
hydrochloride (Sigma Chemical Co., St. Louis, MO) were 
dissolved in sterile, pyrogen-free, 0.9% solution of NaCl 
(saline). Solutions of morphine and naloxone were injected 
intraperitoneally in a volume 10 ml/kg. The doses of nalox­
one (1 and 10 mg/kg) and morphine (3 and 9 mg/kg) were 
selected according to the data available in the literature 
These doses are shown to induce a significant action in the 
place conditioning studies. In the locomotor activity stud­
ies, the higher doses of morphine were applied since the pi­
lot study revealed that only 10 mg/kg of morphine induced 
a significant increase of locomotor activity in mice with 
129sv/C57Bl/6 background.
2.3. Behavioural testing
The animals were brought into the experimental room one 
hour before the experiment. All behavioural experiments 
were performed between 11:00 and 19:00h. The motility 
and conditioned place preference tests were performed on 
separate groups of animals. Since the behavioural experi­
ments lasted 6-8 h, precautions were taken to control the 
possible daily fluctuations in the locomotor activity of an­
imals. Therefore, the experiments were always performed 
in randomised order, that is, wild-type (+ /+ ) mice were al­
ways used in parallel with mutant animals. In the radioli­
gand binding study, we used animals, which had not been 
exposed to behavioural testing.
2.4. Motility test
For the study of locomotor activity, the animals 
were placed singly into the photoelectric motility boxes 
(448 mm x 448 mm x 450 mm) connected to a computer 
(TSE Technical & Scientific Equipment GMBH, Germany). 
The illumination level of the transparent test boxes was 
~7501ux. After removing a mouse from the box the floor
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was cleaned by using 5% alcohol solution. Time in move- 
ment (s), the total distance of movement (m), the number 
of rearing and comer entries were registered during the 
30-min observation period. The locomotor effects of mor­
phine (5 and 10 mg/kg) and naloxone (1 and 10 mg/kg) 
were studied in the separate groups of animals. Morphine 
and naloxone were injected intraperitoneally 15 min before 
the experiment. Naloxone is shown to reduce the locomotor 
activity in rodents. Pommier et al. described that nalox­
one selectively suppressed the locomotor activity in CCK2 
receptor-deficient mice not habituated to the experimental 
environment [23]. The effect of naloxone was studied in 
two different groups of mice. One group of animals was not 
exposed to the motility boxes, whereas the other group was 
adapted to the experimental environment for 3 days before 
naloxone was administered. Similarly to psycho-stimulants 
morphine stimulates the locomotor activity in rodents, and 
the effect of motor stimulants is stronger in animals adapted 
to the experimental conditions [3]. This was a reason why 
the animals were habituated to the motility boxes for 3 days 
before morphine was administered.
2.5. Place preference and avoidance tests
Place preference and avoidance experiments were per­
formed in three identical shuttle boxes (50 cm x 25 cm x 
30 cm). Each shuttle box was divided into two compart­
ments of equal size by a sliding door having a partition. 
The door allows free movement of a test animal between 
the two compartments if opened or restricts the movement 
of a mouse to the other compartment if closed. These 
compartments were distinguished by wall and floor colour 
(dark green versus pale green). The illumination level in 
the shuttle boxes was ~2501ux. The place conditioning 
experiment was performed according to the method de­
scribed by Bespalov et al. [1]. Each experiment consisted of 
pre-conditioning, conditioning, and post-conditioning peri­
ods. During the pre-conditioning period mice were placed 
three times into the apparatus for 15 min. The first and the 
second pre-conditioning tests were held on Day 1. The third 
pre-conditioning test was held on Day 2 of the experiment, 
and the time spent in the pale green compartment was mea­
sured. During the pre-conditioning and post-conditioning 
tests, animals were allowed to explore both compartments 
freely. Each pre- and post-conditioning session began with 
initial placement of an animal into the dark green com­
partment. The shuttle boxes were cleaned carefully by 5% 
ethanol solution after each animal. The conditioning period 
consisted of 30-min experimental session performed twice 
a day for 4 consecutive days (Days 3-6). On each day, 
animals received a saline injection before being placed into 
one compartment and were then injected with morphine (3 
and 9 mg/kg) or naloxone (1 and 10 mg/kg) before place­
ment into the opposite compartment. Injections were given 
immediately before the conditioning sessions. One half of 
the animals received saline as the first injection, whereas the
other half were at first treated with morphine or naloxone. 
The morphine injections were paired with the placement of 
a mouse into the pale green compartment avoided in the 
pre-conditioning test (conditioning of place preference) and 
the naloxone injections were paired with the placement of 
an animal into the preferred compartment (dark green, con­
ditioning of place avoidance). The control animals received 
the injection of saline in both compartments. Fifteen-minute 
post-conditioning tests were performed on the Day 7 of 
experiments and the time spent in the pale green side of the 
shuttle box was measured. The behaviour of animals was 
recorded on the videotape and it was analysed by the expe­
rienced person not aware about the previous conditioning 
sessions and genotype of mice. On the Day 8, we studied 
also the effect of morphine administration on the place 
preference, but the response of the animals did not differ 
from that in the drug-free state. Therefore, these data were 
not included in the further analysis.
2.6. Radioligand binding studies
After decapitation, the brains were quickly dissected on 
ice. The cerebral cortex (including the frontal and parietal 
cortices), striata, mesolimbic structures (nucleus accumbens 
and tuberculum olfactorium) and hippocampus were dis­
sected [7]. The brain structures from six mice were pooled. 
The radioligand binding studies were performed accord­
ing to the method of Kõks et al. [12]. For the labelling 
of opioid receptors [3H]-diprenorphme (specific activity: 
58.0Ci/mmol, Amersham Radiochemicals) was used. The 
parameters of the opioid receptors were determined in the 
presence of 0.05-2.5 nM [3H]-diprenorphine at 23 °C for 
60 min. Naloxone hydrochloride (RBI, 1 цМ), an antagonist 
of opioid receptors, was added to determine the non-specific 
binding at opioid receptors. The brain tissue was ho­
mogenised in 20 volumes of ice-cold 50 mM Tris-HCl 
(pH 7.4 at 4 °C) using a Potter-S glass-teflon homogeniser 
(lOOOrpm, 12 passes). The membranes were washed twice 
in the same buffer by centrifugation (48,000 x g for 20 min) 
and re-suspension. After the last centrifugation, the crude 
brain membranes were suspended in the incubation buffer 
(Tris-HCl, pH 7.4 at 4 °C). The protein content was mea­
sured according to the method of Bradford [2]. The satu­
ration curves of [3H]-diprenorphine binding were analysed 
using GraphPad Prism (Version 3.00) for Windows soft­
ware. The experiment was repeated four times.
2.7. Statistics
The results are expressed as mean values ±  S.E.M. The 
behavioural studies were analysed using two-way analysis 
of variance. Post-hoc comparisons between the individual 
groups were performed by means of the Tukey HSD test 
using the Statistica for Windows software. The Student’s 
f-test was applied for the analysis of radioligand binding 
data.
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Fig. 1. Different adaptation o f wild-type m ice and mice without CCK.2 receptors in motility boxes. The number o f  animals in each group was 25. White 
bars— motor activity o f  mice during the first experiment, black bars— the response o f animals during the third experiment. (*) P  <  0.05; (**) P  <  0.001 
(compared with the first experiment, Tukey HSD test after the significant two-way ANOVA); (+ )  P <  0.05 (compared with the respective group of 
wild-type mice).
3. Results
3.1. Locomotor activity
In the first experiment, the locomotor activity of mutant 
mice did not differ from that of wild-type (+ /+ ) littermates 
(Fig. 1). Only the number of rearing was higher in the ho­
mozygous (—/—) animals. However, during the third exper­
iment some obvious differences became evident. There was 
significantly stronger inhibition of locomotor activity in the 
wild-type mice (+ /+ ) compared to the homozygous (—/—) 
littermates. The application of two-way ANOVA demon­
strated that the wild-type (+ /+ ) animals displayed stronger 
reduction of time in locomotion (two-way ANOVA: geno­
type: Fi 96  =  18.2, P < 0.001; experiment: F\^f, =  51.7, 
P < 0.001; genotype x experiment: Fi.ge =  4.06, P < 
0.05) and distance travelled (two-way ANOVA: genotype: 
Fi,96 — 14.7, P < 0.001; experiment: F [ ,9 6  =  53.5, P < 
0.001; genotype x experiment: F i ,96 =  4 ,32 , P <  0.05) 
compared to the homozygous (—/—) mice (Fig. 1). By con­
trast, the frequency of rearing (two-way ANOVA: genotype: 
Fi ,96  =  32.0, P < 0.001; experiment: Fige =  15.3, P < 
0.001; genotype x experiment: F\^(, =  0.11, P =  0.73) 
and number of corner entries (two-way ANOVA: genotype:
F i,96 =  11.0, P < 0.01; experiment: Fi^ö =  45.3, P < 
0.001; genotype x  experiment: F ],96 =  1.52, P =  0.22) 
did not differ in these two groups of mice according to 
two-way ANOVA. However, the using of post-hoc analysis 
established that these two parameters of locomotor activity 
were also reduced in the wild-type (+ /+ ) mice compared 
to the homozygous (—/—) animals (Tukey HSD test: fre­
quency of rearing, P < 0.001 and number of corner entries, 
P < 0.01) (Fig. 1). The administration of opioid receptor 
antagonist naloxone (1  and 1 0  mg/kg) to the non-habituated 
mice induced a dose-dependent reduction of locomotor 
activity in the wild-type (+ /+ ) and homozygous (—/—) ani­
mals (Fig. 2). However, the application of two-way ANOVA 
did not reveal any significant differences if the action of 
naloxone was compared in the wild-type (+ /+ ) and mutant 
animals. Naloxone induced a decrease of time in locomo­
tion (two-way ANOVA: genotype: F\ n  =  0.95, P = 0.76; 
treatment: F î ,42 =  8.91, P < 0.01; genotype x treatment: 
F 2.42 =  0.87, P =  0.42), distance travelled (two-way 
ANOVA: genotype: F i ,42  =  0.09, P =  0.77; treatment: 
F2 .42  =  12.13, P < 0.01; genotype x treatment: F2 42 =  
1.21, P — 0.30), number of rearing (two-way ANOVA: 
genotype: F\ t42  =  7.94, P < 0.01; treatment: F2.42 =  6.44, 
P < 0.01; genotype x treatment: F 2.42 =  1-06, P =  0.35)
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and frequency of corner entries (two-way ANOVA: geno­
type: F jt42 =  3.05, P — 0.09; treatment: F ia i — 12.6, 
P < 0.01; genotype x treatment: F2, \ i  =  1.79, P  =  0.17). 
Nonetheless, the using of post-hoc analysis demonstrated 
that the administration of naloxone ( 1  and 1 0 mg/kg) inhib­
ited the increased frequency of rearing in the homozygous 
(—/—) mice. Also, the highest dose o f naloxone (10 mg/kg) 
did not induce a significant reduction of time in locomotion 
in the homozygous mice (—/—) (Tukey HSD test: wild-type 
(+ /+ )  mice P <  0.05 and homozygous (—/ —) animals 
P — 0.11) (Fig. 2). In mice, habituated to the experimental 
environment, the application o f two-way ANOVA did not 
distinguish the action of naloxone in the wild-type (+ /+ )  
and homozygous (—/—) mice [time spent in locomotion 
(two-way ANOVA: genotype: Fj ^2 =  0.27, P  =  0.61; 
treatment; Fï.52 =  4.06, P < 0.05; genotype x treatment: 
/*2,52 =  1.41, P =  0.25); distance travelled (two-way 
ANOVA: genotype: F \ts i  =  0.48, P =  0.49; treatment: 
F2>52 =  6.44, P <  0.01; genotype x treatment: F2j52 =  
2.26, P =  0.11); frequency of rearing (two-way ANOVA: 
genotype: F ],52 =  0.44, P  =  0.51 ; treatment: F2,52 =  1.08, 
P =  0.35; genotype x treatment: Fj,52 — 0.77, P =  0.47) 
and number of corner entries (two-way ANOVA: genotype:
F\,52 =  0.38, P =  0.54; treatment: ^ 2,52 =  5.77, P  <  0.01; 
genotype x treatment: F2,52 =  1.06, P =  0.35)] (Fig. 3). 
However, the situation was different after the post-hoc 
analysis. Naloxone (10 mg/kg) induced the inhibition of 
locomotor activity only in the homozygous (—/ —), but not 
in the wild-type (+ /+ )  mice (Tukey HSD test: time in lo­
comotion, P < 0.05; distance travelled, P < 0.01, number 
of corner entries P < 0.05) (Fig. 3). The administration of 
(л-opioid receptor agonist morphine (5 and 10 mg/kg) in­
duced a dose-dependent increase of locomotor activity in the 
wild-type (+ /+ )  mice, adapted to the motility boxes (Fig. 4). 
Already the lower dose (5 mg/kg) of morphine tended to in­
crease the parameters of horizontal locomotor activity in the 
wild-type (+ /+ )  animals, but these changes were not statis­
tically significant. By contrast, the higher dose (10 mg/kg) of 
morphine caused a significant hyper-locomotion in these an­
imals. Morphine (5 and 10 mg/kg) suppressed the number of 
rearing in the wild-type (+ /+ )  mice. Motor stimulation in­
duced by morphine was significantly weaker in the homozy­
gous (—/—) animals [two-way ANOVA: time in locomotion 
(two-way ANOVA: genotype: /4  95 =  0.93, P =  0.33; 
treatment: F2,95 =  16.1, P < 0.001; genotype x treatment: 
F2.95 =  3.70, P < 0.05), distance travelled (two-way
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ANOVA: genotype: Fi,gs =  1.67, P =  0.20; treat­
ment: F2.95 =  28.2, P < 0.001; genotype x treatment: 
F2.95 =  3.48, P < 0.05) and frequency of comer entries 
(two-way ANOVA: genotype: F 19 5  =  3.66, P =  0.059; 
treatment: /*2,95 =  40.2, P < 0.001 ; genotype x treatment: 
/*2,9s =  3.38, P < 0.05)]. The only difference was the fre­
quency of rearing. Two-way ANOVA established a stronger 
suppression of rearing in the homozygous (—/ —) mice, 
because it was, like in the previous experiments, higher in 
the homozygous (—/—) mice (Fig. 4) (two-way ANOVA: 
genotype: F  ,95 =  0.07, P  =  0.80; treatment: Fi$$ —
56.4, P <  0.001; genotype x treatment: F 295 =  6.71, 
P <  0 .01).
3.2. Place conditioning experiments
In the pre-conditioning test the wild-type (+ /+ )  and ho­
mozygous (—/—) mice prefenred to stay in the dark green 
compartment o f shuttle box. The wild-type (+ /+ )  animals 
spent only 115 ±  15 s in the pale green compartment, whereas 
the respective value for the homozygous (—/—) animals was 
177 ±  22 s. The pairing of the dark and pale green box with 
saline injections did not change the preference of animals 
compared to the pre-conditioning session. The pairing of 
the dark green box with naloxone ( 1  and 1 0  mg/kg) induced
a significant shift of exploratory activity from the dark to 
the pale green compartment (Fig. 5A). The application of 
two-way ANOVA did not distinguish the action of naloxone 
in the wild-type (+ /+ )  and mutant mice (two-way ANOVA: 
genotype: F i ,42 =  1.0, P  >  0.3; treatment: F2,42 =  16.7, 
P  <  0.01; genotype x treatment: F2A2 =  1-78, P  >  0.15). 
Nevertheless, the effect of naloxone was stronger in the 
wild-type (+ /+ )  animals compared with the homozygous 
(—/—) mice. Already 1 mg/kg of naloxone tended to shift the 
preference in the wild-type (+ /+ ) mice (Tukey HSD test, 
P =  0.055), whereas in the homozygous (—/—) mice even 
the highest dose ( 10  mg/kg) did not cause any significant ef­
fect (Tukey HSD test, P — 0.16). The highest dose of nalox­
one ( 1 0  mg/kg) induced a significant place aversion in the 
wild-type (+ /+ )  mice, because they started to prefer the ini­
tially non-preferred side (Tukey HSD test P < 0.001). The 
pairing of morphine (3 mg/kg) with the pale green compart­
ment induced a significant shift of exploratory activity from 
the dark green to the pale green part both in the wild-type 
(+ /+ )  and homozygous (—/—) mice (two-way ANOVA: 
genotype: F i ,42 =  0.40, P >  0.8; treatment: F i.n  =  Ю.7, 
P < 0.01; genotype x treatment: F2.42 =  1.30, P > 0.25) 
(Fig. 5B). However, differently from the wild-type (+ /+ ) 
animals the higher dose of morphine (9 mg/kg) induced a 
significant effect only in the homozygous (—/—) mice.
К. Rünkorg e t aL /  Behavioural Brain Research 144 (2003) 125-135 131
1500-1
200 -
100 -
Wild-type Homozygous Wild-type Homozygous
750-1
Wild-type Homozygous
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3.3. Radioligand binding studies
The radioligand binding studies with [3H]-diprenorphine 
demonstrated an increase in the affinity of the opioid binding 
sites in the cerebral cortex of mutant mice compared to the
wild-type (+ /+) littermates (Fig. 6). However, the decreased 
affinity and increased density of the opioid binding sites was 
established in the striatum of homozygous (—/—) mice. The 
parameters of [3H]-diprenorphine binding were not affected 
in the mesolimbic structures and hippocampus.
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Fig. 5. The effect o f  naloxone (I and 1 0 mg/kg) and morphine (3 and 9 mg/kg) on the place conditioning o f  mice without CCK2 receptors. (A) 
Naloxone-induced place aversion. The number o f  animals in cach group was eigh t White bars— saline treatment, striped bars— naloxone (1 mg/kg), 
black bars— naloxone (10 mg/kg). (*) P  <  0.05 (compared with saline-treated wild-type mice, Tukey HSD test after significant one-way ANOVA). (B) 
Morpliine-induced place preference. The number o f  animals in each group was eight. White bars— saline treatment, striped bars— morphine (3 mg/kg), 
black bars— morphine ( 9 mg/kg). (*) P  <  0.05 (compared with the respective saline-treated group, Tukey HSD test after significant one-way ANOVA).
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4. Discussion
The present study yielded four major findings. First, 
the adaptation of CCK2 receptor-deficient mice to a novel 
environment is impaired. Differently from the study of 
Daugé et al. and Pommier et al. we were unable to find 
any significant differences in the horizontal component of 
locomotor activity of the wild-type (+ /+ ) and mutant mice, 
not habituated to the motility boxes [5,23]. Only the fre­
quency of rearing was higher in mice without CCK2 recep­
tors. The repeated exposure of mice to the motility boxes 
caused a significant reduction of locomotor activity in the 
wild-type (4-/+) mice. The described behavioural change 
was significantly weaker in animals, lacking CCK2 recep­
tors. This difference can be explained in the light of the 
suggestion that CCK is an important factor in adaptation of 
rodents to a novel environment. Namely, CCK antagonises 
morphine-induced antinociception in a novel, but not in a 
familiar environment [36]. Also, morphine induces a sig­
nificant anxiolytic-like action in rats, not habituated to the 
experimental conditions, whereas morphine was ineffective 
in habituated rats [14,15]. Therefore, lack of CCK2 recep­
tors, a subtype of CCK receptors preferentially distributed 
in the brain, apparently attenuates a normal adaptation to 
the novel environment. Moreover, the learning ability of the
mice without CCK2 receptors is significantly affected in the 
T-maze and in the Morris water-maze test ([27], our unpub­
lished data], CCK2-deficient mice display an impaired re­
sponse in these learning tasks. However, it is unclear whether 
the affected adaptation to a novel environment and dimin­
ished learning abilities are linked to the same neurochemical 
changes in the brain due to the corrupted function of CCK2 
receptors.
Second, there is dissociation between the morphine-indu­
ced motor and motivational responses. Morphine (3 mg/kg) 
induces a similar effect both in the wild-type (+ /+ ) and 
homozygous (—/—) mice in the conditioned place pref­
erence test, increasing time spent in the drug-associated 
compartment during the post-conditioning phase. It should 
be noted that the pre-conditioning preference of animals for 
one side was very strong. This biased design has often been 
criticised because it may lead to false-positive results in the 
place conditioning test [32]. For example, the drugs with 
a strong anxiolytic action may overcome the initial aver­
sion for the non-preferred compartment. Several steps were 
taken to minimise the problem linked to the biased design. 
The animals having a significantly different response pro­
file in the pre-conditioning session were excluded from the 
further experiments. The effect of morphine was not com­
pared with the pre-conditioning session but with a group of 
animals receiving saline injections in both compartments. 
Although the response of mice after saline treatments did 
no differ from that seen during the pre-conditioning session. 
During the conditioning session half of animals received 
saline treatment as the first daily injection, whereas the 
other half were at first treated with morphine. Our previous 
studies showed that morphine induced an anxiolytic-like 
action in rats [13,14]. However, morphine was effective in 
the elevated plus-maze and zero-maze when its effect was 
studied in rats that were not handled and exposed repeatedly 
to the experimental room [15]. Therefore, we tested the ac­
tion of morphine (3 mg/kg) in the non-habituated wild-type 
(+ /+ ) mice using the dark-light exploration paradigm, and 
no increase of exploratory activity was established (our 
unpublished data). Accordingly, the described shift in the 
behaviour of mice in the place preference test is not linked 
to the anxiolytic-like properties of morphine. The results 
of the present study differ from the data of the pharma­
cological studies where the blockade of CCK2 receptors 
induced a significant potentiation of morphine-induced 
place preference in rats [10,33]. The compensatory changes 
in the other neurotransmitter systems due to the com­
plete inactivation of CCK2 receptors may explain that 
discrepancy.
In the habituated wild-type (+ /+ ) mice, the adminis­
tration of morphine (5 mg/kg) tended to increase the hor­
izontal component of locomotor activity and significantly 
inhibited the frequency of rearing. The higher dose of mor­
phine (10 mg/kg) induced a significant hyper-locomotion 
in the wild-type (+ /+ ) animals. By contrast, in the CCK2 
receptor-deficient mice this dose of morphine induced
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significantly weaker motor activation. This finding contra­
dicts with the study of Pommier et al. demonstrating that 
the administration of morphine and inhibition of enkephalin 
metabolism increases the locomotor activity in mice with­
out CCK.2 receptors [23]. The reason for these differences 
is unclear but could be attributed to the different research 
design and distinct genetic background of mice used in 
these studies. Moreover, the current study established dis­
sociation in the action of morphine in the motor activity and 
place preference tests. It is noteworthy that a significantly 
lower dose of morphine was effective in the place prefer­
ence test compared to the locomotor activity study. It is 
possible that the distinct neural circuits are responsible for 
these two behavioural effects of morphine. The stronger ef­
fect of morphine on the locomotor activity in the wild-type 
(+/+) mice may be a reason why a higher dose of morphine 
causes a weaker effect in the place preference studies in 
the wild-type (+ /+ ) mice compared to mutant animals. In­
creased motor stereotypy (psychosis-like behaviour) in the 
wild-type (+ /+ ) mice under the influence of morphine may 
cause impaired perception of the surrounding environment 
and reduce the conditioning to the drug-paired environ­
ment in comparison with the mutant animals. Interestingly, 
Maldonado et al. have described dissociation between the 
opioid-mediated motor and motivational responses in mice 
lacking dopamine D2 receptors [19]. They established that 
morphine-induced place preference was absent in these 
mice, whereas morphine-induced hyper-locomotion re­
mained unchanged compared with the wild-type (+ /+ ) 
mice. This study clearly demonstrates a role of the dopamine 
D2 receptors of the nucleus accumbens in the mediation of 
the rewarding effects of morphine, whereas dopamine Di re­
ceptors and non-dopaminergic mechanisms are responsible 
for opioid-induced enhancement of locomotion [4,11,18,19].
Third, differently from the study of Pommier et ai. only 
a high dose (10 mg/kg) of naloxone reduced the horizontal 
component of locomotor activity in mice, and this effect was 
similar in the wild-type (+ /+ ) and mutant mice [23]. Nev­
ertheless, the lower dose of naloxone (1 mg/kg) antagonised 
the increased frequency of rearing established in the ho­
mozygous (—/—) mice showing that the elevation of this be­
havioural parameter is probably due to the increased function 
of endopioid system in mice, lacking CCK2  receptors. More­
over, we established that naloxone caused the different effect 
in the wild-type (+ /+ ) and homozygous (—/—) mice adapted 
to the motility boxes. In these mice the high dose of nalox­
one (10 mg/kg) induced a significant inhibition of locomotor 
activity in the homozygous (—/—), but not in the wild-type 
(+/+) mice. It has been shown that naloxone at this high 
dose is lacking selectivity for the subtypes of opioid recep­
tors [31]. Nevertheless, it is likely that the impaired adapta­
tion of CCK2 receptor-deficient mice to the novel environ­
ment is due to the increased function of endopioid system. 
In the place conditioning experiments a lower dose of nalox­
one (1 mg/kg) tended to cause a conditioned place aversion 
in the wild-type (+ /+ ) mice, whereas a high dose of opioid
antagonist (10 mg/kg) caused a significant place aversion. 
By contrast, naloxone-induced place aversion was weaker 
in mice without CCK2 receptors, because the high dose of 
naloxone (10 mg/kg) only tended to shift the behaviour of 
mutant mice from the non-preferred to preferred side. Con­
sequently, there is also dissociation of the behavioural effects 
of naloxone in the CCK2 receptor-deficient mice. These 
data may also reflect an increased tone of the endopioid sys­
tem in the neural circuits responsible for the development 
of place aversion in mutant mice. It was shown that nalox­
one (10 mg/kg) failed to produce conditioned place aversion 
in n-opioid receptor-deficient mice, whereas the effect of 
(i.-opioid agonist U50.488H remained unchanged [29]. This 
finding obviously supports the involvement of jt-opioid 
receptors in the mediation of naloxone-induced place aver­
sion. This behavioural phenomenon can be induced by the 
local administration of naloxone into the ventral tegmental 
area and nucleus accumbens, but not into the striatum and 
medial prefrontal cortex [28]. Recent evidence suggests that 
naloxone-induced action is not linked only to the mesolim­
bic dopaminergic system, because the blockade of jt-opioid 
receptors in the dorsal periaquaductal gray matter caused the 
conditioned place aversion [25]. We did not find differences 
in the density of opioid and dopamine D2 receptors [16] in 
the mesolimbic area, but we established a significant reduc­
tion of pain sensitivity in the CCK2 receptor-deficient mice 
[35]. The role of periaquaductal gray matter in the regulation 
of pain sensitivity is well-known [20]. Therefore, we are 
tempting to speculate that die increased tone of endopioid 
system in this brain region could be linked to the reduced 
effect of naloxone in homozygous (—/—) mice. Moreover, to 
some extent this study tends to support the finding of phar­
macological experiments showing that the CCK2 receptor 
antagonists attenuate naloxone-induced place aversion in 
rats [34].
Fourth, we were unable to repeat the results of radioligand 
binding studies performed by Pommier et al. [23]. First, they 
found that the number of opioid receptors was decreased 
if measured in the whole brain of CCK2 receptor-deficient 
mice in the in vivo conditions. Pommier et al [23] suggested 
that this effect was due to the increased levels of endopioid 
peptides in the brain of homozygous (—/—) mice. Second, 
in the in vitro studies they did not found any changes in the 
parameters of opioid receptors if the membranes were pre­
pared from the whole brain [23]. We measured the density 
of opioid receptors by [3H]-diprenorphine in four distinct 
forebrain structures (cerebral cortex, striatum, mesolimbic 
area, and hippocampus), and at least in these structures no 
decline in the density of opioid receptors was observed. 
Indeed, the number of opioid receptors was elevated in 
the striatum of mutant mice, whereas the other structures 
show no difference in the density of receptors between the 
homozygous (—/—) and wild-type (+ /+ ) animals. On the 
other hand, the affinity of opioid receptors was reduced in 
the striatum. The reduced affinity of opioid receptors in the 
striatum could support the initial idea of Pommier et al.
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[23] that the levels of endopioid peptides are increased in 
certain brain regions and therefore the affinity of opioid 
receptors is decreased. A micro-array study was performed 
in the striatum in order to reveal the differences between 
the wild-type (+ /+ ) and homozygous (—/—) mice in the 
gene expression (our unpublished data). According to this, 
the expression of the n.-opioid receptor gene was increased, 
whereas the expression of pre-proenkephalin, a precursor 
molecule of enkephalins, and nociceptin genes was reduced. 
By contrast from the striatum the affinity of opioid recep­
tors was increased in the cerebral cortex of mutant mice 
compared to wild-type (+ /+ ) littermates. Accordingly, the 
targeted mutation of CCK2 receptors affects differently the 
parameters of opioid receptors in the forebrain structures. 
These distinct changes in the sensitivity of opioid receptors 
in various brain structures may explain dissociation of be­
havioural effects of morphine and naloxone described in an­
imals without CCK2 receptors. The mesolimbic structures, 
and especially the nucleus accumbens, are targets for the re­
warding effect of morphine [19]. However, we did not find 
any differences in the parameters of opioid receptors in the 
mesolimbic area, and no change in morphine-induced place 
preference was established when the wild-type (+ /+ ) and 
mutant mice were compared. Maldonado et al. demonstrated 
the role of dopamine D2 receptors in the nucleus accumbens 
for the motivational effects of morphine [19]. Our previous 
experiments did not reveal any differences in the density of 
dopamine D2 receptors in the mesolimbic area of wild-type 
(+ /+ ) and CCK2 receptor-deficient mice [19]. Accordingly, 
the reduction of morphine-induced motor stimulation in 
mutant mice has to be explained by other mechanisms than 
opioid and dopamine D2 receptors in the mesolimbic struc­
tures. It could be associated with changes in the parameters 
of opioid receptors in the striatum where the increased 
number and reduced affinity was found. This may reflect an 
increased tone of the endogenous opioid system in the stria­
tum and could explain the reduced morphine-induced motor 
stimulation in mice without CCK2 receptors. Altogether, 
the distinct changes of opioid receptors in the striatum and 
mesolimbic area are most likely linked to the dissociation of 
behavioural effects of morphine in CCK2 receptor-deficient 
mice.
In conclusion, the present study to some extent supports 
the initial idea of Pommier et al. that the activity of the 
endogenous opioid system is increased due to the targeted 
invalidation of CCK2 receptor gene in mice [23]. How­
ever, we established a clear dissociation of the behavioural 
effects of morphine and naloxone in mice, lacking CCK2 
receptors. Dissociation of behavioural effects of morphine 
was also established in the previous studies where the 
anti-nociceptive action of ц-opioid agonist was studied in 
mice with the corrupted function of CCK2 receptors [23,35]. 
The molecular background of this phenomenon is unclear 
but could be explained in the light of data that the targeted 
mutation of CCK2 receptors induces distinct changes in the 
properties of opioid receptors in various brain structures.
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